[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 1 of 77 Safety and Immunogenicity of High- Dose Quadrivalent 
Influenza Vaccine Administered by [CONTACT_125613] 65 Years and Older  
Phase III, randomized, modified double-blind, active-controlled, multi- center trial evaluating 
the safety and imm unogenicity of QIV-HD in healthy subjects aged 65 years and older in the 
[LOCATION_002]  
Clinical Trial Protocol  
Health Authority File Number : BB-IND #:  [ZIP_CODE] 
WHO Universal Trial Number 
(UTN): U1111- 1183 -5556 
Trial Code:  QHD00013  
Development Phase:  Phase III  
Sponsor:  [COMPANY_011] Pasteur Inc.  
Discovery Drive, Swiftwater, PA [ADDRESS_141324]:  High -Dose Influenza Vaccine  Quadrivalent, (Zonal Purified, Split Virus) 
2017 –2018 Strains (QIV -HD) 
Form / Route: Liquid / Intramuscular  
Indication For This Study:  Single dose for individuals aged 65 years and older  
Manufacturer:  Same as Sponsor  
Coordinating Investigator: ,
, 
Tel: 
Fax: 
This is a multi- center trial with multiple investigators. Investigators and 
study sites are listed in the “List of Investigators and Centers Involved in the Trial” document.  
Sponsor’s Responsible Medical Officer: , 
, [COMPANY_011] Pasteur Inc.  
Tel: 
Fax: 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.[ADDRESS_141325] number: [STUDY_ID_REMOVED]
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 2 of 77 Pharmacovigilance Global Safety 
Expert: , 
, Sanof i Pasteur Inc.  
Tel: 
Fax: 
Clinical Trial Manager:  
, [COMPANY_011] Pasteur Inc. 
Tel: 
Fax: 
Version and Date of the Protocol:  Versio n 4.[ADDRESS_141326] parties without written authorization from [COMPANY_011] Pasteur . This document may not be reproduced, stored in a 
retrieval system, or transmitted in any form or by [CONTACT_61076] –electronic , mechanical recording, or otherwise –without prior 
authorization from [COMPANY_011] Pasteur . This document must be returned to [COMPANY_011] Pasteur  upon request.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 2 of 78

[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 3 of 77 History of Protocol Versions  
Table 1: Previous versions of the protocol 
Version Date Comments  
1.0 09 February 2017  Version not approved by [CONTACT_6179]/IRB  
2.0 09 May 2017  Version not approved by [CONTACT_6179]/IRB. Change needed to 
be made immediately after document was approved by 
[CONTACT_125614]. 
3.0 15 May 2017  Version submitted to IEC/IRB  
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 3 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141327] ..................................................................... 24  
1.3 Potential Benefits and Risks ........................................................................................... 24  
1.3.1 Potential Benefits to Subjects  ....................................................................................... 24  
1.3.2 Potential Risks to Subjects ........................................................................................... 25  
1.4 Rationale for the Trial  ..................................................................................................... 26  
2 Trial Objectives  ............................................................................................................... 26  
2.1 Primary Objective  ........................................................................................................... 26  
2.2 Secondary Objectives  ...................................................................................................... 27  
3 Investigators and Trial Organization ............................................................................ 27  
4 Independent Ethics Committee / Institutional Review Board  .................................... 27  
5 Investigational Plan  ......................................................................................................... 28  
5.1 Description of the O verall Trial Design and Plan  ........................................................... 28  
5.1.1 Trial Design  .................................................................................................................. 28  
5.1.2 Justification of the Trial Design  ................................................................................... 29  
5.1.3 Trial Plan  ...................................................................................................................... 29  
5.1.4 Visit Procedures  ............................................................................................................ 30  
5.1.5 Planned Trial Calendar ................................................................................................. 33  
5.1.6 Early Safety Data Review ............................................................................................. 33 
5.2 Enrollment and Retention of Trial Population ................................................................ 33  
5.2.1 Recruitment Procedures  ................................................................................................ 33  
5.2.2 Informed Consent Procedures ...................................................................................... 33  
5.2.3 Screening Criteria  ......................................................................................................... 34  
5.2.4 Inclusion Criteria  .......................................................................................................... 34  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 4 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141328] (QIV -HD) ............................................................................. 38  
[IP_ADDRESS] Composition  ............................................................................................................... 39  
[IP_ADDRESS] Preparation and Administration  ................................................................................. 39  
[IP_ADDRESS] Dose Selection and Timing ........................................................................................ [ADDRESS_141329] 1 (Licensed TIV- HD [TIV- HD1])  ................................... 39  
[IP_ADDRESS] Composition  ............................................................................................................... 40  
[IP_ADDRESS] Preparation and Administration  ................................................................................. 40  
[IP_ADDRESS] Dose Selection and Timing ........................................................................................ [ADDRESS_141330] 2 (Investigational TIV- HD [TIV- HD2])  .......................... 40  
[IP_ADDRESS] Composition  ............................................................................................................... 40  
[IP_ADDRESS] Preparation and Administration  ................................................................................. 41  
[IP_ADDRESS] Dose Selection and Timing ........................................................................................ [ADDRESS_141331] Shipment, Storage, and Accountability ........................................................... 41  
[IP_ADDRESS] Product Shipment ....................................................................................................... 41  
[IP_ADDRESS] Product Storage .......................................................................................................... 42  
[IP_ADDRESS] Product Accountability ............................................................................................... 42  
6.3.3 Replacement Doses ....................................................................................................... 42 
6.3.4 Disposal of Unused Products ........................................................................................ 42  
6.3.5 Recall of Products ......................................................................................................... 42  
6.4 Blinding and Code-breaking Procedures ........................................................................ 43  
6.5 Randomization and Allocation Procedures ..................................................................... 44  
6.6 Treatment Compliance  .................................................................................................... 45  
6.7 Concomitant Medications and Other Therapi[INVESTIGATOR_014]  ............................................................. 45  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 5 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 6 of 77 7 Management of Samples ................................................................................................. 46  
7.1 Sample Collection  ........................................................................................................... 46  
7.2 Sample Preparation  ......................................................................................................... 46  
7.3 Sample Storage and Shipment ........................................................................................ 46  
7.4 Future Use of Stored Serum Samples for Research  ........................................................ 47  
8 Clinical Supplies  .............................................................................................................. 47  
9 Endpoints and A ssessment Methods ............................................................................. 48  
9.1 Primary Endpoints and Assessment Methods ................................................................. 48  
9.1.1 Immunogenicity ............................................................................................................ 48  
[IP_ADDRESS] Immunogenicity Endpoints ........................................................................................ 48  
[IP_ADDRESS] Immunogenicity Assessment Methods ...................................................................... 48  
9.1.2 Safety  ............................................................................................................................ 48  
9.1.3 Efficacy  ......................................................................................................................... 49  
9.2 Secondary Endpoints and Assessment Methods ............................................................. 49  
9.2.1 Immunogenicity ............................................................................................................ 49  
[IP_ADDRESS] Immunogenicity Endpoints ........................................................................................ 49  
[IP_ADDRESS].1 Immunogenicity by [CONTACT_35295] ............................................................................ 49  
[IP_ADDRESS].2 Immunogenicity by [CONTACT_125615] .............................................................................. 49  
[IP_ADDRESS] Immunogenicity Assessment Methods ...................................................................... 49  
[IP_ADDRESS].1 Immunogenicity by [CONTACT_35295] ............................................................................ 49  
[IP_ADDRESS].2 Immunogenicity by [CONTACT_125615] .............................................................................. 50  
9.2.2 Safety  ............................................................................................................................ 50  
[IP_ADDRESS] Safety Definitions  ....................................................................................................... 50  
[IP_ADDRESS] Safety Endpoints ........................................................................................................ 53  
[IP_ADDRESS] Safety Assessment Methods ....................................................................................... 53  
[IP_ADDRESS].[ADDRESS_141332] -vaccination Surveillance Period .................................................... 53  
[IP_ADDRESS].2 Reactogenicity (Solicited Reactions From D0 to D7After Vac cination) ................ 54  
[IP_ADDRESS].3 Unsolicited AEs  ....................................................................................................... 59  
[IP_ADDRESS].[ADDRESS_141333]  .......................................................................... 60  
[IP_ADDRESS].[ADDRESS_141334] Has Completed the Study ...................... 62  
10.4 Assessment of Causality  ................................................................................................. 62  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 6 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 7 of 77 10.5 Reporting SAEs to Health Authorities and IECs / IRBs ................................................. 63  
11 Data Collection and Management ................................................................................. 63  
11.1 Data Collection and CRB Completion  ............................................................................ 63  
11.2 Data Management  ........................................................................................................... 64  
11.3 Data Review  .................................................................................................................... 65  
12 Statistical Methods and Determination of Sample Size  ............................................... 65  
12.1 Statistical Methods  .......................................................................................................... 65  
12.1.1 Hypotheses and Statistical Methods f or Primary Objective  ......................................... 65  
[IP_ADDRESS] Immunogenicity ......................................................................................................... 65  
[IP_ADDRESS].1 Hypotheses ............................................................................................................... 65  
[IP_ADDRESS].2 Statistical Methods  ................................................................................................... 66  
12.1.2 Hypotheses and Statistical Methods for Secondary Objectives  ................................... 67  
[IP_ADDRESS] Immunogenicity ......................................................................................................... 67  
[IP_ADDRESS].1 Hypotheses ............................................................................................................... 67  
[IP_ADDRESS].2 Statistical Methods  ................................................................................................... 68  
[IP_ADDRESS] Safety  .......................................................................................................................... 68  
[IP_ADDRESS].1 Hypotheses ............................................................................................................... 68  
[IP_ADDRESS].2 Statistical Methods  ................................................................................................... 69  
12.2 Analysis Sets ................................................................................................................... 69  
12.2.1 Full Analysis Sets  ......................................................................................................... 69  
12.2.2 Safety Analysis Set  ....................................................................................................... 70  
12.2.3 Per-Protocol Analysis Set ............................................................................................. 70  
12.2.4 Populations Used in Analyses ...................................................................................... 70  
12.3 Handling of Missing Data and Outliers .......................................................................... 71  
12.3.1 Safety  ............................................................................................................................ 71  
12.3.2 Immunogenicity ............................................................................................................ 71  
12.4 Interim / Preliminary Analysis  ........................................................................................ 71  
12.5 Determination of Sample Size and Power Calculation  ................................................... 71  
13 Ethical and Leg al Issues and Investigator / Sponsor Responsibilities ........................ [ADDRESS_141335] of the Trial / Good Clinical Practice  .................................................... [ADDRESS_141336] Records ................................................. 73  
13.4 Monitoring, Auditing, and Archiving ............................................................................. 73  
13.4.1 Monitoring .................................................................................................................... 73  
13.4.2 Audits and Inspections ................................................................................................. 74  
13.4.3 Archiving ...................................................................................................................... 74  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 7 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141337]  ................................................................................................................. 76  
15 Signature [CONTACT_68615]  ............................................................................................................... 77  
 
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 8 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141338] of Tables  
Table 1: Previous versions of the protocol ........................................................................................ 3  
Table 6.1: Enrollment of subjects by [CONTACT_125616] . 44  
Table 9.1: Solicited injection site reactions: terminology, definitions, and intensity scales  ........... 55  
Table 9.2: Solicited systemic reactions: terminology, definitions, and intensity scales ................. 57  
 
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 9 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 10 of 77 Synopsis 
Company:  [COMPANY_011] Pasteur  
Investigational Product:  High -Dose Influenza Vaccine Quadrivalent, 2017 -2018 Northern Hemis phere 
Formulation (QIV -HD) 
Active Substances:  A/(H1N1)- like strain, A/(H3N2)- like strain, B (B from primary lineage) -like 
strain, B (B from alternate lineage) -like strain 
  Title of the Trial: Safety and Immunogenicity of High -Dose Quadrivalent Influenz a Vaccine 
Administered by [CONTACT_125617] 65  Years and Older  
Development Phase:  Phase  III 
Coordinating Investigator: ,  
, ,  
Trial Centers: This will be a mul ti-center trial conducted at approximately 36 sites in the 
[LOCATION_002].  
Investigators and sites are listed in the “List of Investigators, Trial Centers, and 
Sponsor’s Personnel Involved in the Trial” document.  
Planned Trial  Period: First visit, first su bject: [ADDRESS_141339]: 04 April 2018  
Trial Design and Methodology: QHD00013 will be a randomized, modified double -blind, active -controlled, 
multi -center trial to be conducted in 2616 healthy subjects aged 65 years and 
older to assess the safety and immunogenicity of the high- dose quadrivalent 
influenza vaccine (QIV -HD) compared to one of the high -dose trivalent influenza 
vaccines (TIV -HDs) containing either the B strain from the primary lineage (TIV -
HD1, which will be the lice nsed vaccine [Fluzone® High -Dose] for the 2017-
2018 Northern Hemisphere [NH] influenza season) or the B strain from the alternate lineage (TIV -HD2, which will be an investigational TIV -HD containing 
an alternate B strain).  
An unblinded administrator at each site will administer the vaccine.  
All subjects will provide a pre -vaccination (baseline) blood sample at Day (D) [ADDRESS_141340]- vaccination blood sample at Visit (V) 02 (D28 [+7 days]) for 
hemagglutination inhibition (HAI) testing. A randomized subset of t hese subjects 
(Expanded Immunogenicity Subset) from each group  (100 subjects per study 
group)  will be selected for seroneutralization (SN) testing.  
Solicited reactions will be collected up to 7 days after vaccination, and unsolicited adverse events (AEs) will be collected up to V02, which is the active phase of the trial (V01 to V02 [D0- D28]). Serious adverse events (SAEs) and 
adverse events of special interest (AESIs*) will be collected throughout the trial 
(D0 through approximately D180 [6- month follow -up period]).  
*Note : AESIs will be captured as SAEs. These include new onset of Guillain -
Barré syndrome (GBS), encephalitis / myelitis (including transverse myelitis), Bell’s palsy, optic neuritis, and brachial neuritis.  
Interactive response  technology (IRT) will be used to randomly assign subjects to 
one of the [ADDRESS_141341] numbers in each of the groups. 
Electronic data capture (EDC) will be used for the collection of data.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 10 of 78

S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  1 1  o f  7 7  E a r l y  S a f e t y  D a t a  R e v i e w :  T h i s  t r i a l  w i l l  n o t  i n c l u d e  a n  e a r l y  r e v i e w  o f  s a f e t y  d a t a  ( i . e . ,  n o  e a r l y  s a f e t y  
r e v i e w [ s ]  o f  p r e l im i n a r y  d a t a  o c c u r r i n g  a t  p r e -d e t e rm i n e d  m i l e s t o n e s  d e f i n e d  i n  
t h e  p r o t o c o l  w i t h  p a u s e  i n  e n r o l lm e n t ) .  H o w e v e r ,  i t  m a y  b e  i n t e r r u p t e d  a t  a n y  
t im e  i f  n e w  d a t a  a b o u t  t h e  i n v e s t i g a t i o n a l  p r o d u c t  b e c om e  a v a i l a b l e ,  a n d / o r  o n  
a d v i c e  o f  t h e  S p o n s o r ,  t h e  I n s t i t u t i o n a l  R e v i e w  B o a r d s  ( I R B s ),  o r  t h e  g o v e r n i n g  
r e g u l a t o r y  a u t h o r i t i e s  i n  t h e  c o u n t r y  w h e r e  t h e  t r i a l  i s  t a k i n g  p l a c e .   
I f  t h e  t r i a l  i s  p r em a t u r e l y  t e rm i n a t e d  o r  s u s p e n d e d ,  t h e  S p o n s o r  w i l l  p r om p t l y  
i n f o rm  t h e  I n v e s t i g a t o r s ,  t h e  I R B s ,  a n d  t h e  r e g u l a t o r y  a u t h o r i t i e s  o f  t h e  r e a s o n  f o r  
t e rm i n a t i o n  o r  s u s p e n s i o n .  I f  t h e  t r i a l  i s  p r em a t u r e l y  t e rm i n a t e d  f o r  a n y  r e a s o n ,  
t h e  I n v e s t i g a t o r  w i l l  p r om p t l y  i n f o rm  t h e  t r i a l  s u b j e c t s  a n d  s h o u l d  a s s u r e  
a p p r o p r i a t e  t h e r a p y  a n d  f o l l o w -u p .  
P r im a r y  O b j e c t i v e :  Imm u n o g e n i c i t y  
T o  d em o n s t r a t e  t h a t  Q I V -H D  i n d u c e s  a n  imm u n e  r e s p o n s e  ( a s  a s s e s s e d  b y  H A I  
g e om e t r i c  m e a n  t i t e r s  [ GM T s ]  a n d  s e r o c o n v e r s i o n  r a t e s )  t h a t  i s  n o n -i n f e r i o r  t o  
r e s p o n s e s  i n d u c e d  b y  t h e  T I V -H D 1  a n d  T I V -H D 2  f o r  t h e  4  v i r u s  s t r a i n s  a t  
2 8  d a y s  p o s t -v a c c i n a t i o n  i n  a l l  s u b j e c t s .  
P r im a r y  E n d p o i n t s :  Imm u n o g e n i c i t y   
• H A I  a n t i b o d y  ( A b )  t i t e r s  o b t a i n e d  o n  D 2 8  
• S e r o c o n v e r s i o n  ( t i t e r  <  1 0  [ 1 / d i l ]  a t  D 0  a n d  p o s t -i n j e c t i o n  t i t e r  ≥ 4 0  [ 1 / d i l ]  
a t  D 2 8 ,  o r  t i t e r  ≥ 1 0  [ 1 / d i l ]  a t  D 0  a n d  a  ≥  4 - f o l d  i n c r e a s e  i n  t i t e r  [ 1 / d i l ]  a t  
D 2 8 )  
S e c o n d a r y  O b j e c t i v e s :  Imm u n o g e n i c i t y  
1 )  T o  d em o n s t r a t e  t h a t  e a c h  B  s t r a i n  i n  Q I V -H D  i n d u c e s  a n  imm u n e  r e s p o n s e  
( a s  a s s e s s e d  b y  H A I  GM T s  a n d  s e r o c o n v e r s i o n  r a t e s )  t h a t  i s  s u p e r i o r  t o  t h e  
r e s p o n s e  i n d u c e d  b y  t h e  T I V -H D  t h a t  d o e s  n o t  c o n t a i n  t h e  c o r r e s p o n d i n g  B  
s t r a i n  i n  a l l  s u b j e c t s .  
2 )  T o  d e s c r i b e  t h e  imm u n e  r e s p o n s e  i n d u c e d  b y  Q I V -H D ,  T I V -H D 1 ,  a n d  
T I V - H D 2  b y  H A I  m e a s u r em e n t  m e t h o d  i n  a l l  s u b j e c t s .  
3 )  T o  d e s c r i b e  t h e  imm u n e  r e s p o n s e  2 8  d a y s  a f t e r  v a c c i n a t i o n  b y  v i r u s  S N  
m e a s u r em e n t  m e t h o d  i n  a  r a n d om i z e d  s u b s e t  o f  s u b j e c t s  f r om  e a c h  s t u d y  
g r o u p .  
S a f e t y  
T o  d e s c r i b e  t h e  s a f e t y  p r o f i l e  o f  a l l  s u b j e c t s  i n  e a c h  t r i a l  g r o u p .  
S e c o n d a r y  E n d p o i n t s :  Imm u n o g e n i c i t y  A s s e s sm e n t  b y  H A I  ( f o r  a l l  s u b j e c t s )  
• H A I  A b  t i t e r s  o b t a i n e d  o n  D 0  a n d  D 2 8  
• I n d i v i d u a l  H A I  t i t e r s  r a t i o  D 2 8 / D 0  
• S e r o c o n v e r s i o n  ( t i t e r  <  1 0  [ 1 / d i l ]  a t  D 0  a n d  p o s t -i n j e c t i o n  t i t e r  ≥ 4 0  [ 1 / d i l ]  
a t  D 2 8 ,  o r  t i t e r  ≥ 1 0  [ 1 / d i l ]  a t  D 0  a n d  a  ≥  4 -f o l d  i n c r e a s e  i n  t i t e r  [ 1 / d i l ]  a t  
D 2 8 )  
• S e r o p r o t e c t i o n  ( t i t e r  ≥  4 0  [ 1 / d i l ] )  a t  D 0  a n d  D 2 8  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
P a g e  1 1  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  1 2  o f  7 7   Imm u n o g e n i c i t y  A s s e s sm e n t  b y  S N  ( f o r  t h e  E x p a n d e d  Imm u n o g e n ic i t y  
S u b s e t )  
N e u t r a l i z i n g  A b  t i t e r s  w i l l  b e  m e a s u r e d  f o r  e a c h  i n f l u e n z a  s t r a i n  w i t h  t h e  S N  
m e t h o d  i n  a  r a n d om l y  s e l e c t e d  s u b s e t  o f  s u b j e c t s  f r om  e a c h  s t u d y  g r o u p .  T h e y  
w i l l  b e  o b t a i n e d  o n  D 0  a n d  D 2 8 .   
• I n d i v i d u a l  n e u t r a l i z a t i o n  t e s t  ( N T )  A b  t i t e r  o n  D 0  a n d  D 2 8   
• I n d i v i d u a l  N T  A b  t i t e r  r a t i o  ( f o l d  i n c r e a s e  i n  s e r um  N T  p o s t -
v a c c i n a t i o n  r e l a t i v e  t o  D 0 )  a t  D 2 8   
• S u b j e c t s  w i t h  N T  A b  t i t e r s  ≥  2 0  ( 1 / d i l ) ,  ≥  4 0  ( 1 / d i l ) ,  ≥  8 0  ( 1 / d i l )  a t  
D 2 8   
• F o l d -i n c r e a s e  i n  N T  A b  t i t e r  [ p o s t / p r e ]  ≥ 2  a n d  ≥  4  a t  D 2 8   
• D e t e c t a b l e  N T  ( N T  A b  t i t e r  ≥  1 0  [ 1 / d i l ] )  a t  D 0  a n d  D 2 8  
S a f e t y  
S a f e t y  w i l l  b e  d e s c r i b e d  f o r  a l l  s u b j e c t s :  
• O c c u r r e n c e ,  n a t u r e  (M e d i c a l  D i c t i o n a r y  f o r  R e g u l a t o r y  A c t i v i t i e s  
[M e d D R A ]  p r e f e r r e d  t e rm  [ P T ] ) ,  d u r a t i o n ,  in t e n s i t y ,  a n d  r e l a t i o n s h i p  t o  
v a c c i n a t i o n  o f  a n y  u n s o l i c i t e d  s y s t em i c  A E s  r e p o r t e d  i n  t h e  3 0  m i n u t e s  a f t e r  
v a c c i n a t i o n .  
• O c c u r r e n c e ,  t im e  t o  o n s e t ,  n um b e r  o f  d a y s  o f  o c c u r r e n c e ,  i n t e n s i t y ,  a c t i o n  
t a k e n ,  a n d  w h e t h e r  t h e  r e a c t i o n  l e d  t o  e a r l y  t e rm i n a t i o n  f r om  t h e  t r i a l ,  o f  
s o l i c i t e d  ( p r e l i s t e d  i n  t h e  s u b j e c t ’ s  d i a r y  c a r d  a n d  C a s e  R e p o r t  B o o k  [ C R B ] )  
i n j e c t i o n  s i t e  r e a c t i o n s  a n d  s y s t em i c  r e a c t i o n s  o c c u r r i n g  u p  t o  7  d a y s  a f t e r  
v a c c i n a t i o n .  
• O c c u r r e n c e ,  n a t u r e  (M e d D R A  P T ) ,  t im e  t o  o n s e t ,  d u r a t i o n ,  i n t e n s i t y ,  
r e l a t i o n s h i p  t o  v a c c i n a t i o n  ( f o r  s y s t em i c  A E s  o n l y ) ,  a n d  w h e t h e r  t h e  e v e n t  
l e d  t o  e a r l y  t e rm i n a t i o n  f r om  t h e  t r i a l ,  o f  u n s o l i c i t e d  A E s  u p  t o  2 8  d a y s  a f t e r  
v a c c i n a t i o n .  
• O c c u r r e n c e ,  n a t u r e  (M e d D R A  P T ) ,  t im e  t o  o n s e t ,  s e r i o u s n e s s  c r i t e r i a ,  
r e l a t i o n s h i p  t o  v a c c i n a t i o n ,  o u t c om e ,  a n d  w h e t h e r  t h e  S A E  l e d  t o  e a r l y  
t e rm i n a t i o n  f r om  t h e  t r i a l ,  o f  S A E s  t h r o u g h o u t  t h e  t r i a l .  
• O c c u r r e n c e ,  n a t u r e  (M e d D R A  P T ) ,  a n d  r e l a t i o n s h i p  t o  v a c c i n a t i o n  o f  A E S I s  
t h r o u g h o u t  t h e  t r i a l . 
P l a n n e d  S am p l e  S i z e :  A  t o t a l  o f  2 6 1 6  s u b j e c t s  a r e  p l a n n e d  t o  b e  e n r o l l e d  a n d  r a n d om i z e d  i n  a  4 : 1 : 1  
r a t i o ,  a s  s h o w n  i n  T a b l e  S 1 .  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
P a g e  1 2  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 13 of 77  S1: QHD00013 Planned Sample Size  
 
QIV-HD TIV- HDs Total 
Subjects 
Enrolled  
 
QIV-HD TIV-
HD1  
(licensed 
TIV-HD) TIV- HD2  
(investigational 
TIV- HD with 
alternate B strain)   
Subjects to be 
Enrolled*  1744 [PHONE_2825] 
Expanded 
Immunogenicity 
Subset† 100 100 100 300 
*Safety data and serum samples for HAI testing will be collected for all 
subjects.  
† A randomized subset of subje cts from each group will be selected for SN 
testing.  
 
Schedule of Trial  Procedures:  Vaccination  
All eligible subjects will be randomized to receive a single injection of either the 
QIV-HD vaccine or one of the TIV -HD vaccines at D0.  
Blood Sampling  
All su bjects will provide a pre -vaccination blood sample at V01 (D0) and a post -
vaccination blood sample at V02 (D28 [+ 7 days]).  
Collection of Safety Data  
Subjects will be asked to notify the site immediately about any potential SAEs at any time during the trial. 
All subjects will be observed for [ADDRESS_141342] information about solicited reactions (D0 -D7), unsolicited 
AEs (D0 -V02), SAEs (D0 -V02), and AESIs (D0 -V02) in a diary card.  Subjects 
will record information about SAEs (V02 -D180 phone call) and AESIs (V02 -
D180 phone call) in a memory aid.  
 Staff will contact [CONTACT_125618] D8 post- vaccinat ion to identify whether 
the subject experienced any SAEs not yet reported and will remind the subjects to bring the completed diary card with them to V02.  
Staff will review the D0 to V02 safety data with subjects at V02.  
Subjects will continue to collect i nformation on SAEs and AESIs in a memory 
aid (from V02 -D180). Staff will contact [CONTACT_125619] D180 (+14 
days) post- vaccination to review the memory aid and to identify the occurrence 
of any SAEs that had not yet been reported.  
Duration of Part icipation in 
the Trial: The duration of each subject’s participation will be approximately 6  months (D0 
through D180).  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 13 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  1 4  o f  7 7  I n v e s t i g a t i o n a l  P r o d u c t :  H i g h -D o s e  I n f l u e n z a  V a c c i n e  Q u a d r i v a l e n t ,  ( Z o n a l  P u r i f i e d ,  S p l i t  V i r u s )  2 0 1 7 –
2 0 1 8  S t r a i n s  ( Q I V -H D )  
 F o rm :  L i q u i d ;  e s s e n t i a l l y  c l e a r  a n d  s l i g h t l y  o p a l e s c e n t  i n  c o l o r  
 C om p o s i t i o n :  E a c h  0 . 7  m L  d o s e  o f  Q I V -H D  w i l l  c o n t a i n :  
S t r a i n s  a r e  b a s e d  o n  W o r l d  H e a l t h  O r g a n i z a t i o n  (W H O )  /  V a c c i n e s  a n d  R e l a t e d  
B i o l o g i c a l  P r o d u c t s  A d v i s o r y  C o m m i t t e e  ( V R B P A C )  r e c o m m e n d a t i o n s  f o r  t h e  
2 0 1 7 -2 0 1 8  N H  i n f l u e n z a  s e a s o n .  
A c t i v e  s u b s t a n c e s :  
• A /M i c h i g a n / 4 5 / 2 0 1 5  ( H 1 N 1 )  s t r a i n    6 0  µ g  H A  
• A / H o n g  K o n g / 4 8 0 1 / 2 0 1 4  ( H 3 N 2 )  s t r a i n  6 0  µ g  H A  
• B / B r i s b a n e / 6 0 / 2 0 0 8  s t r a i n      6 0  µ g  H A  
• B / P h u k e t / 3 0 7 3 / 2 0 1 3  s t r a i n      6 0  µ g  H A  
E x c i p i e n t s :  
• B u f f e r e d  s a l i n e  s o l u t i o n      q u a n t i t y  s u f f i c i e n t  ( q s )  t o   
           a p p r o p r i a t e  v o l um e  
• O c t y l p h e n o l  E t h o x y l a t e  ( T r i t o n  X - 1 0 0 ®)  n o t  m o r e  t h a n  ( NM T )   
           3 5 0  µ g  
P r e s e r v a t i v e  i s  n o t  u s e d  i n  t h e  m a n u f a c t u r e  o f  Q I V -H D .  
 R o u t e :  I n t r am u s c u l a r  ( IM ) ,  i n j e c t e d  i n t o  t h e  u p p e r  a rm  a r e a  
 B a t c h  N um b e r :  T B D  
C o n t r o l  P r o d u c t  1 :  H i g h -d o s e  t r i v a l e n t  i n a c t i v a t e d  i n f l u e n z a  v a c c i n e  ( l i c e n s e d  F l u z o n e ® H i g h -D o s e ,  
T I V - H D 1 )  
 F o rm :  L i q u i d ;  e s s e n t i a l l y  c l e a r  a n d  s l i g h t l y  o p a l e s c e n t  i n  c o l o r  
 C om p o s i t i o n :  E a c h  0 . 5  m L  d o s e  o f  T I V -H D 1  w i l l  c o n t a i n :  
S t r a i n s  a r e  b a s e d  o n  W H O /  V R B P A C  r e c o m m e n d a t i o n s  f o r  t h e  2 0 1 7 -2 0 1 8  N H  
i n f l u e n z a  s e a s o n .  
A c t i v e  S u b s t a n c e s :  
• A /M i c h i g a n / 4 5 / 2 0 1 5  ( H 1 N 1 )  s t r a i n    6 0  µ g  H A  
• A / H o n g  K o n g / 4 8 0 1 / 2 0 1 4  ( H 3 N 2 )  s t r a i n  6 0  µ g  H A  
• B / B r i s b a n e / 6 0 / 2 0 0 8  s t r a i n      6 0  µ g  H A  
E x c i p i e n t s :  
• B u f f e r e d  s a l i n e  s o l u t i o n      q s  t o  a p p r o p r i a t e  v o l um e  
• O c t y l p h e n o l  E t h o x y l a t e  ( T r i t o n  X - 1 0 0 ®)  NM T  2 5 0  µ g  
P r e s e r v a t i v e  i s  n o t  u s e d  i n  t h e  m a n u f a c t u r e  o f  l i c e n s e d  T I V -H D 1 .  
 R o u t e :  IM ,  i n j e c t e d  i n t o  t h e  u p p e r  a rm  a r e a  
 B a t c h  N um b e r :  T B D  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
P a g e  1 4  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  1 5  o f  7 7  C o n t r o l  P r o d u c t  2 :  H i g h -d o s e  t r i v a l e n t  i n a c t i v a t e d  i n f l u e n z a  v a c c i n e  ( I n v e s t i g a t i o n a l  T I V -H i g h -
D o s e  w i t h  a l t e r n a t e  B  s t r a i n ,  T I V -H D 2 )  
 F o rm :  L i q u i d ;  e s s e n t i a l l y  c l e a r  a n d  s l i g h t l y  o p a l e s c e n t  i n  c o l o r  
 C om p o s i t i o n :  E a c h  0 . 5  m L  d o s e  o f  T I V -H D 2  w i l l  c o n t a i n :  
S t r a i n s  a r e  b a s e d  o n  W H O  /  V R B P A C  r e c o m m e n d a t i o n s  f o r  t h e  2 0 1 7 -2 0 1 8  N H  
i n f l u e n z a  s e a s o n .  
A c t i v e  S u b s t a n c e s :  
• A /M i c h i g a n / 4 5 / 2 0 1 5  ( H 1 N 1 )  s t r a i n    6 0  µ g  H A  
• A / H o n g  K o n g / 4 8 0 1 / 2 0 1 4  ( H 3 N 2 )  s t r a i n  6 0  µ g  H A  
• B / P h u k e t / 3 0 7 3 / 2 0 1 3  s t r a i n      6 0  µ g  H A  
E x c i p i e n t s :  
• B u f f e r e d  s a l i n e  s o l u t i o n      q s  t o  a p p r o p r i a t e  v o l um e  
• O c t y l p h e n o l  E t h o x y l a t e  ( T r i t o n  X - 1 0 0 ®)  NM T  2 5 0  µ g  
P r e s e r v a t i v e  i s  n o t  u s e d  i n  t h e  m a n u f a c t u r e  o f  T I V -H D 2 .  
 R o u t e :  IM ,  i n j e c t e d  i n t o  t h e  u p p e r  a rm  a r e a  
 B a t c h  N um b e r :  T B D  
I n c l u s i o n  C r i t e r i a :  A n  i n d i v i d u a l  m u s t  f u l f i l l  a l l  o f  t h e  f o l l o w i n g  c r i t e r i a  i n  o r d e r  t o  b e  e l i g i b l e  f o r  
t r i a l  e n r o l lm e n t :  
1 )  A g e d  ≥  6 5  y e a r s  o n  t h e  d a y  o f  i n c l u s i o n  
2 )  I n f o rm e d  c o n s e n t  f o rm  h a s  b e e n  s i g n e d  a n d  d a t e d  
3 )  A b l e  t o  a t t e n d  a l l  s c h e d u l e d  v i s i t s  a n d  t o  c om p l y  w i t h  a l l  t r i a l  p r o c e d u r e s  
E x c l u s i o n  C r i t e r i a  A n  i n d i v i d u a l  f u l f i l l i n g  a n y  o f  t h e  f o l l o w i n g  c r i t e r i a  i s  t o  b e  e x c l u d e d  f r om  t r i a l  
e n r o l lm e n t :  
1 )  P a r t i c i p a t i o n  a t  t h e  t im e  o f  t r i a l  e n r o l lm e n t  ( o r  i n  t h e  4  w e e k s  p r e c e d i n g  t h e  
t r i a l  v a c c i n a t i o n )  o r  p l a n n e d  p a r t i c i p a t i o n  d u r i n g  t h e  p r e s e n t  t r i a l  p e r i o d  i n  
a n o t h e r  c l i n i c a l  t r i a l  i n v e s t i g a t i n g  a  v a c c i n e ,  d r u g ,  m e d i c a l  d e v i c e ,  o r  
m e d i c a l  p r o c e d u r e  
2 )  R e c e i p t  o f  a n y  v a c c i n e  i n  t h e  4  w e e k s  ( 2 8  d a y s )  p r e c e d i n g  t h e  t r i a l  
v a c c i n a t i o n  o r  p l a n n e d  r e c e i p t  o f  a n y  v a c c i n e  p r i o r  t o  V 0 2  
3 )  P r e v i o u s  v a c c i n a t i o n  a g a i n s t  i n f l u e n z a  ( i n  t h e  p r e c e d i n g  6  m o n t h s )  w i t h  
e i t h e r  t h e  t r i a l  v a c c i n e  o r  a n o t h e r  v a c c i n e  
4 )  R e c e i p t  o f  imm u n e  g l o b u l i n s ,  b l o o d  o r  b l o o d -d e r i v e d  p r o d u c t s  i n  t h e  p a s t  
3  m o n t h s   
5 )  K n o w n  o r  s u s p e c t e d  c o n g e n i t a l  o r  a c q u i r e d  imm u n o d e f i c i e n c y ;  o r  r e c e i p t  
o f  imm u n o s u p p r e s s i v e  t h e r a p y ,  s u c h  a s  a n t i -c a n c e r  c h em o t h e r a p y  o r  
r a d i a t i o n  t h e r a p y ,  w i t h i n  t h e  p r e c e d i n g  6  m o n t h s ;  o r  l o n g -t e rm  s y s t em i c  
c o r t i c o s t e r o i d  t h e r a p y  ( p r e d n i s o n e  o r  e q u i v a l e n t  f o r  m o r e  t h a n  2  
c o n s e c u t i v e  w e e k s  w i t h i n  t h e  p a s t  3  m o n t h s )  
6 )  K n o w n  s y s t em i c  h y p e r s e n s i t i v i t y  t o  a n y  o f  t h e  v a c c i n e  c om p o n e n t s ,  o r  
h i s t o r y  o f  a  l i f e -t h r e a t e n i n g  r e a c t i o n  t o  t h e  v a c c i n e s  u s e d  i n  t h e  t r i a l  o r  t o  a  
v a c c i n e  c o n t a i n i n g  a n y  o f  t h e  s am e  s u b s t a n c e s  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
P a g e  1 5  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  1 6  o f  7 7   7 )  T h r om b o c y t o p e n i a  o r  b l e e d i n g  d i s o r d e r ,  c o n t r a i n d i c a t i n g  IM  v a c c i n a t i o n  
b a s e d  o n  i n v e s t i g a t o r ’ s  j u d gm e n t  
8 )  D e p r i v e d  o f  f r e e d om  b y  a n  a dm i n i s t r a t i v e  o r  c o u r t  o r d e r ,  o r  i n  a n  
em e r g e n c y  s e t t i n g ,  o r  h o s p i t a l i z e d  i n v o l u n t a r i l y  
 9 )  A l c o h o l  o r  s u b s t a n c e  a b u s e  t h a t ,  i n  t h e  o p i n i o n  o f  t h e  i n v e s t i g a t o r ,  m i g h t  
i n t e r f e r e  w i t h  t h e  t r i a l  c o n d u c t  o r  c om p l e t i o n  
1 0 )  C h r o n i c  i l l n e s s  t h a t ,  i n  t h e  o p i n i o n  o f  t h e  i n v e s t i g a t o r ,  i s  a t  a  s t a g e  w h e r e  i t  
m i g h t  i n t e r f e r e  w i t h  t r i a l  c o n d u c t  o r  c om p l e t i o n  
1 1 )  I d e n t i f i e d  a s  a n  I n v e s t i g a t o r  o r  em p l o y e e  o f  t h e  I n v e s t i g a t o r  o r  t r i a l  c e n t e r  
w i t h  d i r e c t  i n v o l v em e n t  i n  t h e  p r o p o s e d  t r i a l ,  o r  i d e n t i f i e d  a s  a n  imm e d i a t e  
f am i l y  m em b e r  ( i . e . ,  p a r e n t ,  s p o u s e ,  n a t u r a l  o r  a d o p t e d  c h i l d )  o f  t h e  
I n v e s t i g a t o r  o r  em p l o y e e  w i t h  d i r e c t  i n v o l v em e n t  i n  t h e  p r o p o s e d  t r i a l  
1 2 )  P e r s o n a l  o r  f am i l y  h i s t o r y  o f  G B S  
1 3 )  N e o p l a s t i c  d i s e a s e  o r  a n y  h em a t o l o g i c  m a l i g n a n c y  ( e x c e p t  l o c a l i z e d  s k i n  
o r  p r o s t a t e  c a n c e r  t h a t  i s  s t a b l e  a t  t h e  t im e  o f  v a c c i n a t i o n  i n  t h e  a b s e n c e  o f  
t h e r a p y  a n d  s u b j e c t s  w h o  h a v e  a  h i s t o r y  o f  n e o p l a s t i c  d i s e a s e  a n d  h a v e  
b e e n  d i s e a s e  f r e e  f o r  ≥  5  y e a r s )   
1 4 )  M o d e r a t e  o r  s e v e r e  a c u t e  i l l n e s s / i n f e c t i o n  ( a c c o r d i n g  t o  I n v e s t i g a t o r  
j u d gm e n t )  o n  t h e  d a y  o f  v a c c i n a t i o n  o r  f e b r i l e  i l l n e s s  ( t em p e r a t u r e  
≥  3 8 . 0 ° C  [ ≥  1 0 0 . 4 ° F ] ) .  A  p r o s p e c t i v e  s u b j e c t  s h o u l d  n o t  b e  i n c l u d e d  i n  t h e  
t r i a l  u n t i l  t h e  c o n d i t i o n  h a s  r e s o l v e d  o r  t h e  f e b r i l e  e v e n t  h a s  s u b s i d e d  
S t a t i s t i c a l  M e t h o d s :  T h e  s t a t i s t i c a l  a n a l y s e s  w i l l  b e  p e r f o rm e d  i n  2  s t e p s :  
1 )  T h e  f i r s t  s t e p  w i l l  b e  t h e  a n a l y s i s  o f  t h e  m a i n  H A I  imm u n o g e n i c i t y  a n d  
s a f e t y  r e s u l t s  o b t a i n e d  o n  d a t a  c o l l e c t e d  w i t h i n  a p p r o x im a t e l y  2 8  d a y s  
f o l l o w i n g  v a c c i n a t i o n  ( f r om  D 0  t o  V 02 ) .  T h e  s t u d y  b l i n d  w i l l  b e  b r o k e n  a t  
t h a t  t im e .  
2 )  T h e  s e c o n d  s t e p  w i l l  b e  a s s e s s i n g  t h e  r em a i n i n g  o b j e c t i v e s  o f  t h e  s t u d y .  
N o  s t a t i s t i c a l  a d j u s tm e n t  f o r  t h e  i n t e r im  a n a l y s i s  i s  n e c e s s a r y  b e c a u s e  t h e r e  a r e  
n o  p l a n n e d  r e p e a t  a n a l y s e s  o f  t h e  s am e  h y p o t h e s e s .  
T h e  P e r -P r o t o c o l  a n a l y s i s  s e t  ( P P A S )  a n d  F u l l  a n a l y s i s  s e t  ( F A S )  w i l l  b e  u s e d  
f o r  t h e  imm u n o g e n i c i t y  a n a l y s e s .  T h e  S a f e t y  a n a l y s i s  s e t  ( S a f A S )  w i l l  b e  u s e d  
f o r  a l l  s a f e t y  a n a l y s e s .  
F o r  t h e  p u r p o s e s  o f  t h e  s t a t i s t i c a l  m e t h o d s  s e c t i o n ,  t h e  4  v i r u s  s t r a i n s  i n  t h e  
Q I V -H D  t r i a l  g r o u p s  a n d  t h e  T I V -H D  t r i a l  g r o u p s  w i l l  b e  l a b e l e d  a s  f o l l o w s :  
• A /M i c h i g a n / 4 5 / 2 0 1 5  ( H 1 N 1 )  s t r a i n    A 1  
• A / H o n g  K o n g / 4 8 0 1 / 2 0 1 4  ( H 3 N 2 )  s t r a i n  A 2  
• B / B r i s b a n e / 6 0 / 2 0 0 8  s t r a i n      B 1  
• B / P h u k e t / 3 0 7 3 / 2 0 1 3  s t r a i n    B 2  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
P a g e  1 6  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  1 7  o f  7 7   P r im a r y  O b j e c t i v e  
Imm u n o g e n i c i t y  
N o n -i n f e r i o r i t y  o f  Q I V -H D  t o  T I V -H D 1  a n d / o r  T I V -H D 2  
T h e  imm u n o g e n i c i t y  o f  Q I V -H D  w i l l  b e  c om p a r e d  t o  t h a t  o f  T I V -H D 1  
a n d  /  o r  T I V -H D 2 .  F o r  e a c h  A  s t r a i n ,  t h e  c om p a r i s o n  w i l l  b e  m a d e  w i t h  
t h e  p o o l e d  T I V -H D  g r o u p s .  F o r  e a c h  B  s t r a i n ,  t h e  c om p a r i s o n  w i l l  b e  
m a d e  w i t h  t h e  T I V -H D  g r o u p  c o n t a i n i n g  t h e  c o r r e s p o n d i n g  B  s t r a i n .   
 F o r  e a c h  s t r a i n ,  a  n o n -i n f e r i o r i t y  a p p r o a c h  w i l l  b e  u s e d  t o  c om p a r e  t h e  
p o s t -v a c c i n a t i o n  GM T s  a n d  t h e  s e r o c o n v e r s i o n  r a t e s  b e t w e e n  t h e  g r o u p s  
u s i n g  a  1 -s i d e d  T y p e  I  e r r o r  r a t e  o f  0 . 0 2 5  w i t h  t h e  g i v e n  i n d i v i d u a l  
h y p o t h e s i s :  
 
•  
 
 
•  
 
w i t h :   
• s :  s t r a i n  i n  { A 1 ,  A 2 ,  B 1  a n d  B 2 }  
• I f  s  i n  { A 1  a n d  A 2 } ,  T I V -H D  r e p r e s e n t s  t h e  p o o l e d  T I V -H D 1  a n d  T I V -
H D 2  g r o u p s   
• I f  s  =  B 1 ,  T I V -H D  r e p r e s e n t s  t h e  T I V -H D 1  g r o u p   
• I f  s  =  B 2 ,  T I V -H D  r e p r e s e n t s  t h e  T I V -H D 2  g r o u p   
• :  T h e  s e r o c o n v e r s i o n  r a t e  
 T h e  s t a t i s t i c a l  m e t h o d o l o g y  w i l l  b e  b a s e d  o n  t h e  u s e  o f  t h e  2 -s i d e d  9 5%  
c o n f i d e n c e  i n t e r v a l s  ( C I s )  o f  t h e  r a t i o  o f  p o s t -v a c c i n a t i o n  GM T s  a n d  d i f f e r e n c e  
i n  s e r o c o n v e r s i o n  r a t e s  b e t w e e n  Q I V -H D  a n d  T I V -H D  g r o u p s .  T h e  9 5%  C I s  
w i l l  b e  c a l c u l a t e d  b y  n o rm a l  a p p r o x im a t i o n  o f  l o g -t r a n s f o rm e d  t i t e r s  f o r  GM T s  
a n d  b y  t h e  N e w c om b e -W i l s o n  s c o r e  m e t h o d  w i t h o u t  c o n t i n u i t y  c o r r e c t i o n  f o r  
s e r o c o n v e r s i o n  r a t e s .  T h e  m a r g i n s  u s e d  f o r  h y p o t h e s i s  t e s t i n g  a r e  1 . 5  f o r  GM T s  
a n d  1 0%  f o r  s e r o c o n v e r s i o n  r a t e s  t o  d em o n s t r a t e  n o n -i n f e r i o r i t y .  
T h e  n o n -i n f e r i o r i t y  o b j e c t i v e  w i l l  b e  a c h i e v e d  o n l y  i f  i t  i s  d em o n s t r a t e d  f o r  4  
s t r a i n s  a n d  f o r  b o t h  GM T s  a n d  s e r o c o n v e r s i o n  r a t e s .  A n a l y s e s  w i l l  b e  p e r f o rm e d  
f o r  b o t h  F A S  a n d  P P A S ,  b u t  t h e  c o n c l u s i o n  w i l l  b e  m a d e  f r om  P P A S  r e s u l t s .  
A  s e n s i t i v i t y  a n a l y s i s  w i l l  b e  p e r f o rm e d  w i t h  a d j u s tm e n t  o n  t h e  p r e -v a c c i n a t i o n  
H A I  t i t e r s .  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
P a g e  1 7  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  1 8  o f  7 7   S e c o n d a r y  O b j e c t i v e s  
Imm u n o g e n i c i t y  
S u p e r i o r i t y  o f  Q I V -H D  t o  T I V -H D 1  o r  T I V -H D 2   
T h e  s u p e r i o r i t y  a n a l y s e s  w i l l  b e  d em o n s t r a t e d  i n  a l l  s u b j e c t s .  F o r  e a c h  B  s t r a i n ,  
t h e  imm u n o g e n i c i t y  o f  Q I V -H D  w i l l  b e  c om p a r e d  t o  t h a t  o f  T I V -H D  g r o u p  
w h i c h  d o e s  n o t  c o n t a i n  t h e  c o r r e s p o n d i n g  B  s t r a i n .  
A  s u p e r i o r i t y  a p p r o a c h  w i l l  b e  u s e d  t o  c om p a r e  p o s t -v a c c i n a t i o n  GM T s  a n d  
s e r o c o n v e r s i o n  r a t e s  b e t w e e n  g r o u p s  u s i n g  a  1 -s i d e d  t e s t  w i t h  T y p e  I  e r r o r  r a t e  
o f  0 . 0 2 5  f o l l o w i n g  t h e  i n d i v i d u a l  h y p o t h e s e s :  
 
•  
 
 
•  
 
w i t h :   
• s :  s t r a i n  i n  { B 1  a n d  B 2 }  
• I f  s  =  B 1 ,  T I V -H D  r e p r e s e n t s  t h e  T I V -H D 2  g r o u p   
• I f  s  =  B 2 ,  T I V -H D  r e p r e s e n t s  t h e  T I V -H D 1  g r o u p   
:  T h e  s e r o c o n v e r s i o n  r a t e  
 T h e  s t a t i s t i c a l  m e t h o d o l o g y  w i l l  b e  b a s e d  o n  t h e  u s e  o f  t h e  2 -s i d e d  9 5%  C I  o f  
t h e  r a t i o  o f  p o s t -v a c c i n a t i o n  GM T s  a n d  d i f f e r e n c e  i n  s e r o c o n v e r s i o n  r a t e s  
b e t w e e n  t h e  Q I V -H D  g r o u p  a n d  T I V -H D  g r o u p .  T h e  9 5%  C I s  w i l l  b e  c a l c u l a t e d  
u s i n g  n o rm a l  a p p r o x im a t i o n  o f  l o g -t r a n s f o rm e d  t i t e r s  f o r  GM T s  a n d  u s i n g  t h e  
N e w c om b e -W i l s o n  s c o r e  m e t h o d  w i t h o u t  c o n t i n u i t y  c o r r e c t i o n  f o r  
s e r o c o n v e r s i o n  r a t e s .  F o r  e a c h  s t r a i n ,  t h e  2 -s i d e d  9 5%  C I  s h o u l d  l i e  a b o v e  1 . 5  
f o r  GM T s  a n d  a b o v e  1 0%  f o r  s e r o c o n v e r s i o n  r a t e s .  
T h e  s u p e r i o r i t y  o b j e c t i v e  w i l l  b e  a c h i e v e d  i f  t h e  s u p e r i o r i t y  i s  d em o n s t r a t e d  f o r  
b o t h  B  s t r a i n s  a n d  f o r  b o t h  GM T s  a n d  s e r o c o n v e r s i o n  r a t e s .  A n a l y s e s  w i l l  b e  
p e r f o rm e d  f o r  b o t h  F A S  a n d  P P A S  b u t  t h e  c o n c l u s i o n  w i l l  b e  m a d e  f r om  F A S  
r e s u l t s .  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
P a g e  1 8  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  1 9  o f  7 7   I m m u n o g e n i c i t y  b y  H A I  M e t h o d  
T h e  p e r c e n t a g e s  o f  s u b j e c t s  a c h i e v i n g  s e r o p r o t e c t i o n  a n d  t h e  c o r r e s p o n d i n g  
9 5%  C I s  ( C l o p p e r -P e a r s o n  m e t h o d )  w i l l  b e  p e r f o rm e d  f o r  p r e -v a c c i n a t i o n  ( V 0 1 )  
a n d  p o s t -v a c c i n a t i o n  imm u n o g e n i c i t y  ( V 0 2 ) .  T h e  g e om e t r i c  m e a n  t i t e r  r a t i o s  
( GM T R s )  w i l l  b e  c a l c u l a t e d  f o r  p o s t -v a c c i n a t i o n  imm u n o g e n i c i t y  ( V 0 2 )  o v e r  t h e  
b a s e l i n e  imm u n o g e n i c i t y  ( V 0 1 )  w i t h  t h e  c o r r e s p o n d i n g  9 5%  C I s  ( a s s um i n g  
n o rm a l  a p p r o x im a t i o n  o f  l o g -t r a n s f o rm e d  v a l u e s ) .  R e v e r s e  c um u l a t i v e  
d i s t r i b u t i o n  c u r v e s  ( R C D C s )  a g a i n s t  e a c h  s t r a i n  w i l l  b e  p e r f o rm e d  f o r  b a s e l i n e  
( V 0 1 )  a n d  p o s t -v a c ci n a t i o n  imm u n o g e n i c i t y  ( V 0 2 ) .  A d d i t i o n a l  p a r am e t e r s  m a y  
b e  d i s p l a y e d  a s  a p p r o p r i a t e .  
I m m u n o g e n i c i t y  b y  S N  M e t h o d  
Imm u n o g e n i c i t y  i n  t e rm s  o f  GM T s ,  s e r o c o n v e r s i o n ,  a n d  p e r c e n t  o f  s u b j e c t s  w i t h  
GM T s  ≥  1 / 4 0  [ d i l ]  w i l l  b e  s umm a r i z e d  a l o n g  w i t h  t h e i r  9 5%  C I s  f o r  p o s t -
v a c c i n a t i o n  imm u n o g e n i c i t y  ( V 0 2 )  i n  t h e  E x p a n d e d  Imm u n o g e n i c i t y  S u b s e t .  
T h e  n o rm a l  a p p r o x im a t i o n  o f  l o g -t r a n s f o rm e d  t i t e r s  w i l l  b e  a p p l i e d  t o  c a l c u l a t e  
t h e  9 5%  C I s  f o r  GM T s .  T h e  9 5%  C I s  w i l l  b e  c a l c u l a t e d  u s i n g  C l o p p e r -P e a r s o n  
m e t h o d  f o r  p e r c e n t a g e s .  T h e  g e om e t r i c  m e a n  t i t e r  r a t i o s  ( GM T R s )  w i l l  b e  
c a l c u l a t e d  f o r  p o s t -v a c c i n a t i o n  imm u n o g e n i c i t y  ( V 0 2 )  o v e r  t h e  b a s e l i n e  
imm u n o g e n i c i t y  ( V 0 1 )  w i t h  t h e  c o r r e s p o n d i n g  9 5%  C I s  ( a s s um i n g  n o rm a l  
a p p r o x im a t i o n  o f  l o g -t r a n s f o rm e d  v a l u e s ) .  R e v e r s e  c um u l a t i v e  d i s t r i b u t i o n  
c u r v e s  ( R C D C s )  a g a i n s t  e a c h  s t r a i n  w i l l  b e  p e r f o rm e d  f o r  b a s e l i n e  ( V 0 1 )  a n d  
p o s t -v a c ci n a t i o n  imm u n o g e n i c i t y  ( V 0 2 ) .  A d d i t i o n a l  p a r am e t e r s  m a y  b e  
d i s p l a y e d  a s  a p p r o p r i a t e .  
S a f e t y  
S a f e t y  r e s u l t s  w i l l  b e  a n a l y z e d  d e s c r i p t i v e l y  f o r  s u b j e c t s  i n  S a f A S  w h o  r e c e i v e d  
o n e  o f  t h e  v a c c i n e s .  S o l i c i t e d  r e a c t i o n s  ( s o l i c i t e d  i n j e c t i o n  s i t e  a n d  s y s t em i c  
r e a c t i o n s ) ,  u n s o l i c i t e d  A E s ,  S A E s ,  a n d  A E S I s  w i l l  b e  s umm a r i z e d .  T h e  m a i n  
p a r am e t e r s  w i l l  b e  d e s c r i b e d  w i t h  9 5%  C I s  ( C l o p p e r -P e a r s o n  m e t h o d ) .  
C a l c u l a t i o n  o f  S am p l e  S i z e  
A  t o t a l  o f  2 6 1 6  a d u l t s  a g e d  6 5  y e a r s  a n d  o l d e r  w i l l  b e  e n r o l l e d .  A  s am p l e  s i z e  o f  
2 6 1 6  i s  d e t e rm i n e d  b a s e d  o n  a n  o v e r a l l  p o w e r  o f  9 0%  f o r  d em o n s t r a t i n g  n o n -
i n f e r i o r i t y  f o r  b o t h  t h e  H A I  GM T s  a n d  s e r o c o n v e r s i o n  r a t e s  c om p a r i n g  Q I V -H D  
v s  T I V -H D 1  a n d  /  o r  T I V -H D 2  f o r  a l l  4  v i r u s  s t r a i n s .  T h e  n o n -i n f e r i o r i t y  
m a r g i n s  a r e  d e f i n e d  a s  1 . 5  f o r  GM T s  a n d  1 0%  f o r  s e r o c o n v e r s i o n  r a t e s .   
 A s s um p t i o n s  f o r  t h e  a b o v e  c a l c u l a t i o n s  a r e :  
• T h e  e x p e c t e d  s e r o c o n v e r s i o n  r a t e s  f o r  t h e  4  s t r a i n s :  4 5%  f o r  A 1  s t r a i n ,  7 0%  
f o r  A 2  s t r a i n ,  a n d  4 0%  f o r  b o t h  B  s t r a i n s .   
• A s s um e d  s t a n d a r d  d e v i a t i o n s  f o r  H A I  GM T s  a r e  0 . 6 3  f o r  b o t h  A  s t r a i n s  a n d  
0 . 5 5  f o r  b o t h  B  s t r a i n s .   
• A n  8%  a t t r i t i o n  r a t e  w h i c h  p r o v i d e s  a p p r o x im a t e l y  2 4 0 7  e v a l u a b l e  a d u l t s  
f o r  imm u n o g e n i c i t y  a n a l y s i s  ( P P A S ) .  
B a s e d  o n  c u r r e n t  s am p l e  s i z e ,  t h e r e  i s  5 5 . 4%  p o w e r  t o  d e t e c t  t h e  s u p e r i o r i t y  o f  
e a c h  B  s t r a i n  c om p a r i n g  Q I V -H D  g r o u p s  v e r s u s  e i t h e r  t h e  T I V -H D 1  o r  T I V -
H D 2  g r o u p  i n  t h e  s e c o n d a r y  o b j e c t i v e .  I t  i s  b a s e d  o n  a n  a s s um p t i o n  o f  e x p e c t e d  
GM T  r a t i o  o f  1 . 8  w i t h  a  s t a n d a r d  d e v i a t i o n  o f  0 . 5 5 ,  s e r o c o n v e r s i o n  r a t e  o f  8%  i n  
t h e  g r o u p  w i t h o u t  t h e  B  s t r a i n  a n d  2 2%  i n c r e a s e  i n  t h e  g r o u p  w i t h  t h e  B  s t r a i n ,  
a n d  a  5%  a t t r i t i o n  r a t e  i n  F A S .  
A  s u b s e t  o f  3 0 0  s u b j e c t s  w i t h  1 0 0  s u b j e c t s  f r om  e a c h  s t u d y  g r o u p  w i l l  b e  
r a n d om l y  s e l e c t e d  f o r  S N  t e s t i n g .  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
 
P a g e  1 9  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141343] 
Visit/Contact  [CONTACT_4838] 1 D8 Telephone 
Call  Visit 2 D180 Safety Follow -
up Call 
Trial timelines (days)  D0 D08 D28 D180 
Time windows (days)  NA [+2D]  [+7D]  [+14D]  
Informed consent  X    
Inclusion/exclusion criteria  X    
Demographic data  X    
History of seasonal influenza vaccination  X    
Medical history  X    
Reportable concomitant medications  X    
Physical examination * X    
Randomization/allocation of subje ct number 
and unique dose number  X    
Blood sampling (BL), 10 mL  BL1†  BL2  
Vaccination  X    
Immediate surveillance (30 min)  X    
Diary card provided‡ X    
Recording of solicited injection site & systemic 
reactions  D0-D7    
Follow -up phone call  X§  X** 
Collection of unsolicited AEs  D0-V02  
Diary card collected and reviewed    X  
Memory Aid provided††   X  
Memory Aid reviewed    X 
Trial  active phase termination record    X  
Reporting of SAEs and AESIs‡‡ To be reported at any time during the trial 
* Targeted physical examination based on medical history  will be performed at V01. Targeted physical examination may also 
be performed at V02, as necessary . 
† Collection of the first blood sample (BL1) before vaccination. 
‡ Subjects will use this diary ca rd to record information about solicited reactions, unsolicited AEs, SAEs, and AESIs from D0 
to D7 after vaccination and will continue to record information about unsolicited AEs, SAEs, and AESIs from D8 
to Visit (V) 02.  
§ During this phone call, staff will find out whether the subject experienced any SAEs and AESIs not yet reported and will 
remind the subjects to bring the completed diary card to V02.  
** During this phone call, staff will review the memory aid and to identify the occurrence of any SAEs and AESIs that had not 
yet been reported.  
†† Subjects will use this memory aid to collect information on SAEs and AESIs from V02 to the D180 Safety Follow -up Call.  
‡‡ AESIs will be captured as SAEs. These include new onset of Guillain -Barré Syndrome, encepha litis / myelitis (including 
transverse myelitis), Bell’s Palsy, optic neuritis, and brachial neuritis.  
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 20 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141344]  
CDM  Clinical Data Management  
CI confidence interval 
CQA  Clinical Quality Assessment 
CRA Clinical Research Associate 
CRB (electronic) case report book [all the case report forms for a subject]  
CRF (electronic) case report form  
CTA clinical trial agreement  
CTL  Clinical Team Leader  
D Day 
DS drug substance  
EDC  electronic data capture  
ELISA  enzyme linked immunosorbent assay  
FAS full analysis set  
FDA  Food and Drug Administration  
FVFS first visit, first subject 
FVLS first visit, las t subject  
GBS  Guillain-Barré syndrome  
GCI Global Clinical Immunology 
GCP  Good Clinical Practice  
GM geometric mean  
GMT  geometric mean titer 
GPE Global Pharmaco vigilance & Epi[INVESTIGATOR_125607] i nhibition  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
IRB Institutional Review Board  
IRT interactive response technology  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 21 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141345] -dose trivalent influenza vaccine 
TMF trial master file 
ULOQ  upper limit of quantification 
VRBPAC Vaccines and Related Biological Products Advisory Committee  
V Visit  
WHO  World Health Organization  
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 22 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 23 of 77 1 Introduction 
1.1 Background 
This trial wil l evaluate the safety and immunogenicity of high-dose quadrivalent influenza vaccine 
(QIV -HD) administered by [CONTACT_33813] (IM) route in subjects aged 65 years and older. 
Influenza is a highly contagious, acute viral respi[INVESTIGATOR_35263] A and 
type B viruses. Typi[INVESTIGATOR_35265], myalgia, sore throat, and non-productive cough, influenza can also cause severe malaise lasting for several days. Members of high risk groups (e.g., adults aged 65 years and older and persons with underlying medical conditions) are at high risk of influenza and its complications including primary viral pneumonia, 
secondary bacterial pneumonia, and/or exacerbation of underlying medical conditions such as chronic obstructive pul monary disease and congestive heart failure (1) (2).  
Vaccination currently represents the most effective medical intervention against influenza. The World Health Organization ( WHO ) (the Advisory Committee on Immunization Practices [ACIP] 
in the US) recommends annual vaccination against influenza because it has been shown to be effective in reducing influenza-associated morbidity and mortality (1) (3). The effectiveness of the 
influenza vaccine in preventing or attenuating illness depends in part on the age and immune competence of the vaccine recipi[INVESTIGATOR_841].  
Standard trivalent influenza vaccines (TIVs) administered by [CONTACT_125620] (IM) route (hereafter referred to as standard -dose TIV [TIV -SD]) contain 15 µg hemagglutinin (HA) of each 
of the 3 virus strains recommended by [CONTACT_125621] ( VRBPAC) for use in the upcoming influenza season, for a total of 45 µg of HA 
antigen per dose. Despi[INVESTIGATOR_125608], adults aged 65 years and older remain at increased risk for influenza because t heir immune response to a TIV -SD (15  µg/strain/dose) is 
lower tha n the immune response generated in younger healthy adults. Thus, Fluzone
® High -Dose 
vaccine (hereafter referred to as TIV -HD), containing 60 µg HA of each of the 3 virus strains (4-
times more antigen than the TIV -SD, for a total of 180 µg of HA antigen per dose), was 
developed and subsequently licensed by [CONTACT_125622] 65  years and older  (4). 
In parallel, to reduce the risk of B -lineage mismatch and offer broader protection against seasonal 
influenza virus strains, [COMPANY_011] Pasteur has been  transitioning the influenza vaccines portfolio from 
trivalent to quadrivalent formulations with the launch of Fluzone
® Quadrivalent (a quadrivalent 
standard -dose influenza vaccine administered via IM  route [hereafter referred to as QIV -SD] for 
persons aged 6 months and older, licensed in the US in 2013). In contrast to TIVs, which contain only one B- strain, the QIVs contain two B strains, one from each of the Victoria and Yamagata 
lineages, which have been co-circulating globally since the early 2000s. Thus, QIVs offer protection against both lineages simultaneously and reduce the risk of lack of protection against 
the alternate B lineage.   
Thus, the goal of the QIV- HD project is to license a seasonal quadrivalent influenza high -dose 
vaccine for adults a ged 65 years and older for IM administration . 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 23 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141346]  
[COMPANY_011] Pasteur’s TIV -HD, containing 60 µg  HA of each of the 3 virus strains (4 -times  more than 
the TIV -SD), for a total of 180 µg of HA antigen per dose, was developed and subsequently 
licensed by [CONTACT_125623] 2009 and Canada in 2015 in order to improve immune 
responses to the influenza vaccine in people 65 years of age and older  (4). In a large scale, 
multicenter efficacy trial (FIM12) conducted during the 2011-2012 and 2012-2013 influenza 
seasons in the Northern Hemisphere (NH), TIV -HD was com pared to TIV-SD in adults aged  
65 years and older. This efficacy study concluded that TIV- HD is safe, induces significantly 
higher antibody (Ab) responses, and was 24.2% (95% confidence interval [CI], 9.7 to 36.5) more 
effective in preventing laboratory- confirmed influenza illness against any circulating strain 
compared to the TIV-SD vaccine, or in other words, one in four breakthrough cases of influenza 
could be prevented if TIV- HD were used instead of the TIV -SD vaccine in this population (5). 
Additionally , relative efficacy was 35.4%  (95% CI, 12.5 to 52.5) in an analysis restricted to 
influ enza cases caused by [CONTACT_29298] -similar strains.  
Until recently, influenza vaccines contained a single influenza B strain. Two distinct genetic lineages of influenza B virus (the Victoria and the Yamagata lineages) have been co -circulating 
worldwide; both ar e responsible for influenza illnesses. However, the B strain included in 
seasonal influenza vaccines was not the dominant circulating B lineage (mismatched strains) in approximately 25% of the seasons between 2000 and 2013 (6). To overcome the problem of B-strain selection and improve protection of the population against seasonal influenza vi rus strains, 
[COMPANY_011] Pasteur has been transitioning the Fluzone influenza vaccine portfolio from trivalent to quadrivalent formulations. The quadrivalent formulations contain 1 Victoria lineage B strain and 1 Yamagata lineage B strain. Thus, the issue of ha ving to choose a strain from only one B lineage 
for the seasonal influenza vaccine and the resulting risk posed by [CONTACT_35315] a strain from the alternate B lineage is eliminated  (7).  
An unmet need in adults aged [ADDRESS_141347] s who will receive one of the controls (TIV -HD1  [the licensed vaccine containing the B 
strain from the primary lineage] or TIV -HD2 [the investigational vaccine containing the B strain 
from the alternate lineage) will be vaccinated against the influenza A/H 1N1 and A/H3N2  strains,  
as well as a B -strain from the primary or alternate lineage,  which are chosen by [CONTACT_120055] / VRBPAC 
for TIVs for the 2017- 2018 NH season.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 24 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  2 5  o f  7 7  S u b j e c t s  w h o  w i l l  r e c e i v e  t h e  i n v e s t i g a t i o n a l  v a c c i n e  ( Q I V -H D )  w i l l  b e n e f i t  f r om  v a c c i n a t i o n  
a g a i n s t  t h e  s am e  i n f l u e n z a  A  s t r a i n s  c o n t a i n e d  i n  T I V - H D 1  a n d  T I V - H D 2 .  I n  a d d i t i o n ,  t h e s e  
s u b j e c t s  w i l l  b e n e f i t  f r om  v a c c i n a t i o n  a g a i n s t  t h e  B  s t r a i n s  f r om  b o t h  t h e  V i c t o r i a  a n d  Y am a g a t a  
l i n e a g e s  c h o s e n  a n d  r e c omm e n d e d  b y  W H O  /  V R B P A C  f o r  t h e  c om p o s i t i o n  o f  Q I V s  f o r  t h e  
2 0 1 7 - 2 0 1 8  N H  s e a s o n .  
R e g a r d i n g  imm u n o g e n i c i t y ,  t h e  i n v e s t i g a t i o n a l  Q I V -H D  i s  e x p e c t e d  t o  i n d u c e  a n  e f f e c t i v e  
imm u n e  r e s p o n s e  a g a i n s t  4  i n f l u e n z a  s t r a i n s ,  c om p a r a b l e  t o  t h e  3  s t r a i n s  c o v e r e d  b y  T I V -H D .  
T h e r e f o r e ,  t h e  i n v e s t i g a t i o n a l  Q I V - H D  i s  l i k e l y  t o  b r i n g  a n  i n c r e a s e d  b e n e f i t  v e r s u s  T I V -H D  i n  
t e rm s  o f  imm u n o g e n i c i t y  a g a i n s t  i n f l u e n z a  B  v i r u s  a n d  w i t h  a  r i s k - b e n e f i t  p r o f i l e  o f  Q I V - H D  t h a t  
i s  e x p e c t e d  t o  r em a i n  f a v o r a b l e ,  w i t h o u t  a n y  im p a c t  o n  i t s  s a f e t y  p r o f i l e .  
1 . 3 . 2  P o t e n t i a l  R i s k s  t o  S u b j e c t s  
A s  w i t h  a n y  v a c c i n e ,  Q I V - H D  m a y  n o t  p r o t e c t  a l l  r e c i p i e n t s  a g a i n s t  t h e  d i s e a s e  i t  i s  d e s i g n e d  t o  
p r e v e n t  ( i . e . ,  i n f l u e n z a ) .  S e e  b e l o w  f o r  o t h e r  p o t e n t i a l  r i s k s .  
P o s s i b l e  R e a c t i o n s  t o  B l o o d  D r a w  
V e n i p u n c t u r e  c a u s e s  t r a n s i e n t  d i s c om f o r t  a n d  m a y  c a u s e  t em p o r a r y  h y p o t e n s i o n  f r om  a  v a s o v a g a l  
r e s p o n s e  ( e . g . ,  f a i n t i n g ) .  I f  p r e s s u r e  i s  n o t  a p p l i e d  l o n g  e n o u g h  t o  t h e  v e n i p u n c t u r e  s i t e ,  b r u i s i n g  
d u e  t o  b l e e d i n g  b e n e a t h  t h e  s k i n  m a y  o c c u r .  I n f e c t i o n  a t  t h e  s i t e  o f  n e e d l e  i n s e r t i o n  c o u l d  
t h e o r e t i c a l l y  o c c u r  b u t  i s  e x c e e d i n g l y  r a r e  w h e n  t h e  s t a n d a r d  s t e r i l e  t e c h n i q u e  i s  u t i l i z e d .  
P o s s i b l e  R e a c t i o n s  t o  V a c c i n a t i o n  
V a c c i n e  i n j e c t i o n  i n t o  t h e  u p p e r  a rm  m u s c l e  c a u s e s  t r a n s i e n t  d i s c om f o r t .  Imm e d i a t e  a n d  
p o t e n t i a l l y  l i f e -t h r e a t e n i n g  a l l e r g i c  r e a c t i o n s  t o  t h e  v a c c i n e  c o u l d  b e  m a n i f e s t e d  b y  a d v e r s e  e v e n t s  
(A E s )  s u c h  a s  l a r y n g e a l  e d em a ,  a s t hm a ,  o r  h y p o t e n s i o n .  T h e s e  t y p e s  o f  r e a c t i o n s  a r e  e x c e e d i n g l y  
r a r e  a n d  w o u l d  m o s t  l i k e l y  o c c u r  i n  p e r s o n s  w i t h  a  s e v e r e  r e a c t i o n  t o  i n f l u e n z a  v a c c i n e  i n  t h e  p a s t .  
P o s t -m a r k e t i n g  E x p e r i e n c e  w i t h  Q I V -S D  ( F l u z o n e  Q u a d r i v a l e n t ) ,  T I V - H D  ( F l u z o n e  
H i g h - D o s e ) ,  a n d  T I V - S D  ( F l u z o n e )  
T h e r e  i s  n o  p o s t - m a r k e t i n g  e x p e r i e n c e  f o r  Q I V -H D  a s  i t  h a s  n o t  b e e n  l i c e n s e d  y e t .  
P o s t -m a r k e t i n g  e x p e r i e n c e  w i t h  Q I V -S D  a n d  T I V - H D  h a s  n o t  i d e n t i f i e d  a n y  e v e n t s  o t h e r  t h a n  
t h o s e  d e s c r i b e d  b e l o w ,  w h i c h  w e r e  s p o n t a n e o u s l y  r e p o r t e d  d u r i n g  t h e  p o s t - a p p r o v a l  u s e  o f  
T I V - S D ,  f o r  a d d i t i o n  t o  t h e  Q I V - S D  p a c k a g e  i n s e r t  ( 8 ) .  
T h e  f o l l o w i n g  e v e n t s  h a v e  b e e n  s p o n t a n e o u s l y  r e p o r t e d  d u r i n g  t h e  p o s t - a p p r o v a l  u s e  o f  T I V - S D  
a n d  T I V - H D  ( 9 ) .  T h e s e  e v e n t s  a r e  r e p o r t e d  v o l u n t a r i l y  f r om  a  p o p u l a t i o n  o f  u n c e r t a i n  s i z e ,  
c o n s e q u e n t l y  i t  i s  n o t  a l w a y s  p o s s i b l e  t o  r e l i a b l y  e s t im a t e  t h e  f r e q u e n c y  o f  t h e  e v e n t s  o r  e s t a b l i s h  
a  c a u s a l  r e l a t i o n s h i p  t o  v a c c i n e  e x p o s u r e .  A E s  w e r e  i n c l u d e d  b a s e d  o n  o n e  o r  m o r e  o f  t h e  
f o l l o w i n g  f a c t o r s :  s e v e r i t y ,  f r e q u e n c y  o f  r e p o r t i n g ,  o r  s t r e n g t h  o f  e v i d e n c e  f o r  a  c a u s a l  
r e l a t i o n s h i p  t o  T I V -S D :  
• B l o o d  a n d  L y m p h a t i c  S y s t e m  D i s o r d e r s :  t h r om b o c y t o p e n i a ,  l ym p h a d e n o p a t h y  
• I m m u n e  S y s t e m  D i s o r d e r s S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
:  a n a p h y l a x i s ,  o t h e r  a l l e r g i c / h y p e r s e n s i t i v i t y  r e a c t i o n s  ( i n c l u d i n g  
u r t i c a r i a ,  a n g i o e d em a )  
P a g e  2 5  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  2 6  o f  7 7  N o t e :  T h i s  t y p e  o f  r e a c t i o n  i s  r a r e  a n d  w o u l d  m o s t  l i k e l y  o c c u r  i n  p e r s o n s  w i t h  a  s e v e r e  
r e a c t i o n  t o  i n f l u e n z a  v a c c i n e  i n  t h e  p a s t .  
• E y e  D i s o r d e r s :  o c u l a r  h y p e r em i a  
• N e r v o u s  S y s t e m  D i s o r d e r s :  G u i l l a i n -B a r r é  s y n d r om e  ( G B S ) ,  c o n v u l s i o n s ,  f e b r i l e  c o n v u l s i o n s ,  
m y e l i t i s  ( i n c l u d i n g  e n c e p h a l om y e l i t i s  a n d  t r a n s v e r s e  m y e l i t i s ) ,  f a c i a l  p a l s y  ( B e l l ’ s  p a l s y ) ,  
o p t i c  n e u r i t i s / n e u r o p a t h y ,  b r a c h i a l  n e u r i t i s ,  s y n c o p e  ( s h o r t l y  a f t e r  v a c c i n a t i o n ) ,  d i z z i n e s s ,  
p a r e s t h e s i a  
• V a s c u l a r  D i s o r d e r s :  v a s c u l i t i s ,  v a s o d i l a t i o n / f l u s h i n g  
• R e s p i r a t o r y ,  T h o r a c i c  a n d  M e d i a s t i n a l  D i s o r d e r s :  d y s p n e a ,  p h a r y n g i t i s ,  r h i n i t i s ,  c o u g h ,  
w h e e z i n g ,  t h r o a t  t i g h t n e s s  
• S k i n  a n d  S u b c u t a n e o u s  T i s s u e  D i s o r d e r s :  S t e v e n - J o h n s o n  s y n d r om e  
• G e n e r a l  D i s o r d e r s  a n d  A d m i n i s t r a t i o n  S i t e  C o n d i t i o n s :  p r u r i t u s ,  a s t h e n i a / f a t i g u e ,  p a i n  i n  
e x t r em i t i e s ,  c h e s t  p a i n  
• G a s t r o i n t e s t i n a l  D i s o r d e r s :  v om i t i n g  
O t h e r  e v e n t s  r e p o r t e d  d u r i n g  p o s t - a p p r o v a l  u s e  o f  t h e  T I V - H D  v a c c i n e  i n c l u d e  t h e  f o l l o w i n g :  
• G a s t r o i n t e s t i n a l  D i s o r d e r s :  n a u s e a ,  d i a r r h e a  
• G e n e r a l  D i s o r d e r  a n d  A d m i n i s t r a t i o n  S i t e  C o n d i t i o n s :  c h i l l s  
1 . 4  R a t i o n a l e  f o r  t h e  T r i a l  
W h i l e  t h e  l a r g e -s c a l e ,  m u l t i -c e n t e r  e f f i c a c y  t r i a l  ( F IM 1 2 )  c o n c l u d e d  t h a t  T I V - H D  w a s  s a f e ,  
i n d u c e d  s i g n i f i c a n t l y  h i g h e r  A b  r e s p o n s e s ,  a n d  p r o v i d e d  s u p e r i o r  p r o t e c t i o n  a g a i n s t  l a b o r a t o r y - 
c o n f i rm e d  i n f l u e n z a  i l l n e s s  c om p a r e d  t o  t h e  T I V - S D  v a c c i n e  i n  p e r s o n s  a g e d  6 5  y e a r s  a n d  o l d e r ,  a  
r em a i n i n g  u nm e t  n e e d  i n  a d u l t s  a g e d  6 5  y e a r s  a n d  o l d e r  i s  t o  im p r o v e  p r o t e c t i o n  o f  t h i s  
p o p u l a t i o n  a g a i n s t  t h e  c i r c u l a t i n g  B - s t r a i n  t h a t  m a y  n o t  b e  i n c l u d e d  i n  t h e  t r i v a l e n t  v a c c i n e s .  
T h e r e f o r e ,  S a n o f i  P a s t e u r  i s  d e v e l o p i n g  a  Q I V - H D  v a c c i n e  c o n t a i n i n g  6 0  µ g  H A  o f  e a c h  o f  
4  v i r u s  s t r a i n s  f o r  a  t o t a l  o f  2 4 0  µ g  o f  H A  a n t i g e n  p e r  d o s e  f o r  l i c e n s u r e  i n  a d u l t s  a g e d  6 5  y e a r s  
a n d  o l d e r  a n d  t h u s  e l im i n a t i n g  t h e  i s s u e  o f  h a v i n g  t o  c h o o s e  a  s t r a i n  f r om  o n l y  o n e  B  l i n e a g e  f o r  
t h e  s e a s o n a l  T I V - H D  a n d  t h e  r e s u l t i n g  r i s k  p o s e d  b y  t h e  p o t e n t i a l  w i d e s p r e a d  c i r c u l a t i o n  o f  a  
s t r a i n  f r om  t h e  a l t e r n a t e  B  l i n e a g e .  
2 T r i a l  O b j e c t i v e s  
2 . 1  P r im a r y  O b j e c t i v e  
Imm u n o g e n i c i t y  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
T o  d em o n s t r a t e  t h a t  Q I V -H D  i n d u c e s  a n  imm u n e  r e s p o n s e  ( a s  a s s e s s e d  b y  h em a g g l u t i n a t i o n  
i n h i b i t i o n  [ H A I ]  g e om e t r i c  m e a n  t i t e r s  [ GM T s ]  a n d  s e r o c o n v e r s i o n  r a t e s )  t h a t  i s  n o n -i n f e r i o r  t o  
P a g e  2 6  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141348]-
vaccination in all subjects. 
The endpoints for the primary immunogenicity objective are presented  in Section [IP_ADDRESS]. 
2.2 Secondary Objective s 
Immunogenicity  
1) To demonstrate that each B strain in QIV -HD induces an immune response (as assessed by 
[CONTACT_125624]) that is superior to the response induced by [CONTACT_125625]- HD 
that does not contain the corresponding B strain in all subjects. 
2) To describe the immune response induced by [CONTACT_125626]- HD, TIV-HD1, and TIV- HD2 by [CONTACT_125627].   
3) To describe the immune response 28 days after vaccination by [CONTACT_125628] a random ized subset of subjects from each study group.  
The endpoints for the secondary immunogenicity objectives  are presented in  Section [IP_ADDRESS].1 for 
the HAI method and in Section [IP_ADDRESS].2 for the SN method. 
Safety 
To describe the safety profile of all subjects in each trial group.  
The endpoints for the secondary safety objective are presented in Section [IP_ADDRESS]. 
3 Investigators and Trial Organization 
This trial wil l be conducted in approximately 36 centers in the US. The Principal Investigators and 
any sub- investigators at the i ndividual sites will be coordinated by 1 Coordinating Investigator. 
Details of the trial centers, the Investigators at each center, and the Coordinating Investigator [INVESTIGATOR_35268] “List of Investigators and Centers Involved in the Trial” document. 
The Sponsor’s Responsible Medical Officer (the person authorized to sign this protocol and any 
amendments on behalf of the Sponsor) is ,  
4 Independent Ethics Committee / Institutional Review Board 
Before the investi gational product can be shipped to the investigational site and before the 
inclusion of the first subject, this protocol, the informed consent form (ICF ), subject recruitment 
procedures, and any other written information to be provided to subjects must be approved by, 
and / or receive favorable opi[INVESTIGATOR_35269], the appropriate Independent Ethics Committee (IEC) or 
Institutional Review Board (IRB).  
In accordance with Good Clinical Practice (GCP) and local regulations, each Investigator and  / or 
the Sponsor are responsible for obtaining this approval and / or favorable opi[INVESTIGATOR_125609]. If the protocol is subsequently amended, approval must be re-obtained for each 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 27 of 78

S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  2 8  o f  7 7  s u b s t a n t i a l  am e n dm e n t .  C o p i e s  o f  t h e s e  a p p r o v a l s ,  a l o n g  w i t h  i n f o rm a t i o n  o n  t h e  t y p e ,  v e r s i o n  
n um b e r ,  a n d  d a t e  o f  d o c um e n t ,  a n d  t h e  d a t e  o f  a p p r o v a l ,  m u s t  b e  f o r w a r d e d  b y  t h e  I n v e s t i g a t o r  t o  
t h e  S p o n s o r  t o g e t h e r  w i t h  t h e  c om p o s i t i o n  o f  t h e  I E C  /  I R B  ( t h e  n am e s  a n d  q u a l i f i c a t i o n s  o f  t h e  
m em b e r s  a t t e n d i n g  a n d  v o t i n g  a t  t h e  m e e t i n g s ) .  
Th e  I n v e s t i g a t o r  w i l l  s u bm i t  w r i t t e n  s umm a r i e s  o f  t h e  s t a t u s  o f  t h e  t r i a l  t o  t h e  I E C  /  I R B  a n n u a l l y ,  
o r  m o r e  f r e q u e n t l y  i f  r e q u e s t e d .  A l l  s e r i o u s  a d v e r s e  e v e n t s  ( S A E s )  o c c u r r i n g  d u r i n g  t h e  t r i a l  t h a t  
a r e  r e l a t e d  t o  t h e  p r o d u c t  a dm i n i s t e r e d  w i l l  b e  r e p o r t e d  b y  t h e  I n v e s t i g a t o r  t o  t h e  I E C  /  I R B ,  
a c c o r d i n g  t o  t h e  I E C  /  I R B  p o l i c y .  
5 I n v e s t i g a t i o n a l  P l a n  
5 . 1  D e s c r i p t i o n  o f  t h e  O v e r a l l  T r i a l  D e s i g n  a n d  P l a n  
5 . 1 . 1  T r i a l  D e s i g n  
Q H D 0 0 0 1 3  w i l l  b e  a  r a n d om i z e d ,  m o d i f i e d  d o u b l e - b l i n d ,  a c t i v e - c o n t r o l l e d ,  m u l t i -c e n t e r  t r i a l  t o  
b e  c o n d u c t e d  i n  2 6 1 6  h e a l t h y  s u b j e c t s  a g e d  6 5  y e a r s  a n d  o l d e r  t o  a s s e s s  t h e  s a f e t y  a n d  
imm u n o g e n i c i t y  o f  t h e  Q I V - H D  c om p a r e d  t o  o n e  o f  t h e  T I V -H D s  c o n t a i n i n g  e i t h e r  t h e  B  s t r a i n  
f r om  t h e  p r im a r y  l i n e a g e  ( T I V - H D 1 ,  w h i c h  w i l l  b e  t h e  l i c e n s e d  v a c c i n e  [ F l u z o n e  H i g h - D o s e ]  f o r  
t h e  2 0 1 7 - 2 0 1 8  N o r t h e r n  H em i s p h e r e  [ N H ]  i n f l u e n z a  s e a s o n )  o r  t h e  B  s t r a i n  f r om  t h e  a l t e r n a t e  
l i n e a g e  ( T I V - H D 2 ,  w h i c h  w i l l  b e  a n  i n v e s t i g a t i o n a l  T I V - H D  c o n t a i n i n g  a n  a l t e r n a t e  B  s t r a i n ) .  
S u b j e c t s  w i l l  b e  r a n d om i z e d  i n t o  3  g r o u p s  a s  s h o w n  b e l o w :  
• Q I V - H D :   N  =  1 7 4 4  
• T I V -H D 1 :  N  =  4 3 6  
• T I V -H D 2 :  N  =  4 3 6  
F o r  f u r t h e r  d e t a i l s  c o n c e r n i n g  t h e  n um b e r  o f  s u b j e c t s  a l l o c a t e d  t o  e a c h  s t u d y  g r o u p ,  s e e  T a b l e  6 . 1 .  
A n  u n b l i n d e d  a dm i n i s t r a t o r  a t  e a c h  s i t e  w i l l  a dm i n i s t e r  t h e  v a c c i n e .  
A l l  s u b j e c t s  w i l l  p r o v i d e  a  p r e - v a c c i n a t i o n  ( b a s e l i n e )  b l o o d  s am p l e  a t  D a y  ( D )  0  a n d  a  p o s t - 
v a c c i n a t i o n  b l o o d  s am p l e  a t  V i s i t  ( V )  0 2  ( D 2 8  [ + 7  d a y s ] )  f o r  H A I  t e s t i n g .  A  r a n d om i z e d  s u b s e t  o f  
t h e s e  s u b j e c t s  ( E x p a n d e d  Imm u n o g e n i c i t y  S u b s e t )  f r o m  e a c h  g r o u p  ( 1 0 0  s u b j e c t s  p e r  s t u d y  
g r o u p )  w i l l  b e  s e l e c t e d  f o r  s e r o n e u t r a l i z a t i o n  ( S N )  t e s t i n g .  
S o l i c i t e d  r e a c t i o n s  w i l l  b e  c o l l e c t e d  u p  t o  7  d a y s  a f t e r  v a c c i n a t i o n ,  a n d  u n s o l i c i t e d  A E s  w i l l  b e  
c o l l e c t e d  u p  t o  V 0 2 ,  w h i c h  i s  t h e  a c t i v e  p h a s e  o f  t h e  t r i a l  ( V 0 1  t o  V 0 2  [ D 0 - D 2 8 ] ) .  S A E s  a n d  
a d v e r s e  e v e n t s  o f  s p e c i a l  i n t e r e s t  ( A E S I s * )  w i l l  b e  c o l l e c t e d  t h r o u g h o u t  t h e  t r i a l  ( D 0  t h r o u g h  
a p p r o x im a t e l y  D 1 8 0  [ 6 -m o n t h  f o l l o w - u p  p e r i o d ] ) .  
*N o t e :  A E S I s  w i l l  b e  c a p t u r e d  a s  S A E s .  T h e s e  i n c l u d e  n e w  o n s e t  o f  G B S ,  e n c e p h a l i t i s  /  m y e l i t i s  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
( i n c l u d i n g  t r a n s v e r s e  m y e l i t i s ) ,  B e l l ’ s  p a l s y ,  o p t i c  n e u r i t i s ,  a n d  b r a c h i a l  n e u r i t i s .  
P a g e  2 8  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  2 9  o f  7 7  I n t e r a c t i v e  r e s p o n s e  t e c h n o l o g y  ( I R T )  w i l l  b e  u s e d  t o  r a n d om l y  a s s i g n  s u b j e c t s  t o  o n e  o f  t h e  3  
t r i a l  g r o u p s  a n d  t o  a s s i g n  s u b j e c t  n um b e r s  i n  e a c h  o f  t h e  g r o u p s .  E l e c t r o n i c  d a t a  c a p t u r e  ( E D C )  
w i l l  b e  u s e d  f o r  t h e  c o l l e c t i o n  o f  d a t a .  
5 . 1 . 2  J u s t i f i c a t i o n  o f  t h e  T r i a l  D e s i g n  
T h e  o v e r a l l  s t r a t e g y  f o r  t h e  Q I V - H D  p r o j e c t  i s  t o  d em o n s t r a t e  c l i n i c a l l y  t h a t  t h e  a d d i t i o n  o f  a  
s e c o n d  i n f l u e n z a  B  s t r a i n  t o  T I V - H D  w o u l d  n o t  i n t e r f e r e  w i t h  t h e  imm u n e  r e s p o n s e  t o  o t h e r  
v a c c i n e  s t r a i n s  o r  a d v e r s e l y  a l t e r  t h e  s a f e t y  p r o f i l e  o f  t h e  v a c c i n e  i n  h e a l t h y  a d u l t s  a g e d  6 5  y e a r s  
a n d  o l d e r .  
T h e  p r im a r y  o b j e c t i v e  o f  Q H D 0 0 0 1 3  i s  a s s e s s  t h e  s a f e t y  o f  Q I V - H D  a n d  t o  d em o n s t r a t e  t h a t  
Q I V - H D  i n d u c e s  a n  imm u n e  r e s p o n s e  ( a s  a s s e s s e d  b y  H A I  GM T s  a n d  s e r o c o n v e r s i o n  r a t e s )  t h a t  
i s  n o n - i n f e r i o r  t o  r e s p o n s e s  i n d u c e d  b y  t h e  l i c e n s e d  T I V - H D  ( T I V - H D 1 )  a n d  T I V - H D 2  
( c o n t a i n i n g  t h e  a l t e r n a t e  B  s t r a i n  l i n e a g e ) .  
I n  a d d i t i o n ,  d em o n s t r a t i o n  o f  c om p a r a b i l i t y  b e t w e e n  Q I V - H D  a n d  t h e  l i c e n s e d  T I V -H D ,  w h i c h  i s  
r e p r e s e n t a t i v e  o f  t h e  l o t s  u s e d  i n  F IM 1 2  ( S a n o f i  P a s t e u r ’ s  P h a s e  I I I b / I V  e f f i c a c y  t r i a l  c om p a r i n g  
T I V -H D  t o  t h e  T I V -S D  i n  a d u l t s  a g e d  6 5  y e a r s  a n d  o l d e r ) ,  w i l l  b e  a n  i n d i c a t o r  i n  t e rm s  o f  
e x p e c t e d  v a c c i n e  e f f i c a c y .  
G i v e n  t h e  d i f f e r e n t  v o l um e s  i n  t h e  Q I V - H D  a n d  T I V -H D  v a c c i n e s ,  Q H D 0 0 0 1 3  w i l l  b e  a  m o d i f i e d  
d o u b l e - b l i n d  t r i a l  w i t h  a n  u n b l i n d e d  a dm i n i s t r a t o r  u s e d  a t  e a c h  t r i a l  s i t e .  T h e  a dm i n i s t r a t o r  w i l l  
n o t  b e  i n v o l v e d  i n  a n y  o f  t h e  b l i n d e d  s t u d y  a s s e s sm e n t s  ( e . g . ,  s a f e t y ) .  
T h e  r i s k  /  b e n e f i t  r a t i o  i s  a p p r o p r i a t e  f o r  t h e  c o n d u c t  o f  a  P h a s e  I I I  c l i n i c a l  t r i a l  w i t h  Q I V -H D  
w i t h o u t  a n  e a r l y  s a f e t y  d a t a  r e v i e w  f o r  t h e  f o l l o w i n g  r e a s o n s :  
• T h e r e  w e r e  a c c e p t a b l e  s a f e t y  d a t a  g e n e r a t e d  f r om  a  P h a s e  I I  s t u d y  ( Q H D 0 1 )  e v a l u a t i n g  a  
d i f f e r e n t  Q I V - H D  v a c c i n e  f o rm u l a t i o n  t h a n  t h e  Q I V - H D  t h a t  w i l l  b e  u s e d  i n  Q H D 0 0 0 1 3 ,  b u t  
w h i c h  a l s o  c o n t a i n e d  2 4 0  µ g  H A / d o s e .  
• Th e  Q I V -H D  v a c c i n e  a s s e s s e d  i n  Q H D 0 0 0 1 3  i s  m a n u f a c t u r e d  u s i n g  t h e  s am e  d r u g  s u b s t a n c e  
( D S )  m a n u f a c t u r i n g  p r o c e s s  a s  t h e  c u r r e n t l y  l i c e n s e d  T I V - H D  m a n u f a c t u r i n g  p r o c e s s .  
• T h e r e  i s  a  l a r g e  v a c c i n e  s a f e t y  d a t a b a s e  g e n e r a t e d  f o l l o w i n g  s i g n i f i c a n t  p o s t -m a r k e t i n g  u s e  o f  
T I V -H D .  
• I t  i s  t o  b e  n o t e d  t h a t  o t h e r  l i c e n s e d  v a c c i n e s  i n  t h e  U S  w i t h  a  d o s e  v o l um e  g r e a t e r  t h a n  0 . 5  m L  
i n c l u d e  T w i n r i x ®,  E n g e r i x ®-B ,  H a v r i x ®,  V a q t a ®,  Im o v a x ® R a b i e s ,  a n d  Z o s t a v a x ®.  
5 . 1 . 3  T r i a l  P l a n  
T h e  t r i a l  p l a n  i s  s umm a r i z e d  i n  t h e  T a b l e  o f  S t u d y  P r o c e d u r e s .  
V a c c i n a t i o n  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
A l l  e l i g i b l e  s u b j e c t s  w i l l  b e  r a n d om i z e d  t o  r e c e i v e  a  s i n g l e  i n j e c t i o n  o f  e i t h e r  t h e  Q I V -H D  v a c c i n e  
o r  o n e  o f  t h e  T I V -H D  v a c c i n e s  a t  D 0 .  
P a g e  2 9  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 30 of 77 Blood Sampling 
All subjects will provide a pre -vaccination blood sample at V01 (D0) and a post-vaccination 
blood sample at V02 (D28 [+ 7 days]). 
Collection of Safety Data  
Subjects will be asked to notify the site immediately about any potential SAEs at any time during 
the trial. 
All subjects will be observed for 30 minutes after vaccination, and any unsolicited systemic AEs 
occurring during that time will be recorded as immediate unsolicited systemic AEs in the  Case 
Report Book ( CRB). 
Subjects will record information about solicited reactions (D0 -D7), unsolicited AEs (D0-V02), 
SAEs (D0 -V02), and AESIs (D0-V02) in a diary card. 
Staff will contact [CONTACT_125618] D8 post-vaccination to identify whether the subject experienced any SAE s not yet reported and will remind the subjects to bring the completed diary 
card with them to V02. 
Staff will review the D0 to V02 safety data with subjects at V02.  
Subjects will continue to collect information on SAEs and AESIs in a memory aid (from V02-
D180). Staff will contact [CONTACT_125619] D180 (+14 days) post- vaccination to review the 
memory aid and to identify the occurrence of any SAEs that had not yet been reported. 
5.1.4 Visit Procedures 
Visit 1 (D0): Inclusion, Randomization, Blood Sample, and Vaccination  
1) Explain the trial to the subject, answer any of his / her questions and ensure that he / she has 
been informed of all aspects of the trial that are relevant to his / her decision and obtain a 
written informed consent signed by [CONTACT_423]. I f the subject is illiterate, an independent 
witness/legal representative is required to sign the consent form.  
The Investigator / delegate will also sign and date the ICF. The Investigator / delegate will then retain one original and give the copy to the subject. 
2) Check all inclusion and exclusion criteria (see Section 5.2.[ADDRESS_141349] ively) 
through physical examination and medical interview. If the subject is not eligible, only the specific form entitled “Recruitment log” will state the subject identification, no CRB  will be 
completed.  
3) Collect relevant demographic information (e.g., date of birth and gender). 
4) Obtain information about history of influenza vaccination in the previous year. 
5) Collect significant medical history and record any planned hospi[INVESTIGATOR_125610]. 
6) Collect reportable concomitant medications (see Section 6.7 ). 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 30 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  3 1  o f  7 7  7 )  P e r f o rm  a n d  d o c um e n t  a  t a r g e t e d  p h y s i c a l  e x am i n a t i o n  p e r  s t a n d a r d  s i t e - s p e c i f i c  
imm u n i z a t i o n  p r a c t i c e s  a n d  r e c o r d  o r a l  t em p e r a t u r e a i n  t h e  m e d i c a l  c h a r t .  
8 )  C a l l  t h e  I R T  t o  a s s i g n  t o  t h e  s u b j e c t  a  1 2 - d i g i t  s u b j e c t  n um b e r  a n d  a l l o c a t e  a  m e d i c a t i o n  
n um b e r  ( s e e  S e c t i o n  6 . 5 ).  A t  t h i s  t im e ,  s om e  s u b j e c t s  w i l l  b e  a s s i g n e d  t o  t h e  E x p a n d e d  
Imm u n o g e n i c i t y  S u b s e t .  
9 )  D r a w  a n  a p p r o x im a t e l y  1 0  m L  b l o o d  s am p l e  ( T h i s  b l o o d  s am p l e  s h o u l d  b e  p e r f o rm e d  b e f o r e  
v a c c i n a t i o n ) .  P r o c e s s  t h e  b l o o d  s am p l e  a s  s p e c i f i e d  i n  t h e  “M a n a g em e n t  o f  S am p l e s ”  s e c t i o n  
( s e e  S e c t i o n  7 ) .  N o t e :  I f  t h e  s u b j e c t  w i t h d r a w s  c o n s e n t  b e f o r e  b l o o d  s am p l i n g  ( b e f o r e  a n y  
i n v a s i v e  p r o c e d u r e  h a s  b e e n  p e r f o rm e d ) ,  d o  n o t  v a c c i n a t e  t h e  s u b j e c t .  T h e  s u b j e c t  s h o u l d  b e  
t e rm i n a t e d  f r om  t h e  s t u d y .  N o t e :  I f  t h e  a t t em p t ( s )  t o  c o l l e c t  b l o o d  i s  ( a r e )  u n s u c c e s s f u l  ( 3  
a t t em p t s ) ,  t h e n  t h e  s u b j e c t  i s  s t i l l  t o  b e  i n c l u d e d  i n  t h e  s t u d y  a n d  v a c c i n a t e d .  
1 0 )  A dm i n i s t e r  t h e  c o r r e s p o n d i n g  v a c c i n e  t o  t h e  s u b j e c t  i n  t h e  r e g i o n  o f  t h e  u p p e r  a rm  m u s c l e  
( t h e  v a c c i n e  m u s t  b e  a dm i n i s t e r e d  o n  t h e  s i d e  o p p o s i t e  t o  t h a t  o f  t h e  b l o o d  s am p l i n g ) .  
1 1 )  R e c o r d  t h e  i n j e c t i o n  s i t e  /  s i d e  /  r o u t e  /  m e d i c a t i o n  n um b e r  i n  t h e  C R B  a n d  a f f i x  t h e  
d e t a c h a b l e  c o r r e s p o n d i n g  l a b e l  i n  t h e  m e d i c a l  c h a r t  a n d  v a c c i n a t i o n  c a r d  i f  a n y .  
1 2 )  K e e p  t h e  s u b j e c t  u n d e r  m e d i c a l  s u r v e i l l a n c e  f o r  a t  l e a s t  3 0  m i n u t e s  a f t e r  t h e  i n j e c t i o n  a n d  
r e p o r t  t h e  o c c u r r e n c e  o r  n o n - o c c u r r e n c e  o f  a n y  A E  i n  t h e  C R B .  
1 3 )  G i v e  t h e  s u b j e c t  t h e  d i a r y  c a r d  t o  r e c o r d  a n y  i n j e c t i o n  s i t e  r e a c t i o n s  a n d  s y s t em i c  A E s ,  
t o g e t h e r  w i t h  i n s t r u c t i o n s  f o r  i t s  c om p l e t i o n ,  i n c l u d i n g  e x p l a n a t i o n s  o n  t h e  d e f i n i t i o n  a n d  u s e  
o f  i n t e n s i t y  s c a l e s  f o r  c o l l e c t i o n  o f  A E s .  
1 4 )  G i v e  t h e  s u b j e c t  a  r u l e r  t o  m e a s u r e  t h e  s i z e  o f  a n y  i n j e c t i o n  s i t e  r e a c t i o n ,  a  t h e rm om e t e r  f o r  
t em p e r a t u r e  m e a s u r em e n t ,  a n d  i n s t r u c t i o n s  o n  h o w  t o  u s e  t h em .  
1 5 )  R em i n d  t h e  s u b j e c t  t o  e x p e c t  a  t e l e p h o n e  c a l l  8  d a y s  a f t e r  V i s i t  1 .  
1 6 )  I n s t r u c t  o n  t h e  n e e d  t o  p r om p t l y  r e p o r t  a n y  S A E  t h a t  m a y  o c c u r  a t  a n y  t im e  d u r i n g  t h e  t r i a l .  
1 7 )  C om p l e t e  t h e  r e l e v a n t  c a s e  r e p o r t  f o rm s  ( C R F s )  f o r  t h i s  v i s i t .  
D 8  T e l e p h o n e  C a l l  1  ( 8  d a y s  [ + 2  d a y s ]  a f t e r  V i s i t  1 )  
N o t e :  I f  D 8  [ + 2  d a y s ]  f a l l s  o n  a  w e e k e n d  o r  a  h o l i d a y ,  t h e  t e l e p h o n e  c a l l  m a y  b e  m a d e  o n  t h e  
f o l l o w i n g  b u s i n e s s  d a y .  
1 )  R e c o r d  r e l e v a n t  i n f o rm a t i o n  c o n c e r n i n g  t h e  s u b j e c t ’ s  h e a l t h  s t a t u s  o n  t h e  t e l e p h o n e  c o n t a c t  
f o rm .  I f  a n  S A E  o c c u r r e d ,  f o l l o w  t h e  i n s t r u c t i o n s  i n  S e c t i o n  1 0  f o r  r e p o r t i n g  i t .  
2 )  R em i n d  t h e  s u b j e c t  t o  d o  t h e  f o l l o w i n g :  
• C om p l e t e  t h e  D 0 – D 7  p a g e s  o f  t h e  d i a r y  c a r d  
• C om p l e t e  t h e  r em a i n i n g  p a g e s  o f  t h e  d i a r y  c a r d  a n d  b r i n g  t h em  t o  V i s i t  2  
• N o t i f y  t h e  s i t e  i n  c a s e  o f  a n  S A E  
                                                 
aS a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
  T ym p a n i c  a n d  t em p o r a l  a r t e r y  t h e rm om e t e r  s h o u l d  n o t  b e  u s e d .  
P a g e  3 1  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  3 2  o f  7 7  V i s i t  2  ( D 2 8  [ + 7 ]  d a y s  a f t e r  V i s i t  1 ) :  C o l l e c t i o n  o f  S a f e t y  I n f o rm a t i o n  a n d  B l o o d  S am p l e  
1 )  C o l l e c t  a n d  r e v i e w  t h e  d i a r y  c a r d  s i n c e  V i s i t  1 ,  i n c l u d i n g  a n y  A E s ,  m e d i c a t i o n s ,  o r  t h e r a p y  
t h a t  o c c u r r e d  s i n c e  v a c c i n a t i o n .  T h e  o c c u r r e n c e  o f  a n y  i n j e c t i o n  s i t e  r e a c t i o n ,  s y s t em i c  
e v e n t / r e a c t i o n ,  a n d / o r  a n y  S A E  s h o u l d  h a v e  b e e n  r e p o r t e d  i n  t h e  d i a r y  c a r d .  
2 )  D r a w  a n  a p p r o x im a t e l y  1 0  m L  b l o o d  s am p l e  f o r  t h e  t i t r a t i o n  o f  A b s .  N o t e :  I f  t h e  a t t em p t ( s )  
t o  c o l l e c t  b l o o d  i s  ( a r e )  u n s u c c e s s f u l  ( 3  a t t em p t s ) ,  t h e  s u b j e c t  s h o u l d  b e  g i v e n  t h e  
o p p o r t u n i t y  t o  r e t u r n  t o  t h e  s t u d y  s i t e  f o r  a n o t h e r  a t t em p t  w i t h i n  t h e  v i s i t  w i n d o w .  I f  a  b l o o d  
s am p l e  c a n n o t  b e  o b t a i n e d ,  t h e  r e a s o n  w i l l  b e  r e c o r d e d  i n  t h e  b l o o d  s am p l i n g  p a g e  o f  t h e  
C R B .  
3 )  P r o v i d e  t h e  s u b j e c t  w i t h  a  M em o r y  A i d  a n d  r e v i e w  t h e  d i r e c t i o n s  f o r  i t s  u s e .  
4 )  R em i n d  t h e  s u b j e c t  t o  e x p e c t  a  s a f e t y  f o l l o w - u p  t e l e p h o n e  c a l l  1 8 0  d a y s  a f t e r  V i s i t  1 .  
5 )  R em i n d  t h e  s u b j e c t  t o  r e p o r t  a n y  S A E  t h a t  m a y  o c c u r  b e t w e e n  V i s i t  2  a n d  t h e  6 -m o n t h  
f o l l o w - u p  c a l l .  
6 )  C om p l e t e  t h e  r e l e v a n t  C R F s  f o r  t h i s  v i s i t .  
D 1 8 0  S a f e t y  F o l l o w - u p  T e l e p h o n e  C a l l  ( 1 8 0  d a y s  [ + 1 4  d a y s ] ,  a p p r o x im a t e l y  6  m o n t h s  a f t e r  
v a c c i n a t i o n ) :  C o l l e c t i o n  o f  S A E s  
1 )  I n q u i r e  w h e t h e r  t h e  s u b j e c t  h a s  r e c e i v e d  a n y  v a c c i n a t i o n s  s i n c e  t h e  l a s t  c o n t a c t  ( t o  b e  t a k e n  
i n t o  a c c o u n t  f o r  t h e  c o l l e c t i o n  o f  i n f o rm a t i o n  i n  t h e  “ C o n c om i t a n t  V a c c i n a t i o n ”  S e c t i o n  ( s e e  
S e c t i o n  6 . 7 ). 
2 )  I n q u i r e  a b o u t  n e w  o c c u r r e n c e s  o f  S A E s  a n d  p e r f o rm  f o l l o w - u p  o n  S A E s .  
3 )  E x p l a i n  t h a t  t h i s  w i l l  b e  t h e  l a s t  c o n t a c t  w i t h  t h e  s i t e  f o r  t h i s  t r i a l  ( e x c e p t  f o r  s u b j e c t s  w i t h  
S A E s  t h a t  n e e d  f u r t h e r  f o l l o w - u p ,  a s  s t a t e d  b e l o w ) .  
I f  t h e  f i r s t  c o n t a c t  a t t em p t  t o  c om p l e t e  t h e  l a s t  t e l e p h o n e  c a l l  i s  u n s u c c e s s f u l ,  a t  l e a s t  2  s e p a r a t e  
a d d i t i o n a l  a t t em p t s ,  c o n d u c t e d  o n  d i f f e r e n t  d a y s ,  s h o u l d  b e  m a d e  t o  c o n t a c t  t h e s e  s u b j e c t s .  A l l  
a t t em p t s  m u s t  b e  d o c um e n t e d  i n  t h e  s u b j e c t ’ s  s o u r c e  n o t e s .  I f ,  a f t e r  a t  l e a s t  3  d o c um e n t e d  
a t t em p t s ,  c o n t a c t  c a n n o t  b e  e s t a b l i s h e d ,  t h e  s u b j e c t  s h o u l d  b e  c l a s s i f i e d  a s  L o s t  t o  F o l l o w -U p  ( s e e  
S e c t i o n  5 . 2 . 9  fo r  f u r t h e r  d e t a i l s ) .  
T h e  e x c e p t i o n s  f o r  t h e  f i n a l  p h o n e  c a l l s  a r e :   
• S u b j e c t s  w h o  v o l u n t a r i l y  w i t h d r e w  
• S u b j e c t s  w h o  h a v e  b e e n  p r e v i o u s l y  c l a s s i f i e d  a s  l o s t  t o  f o l l o w - u p  
F o l l o w - u p  o f  s u b j e c t s  w i t h  R e l a t e d  A E s  o r  w i t h  A E s  T h a t  L e d  t o  S t u d y / V a c c i n a t i o n  
D i s c o n t i n u a t i o n :  
A  s u b j e c t  w h o  e x p e r i e n c e s  a n  A E  ( w h e t h e r  s e r i o u s  o r  n o n - s e r i o u s )  d u r i n g  t h e  s t u d y  m u s t  b e  
f o l l o w e d  u n t i l  t h e  c o n d i t i o n  r e s o l v e s ,  b e c om e s  s t a b l e ,  o r  b e c om e s  c h r o n i c  ( e v e n  a f t e r  t h e  e n d  o f  
t h e  s u b j e c t ' s  p a r t i c i p a t i o n  i n  t h e  s t u d y )  i f  e i t h e r  o f  t h e  f o l l o w i n g  i s  t r u e :  
• T h e  A E  i s  c o n s i d e r e d  b y  t h e  I n v e s t i g a t o r  t o  b e  r e l a t e d  t o  t h e  p r o d u c t  a dm i n i s t e r e d .  
• S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
T h e  A E  c a u s e d  t h e  d i s c o n t i n u a t i o n  o f  t h e  s u b j e c t  f r om  t h e  s t u d y .  
P a g e  3 2  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141350] been obtained. 
Planned trial  period (active phase)  - FVFSa to LV LSb:  [ADDRESS_141351] 2017 
Planned inclusion period - FVFS to  FVLSc:   01 SEP 2017 to 22 SEP 2017 
Planned end of trial (LCLSd):    04 APR 2018 
Planned date of final clinical study report:   14 SEP 2018 
5.1.6 Early Safety Data Review 
This trial will not include an early review of safety data (i.e., no early safety review[s] of 
preliminary data occurring at pre-determined milestones defined in the protocol with pause in 
enrollment). However, it may be interrupted at any time if new data about the investigational product become available, and/or on advice of the Sponsor, the IRBs, or the governing regulatory authorities in the country where the trial is taking place.  
If the trial is prematurely terminated or suspended, the Sponsor will promptly inform the 
Investigators, the IRBs, and the regulatory authorities of the reason for termination or suspension. If the trial is prematurely terminated for any reason, the Investigator will promptly inform the trial 
subjects and should assure appropriate therapy and follow-up. 
5.[ADDRESS_141352] an appropriate pool of 
potential subjects and invite them to participate in the study. The site will ensure that any advertisements used to recruit subjects (e.g., letters, pamphlets, posters) are submitted to [COMPANY_011] Pasteur prior to submission to the IEC / IRB for approval.  
5.2.[ADDRESS_141353] be obtained before any study procedures are performed. The process is documented by [CONTACT_3553] a written, signed, and dated ICF. 
                                                 
a  FVFS: first visit, first subject  
b  LVLS: last visit, last subject  
c  FVLS: first visit, last subject  
d  LCLS: last contact, last subject (phone call at end of D180 follow -up period)  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 33 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141354] or his / her representative. 
The actual ICF used at each center may differ, depending on local regulations and IEC / IRB 
requirements. However, all versions must contain the standard information found in the sample 
ICF provided by [CONTACT_1034]. Any change to the content of the ICF must be approved by [CONTACT_29540] / IRB prior to the form being used. 
If new information becomes available that may be relevant to the subject’s willingness to continue participation in the trial, this will be communicated to him / her in a timely manner. Such 
information will be provided via a revised ICF or an addendum to the original ICF.  
Informed consent forms will be provided in duplicate, or a photocopy of the signed consent will be made. The original will be kept by [CONTACT_737], and the copy will be kept by [CONTACT_70579] t. 
Documentation of the consent process should be recorded in the source documents. 
5.2.[ADDRESS_141355] fulfill all of the following criteria in order to be eligible for trial enrol lment:  
1) Aged ≥ 65 years on the day of inclusion 
2) Informed consent form has been signed and dated 
3) Able to attend all scheduled visits and to comply with all trial  procedures 
5.2.5 Exclusion Criteria  
An individual fulfilling any of the following criteria is to be excluded from trial enrollment: 
1) Participation at the time of trial enrollment (or in the 4 weeks preceding the trial vaccination) 
or planned participation during the present trial period in another clinical trial investigating a 
vaccine, drug, medical device, or medical procedure  
2) Receipt of any vaccine in the 4 weeks (28 days) preceding the trial vaccination or planned 
receipt of any vaccine prior to V02 
3) Previous vaccination against influenza (in the preceding 6 months) with either the trial 
vaccine or another vacci ne 
4) Receipt of immune globulins, blood or blood-derived products in the past 3 months  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 34 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 35 of 77 5) Known or suspected congenital or acquired immunodeficiency; or receipt of 
immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within 
the preceding 6 months; or long- term systemic corticosteroid therapy (prednisone or 
equivalent for more than [ADDRESS_141356] 3 months) 
6) Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the 
same substances
a 
7) Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on investigator’s judgment 
8) Deprived of freedom by [CONTACT_29511], or in an emergency setting, or hospi[INVESTIGATOR_29476] 
9) Alcohol or substance abuse that, in the opi[INVESTIGATOR_871], might interfere with the trial conduct or completion 
10) Chronic illness that, in the opi[INVESTIGATOR_871], is at a stage where it m ight interfere 
with trial conduct or completion
b 
11) Identified as an Investigator or employee of the Investigator or trial center with direct involvement in the proposed trial, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed trial  
12) Personal or family history of GBS 
13) Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy and subjects who have a 
history of neoplastic disease and have been disease free for ≥ 5 years)  
14) Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥  38.0°C [≥ 100.4°F]). A prospective subject 
should not be included in the trial until the condition has resolved or the febrile event has subsided 
5.2.[ADDRESS_141357] 
and ongoing. Any such conditions will be documented in the source document. Significant medical history (reported as diagnosis) including conditions for which the subject is or has been followed by a physician or conditions that could resume during the course of the study or lead to 
an SAE or to a repetitive outpatient care will be collected in the CRB. The significant medical 
history section of the CRB contains a core list of body systems and disorders that could be used to 
prompt comprehensive reporting, as well as space for the reporting of specific conditions and illnesses.  
                                                 
a  The components of the QIV- HD and TIV -HD vaccines  are listed in the Investigator’s Brochure.  
b  Chronic illness may include, but is not limited to , cardiac disorders, renal disorders, autoimmune disorders , 
diabetes, psychiatric disorders or chronic infection.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 35 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  3 6  o f  7 7  T h e  p e r t i n e n t  m e d i c a l  h i s t o r y  f o r  s t u d y  p u r p o s e s  i n c l u d e s  c o n d i t i o n s  b e l o n g i n g  t o  t h e  f o l l o w i n g  
c a t e g o r i e s :   
1 )  C h r o n i c  c o -m o r b i d  i l l n e s s e s  c o n s i d e r e d  t o  i n c r e a s e  t h e  r i s k  f o r  i n f l u e n z a  c om p l i c a t i o n s  
( i n c l u d i n g  p r e - s p e c i f i e d  d i a g n o s e s  [ e . g .  r e s p i r a t o r y ,  c a r d i a c ,  b l o o d ,  n e u r o l o g i c ,  k i d n e y ,  a n d  
li v e r  d i s o r d e r s ]  l i s t e d  i n  t h e  C R B  a n d  o t h e r  s i g n i f i c a n t  c h r o n i c  c o n d i t i o n s ,  a s  j u d g e d  b y  t h e  
i n v e s t i g a t o r )  
2 )  O t h e r  c o n d i t i o n s  ( e . g . ,  a u t o imm u n e  d i s o r d e r s ,  t o b a c c o  u s e ,  r e s i d e n c e  a t  a n  a s s i s t e d - l i v i n g  
f a c i l i t y  o r  n u r s i n g  h om e  w i t h i n  t h e  l a s t  6  m o n t h s )  
F o r  e a c h  c o n d i t i o n ,  t h e  d a t a  c o l l e c t e d  w i l l  b e  l im i t e d  t o :  
• D i a g n o s i s  ( t h i s  i s  p r e f e r a b l e  t o  r e p o r t i n g  s i g n s  a n d  s ym p t om s )  
• P r e s e n c e  o r  a b s e n c e  o f  t h e  c o n d i t i o n  a t  e n r o l lm e n t  
T h e  r e p o r t i n g  o f  s i g n s  a n d  s ym p t om s  i s  s t r o n g l y  d i s c o u r a g e d .  
D a t e s ,  m e d i c a t i o n s ,  a n d  b o d y  s y s t em s  a r e  n o t  t o  b e  r e c o r d e d ,  a n d  t h e  i n f o rm a t i o n  c o l l e c t e d  w i l l  n o t  
b e  c o d e d .  I t s  p u r p o s e  i s  t o  a s s i s t  i n  t h e  l a t e r  i n t e r p r e t a t i o n  o f  s a f e t y  d a t a  c o l l e c t e d  d u r i n g  t h e  t r i a l .  
5 . 2 . 7  C o n t r a i n d i c a t i o n s  f o r  S u b s e q u e n t  V a c c i n a t i o n  
N o t  a p p l i c a b l e  s i n c e  o n l y  o n e  d o s e  o f  v a c c i n e  w i l l  b e  a dm i n i s t e r e d  i n  t h i s  t r i a l .  
5 . 2 . 8  C o n d i t i o n s  f o r  W i t h d r a w a l   
S u b j e c t s  w i l l  b e  i n f o rm e d  t h a t  t h e y  h a v e  t h e  r i g h t  t o  w i t h d r a w  f r om  t h e  t r i a l  a t  a n y  t im e .  A  s u b j e c t  
m a y  b e  w i t h d r a w n  f r om  t h e  s t u d y :  
• A t  t h e  r e q u e s t  o f  t h e  s u b j e c t  ( d r o p o u t )   
T h e  r e a s o n  f o r  a  w i t h d r a w a l  o r  d r o p o u t  s h o u l d  b e  c l e a r l y  d o c um e n t e d  i n  t h e  s o u r c e  d o c um e n t s  
a n d  o n  t h e  C R B .   
T h e  I n v e s t i g a t o r  m u s t  d e t e rm i n e  w h e t h e r  v o l u n t a r y  w i t h d r a w a l  i s  d u e  t o  s a f e t y  c o n c e r n s  ( i n  
w h i c h  c a s e ,  t h e  r e a s o n  f o r  d i s c o n t i n u a t i o n  w i l l  b e  n o t e d  a s  “ A d v e r s e  E v e n t ”  o r  f o r  a n o t h e r  r e a s o n .  
W i t h d r a w n  s u b j e c t s  w i l l  n o t  b e  r e p l a c e d .  
5 . 2 . 9  L o s t  t o  F o l l o w - u p  P r o c e d u r e s  
I n  t h e  c a s e  o f  s u b j e c t s  w h o  f a i l  t o  r e t u r n  f o r  a  f o l l o w - u p  e x am i n a t i o n ,  d o c um e n t e d  r e a s o n a b l e  
e f f o r t  ( i . e . ,  d o c um e n t e d  t e l e p h o n e  c a l l s  a n d  c e r t i f i e d  m a i l )  s h o u l d  b e  u n d e r t a k e n  t o  l o c a t e  o r  r e c a l l  
t h em ,  o r  a t  l e a s t  t o  d e t e rm i n e  t h e i r  h e a l t h  s t a t u s  w h i l e  f u l l y  r e s p e c t i n g  t h e i r  r i g h t s .  T h e s e  e f f o r t s  
s h o u l d  b e  d o c um e n t e d  i n  t h e  C R B  a n d  i n  t h e  s o u r c e  d o c um e n t s .  
5 . 2 . 1 0  C l a s s i f i c a t i o n  o f  S u b j e c t s  W h o  D i s c o n t i n u e  t h e  T r i a l  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
F o r  a n y  s u b j e c t  w h o  d i s c o n t i n u e s  t h e  t r i a l  p r i o r  t o  c om p l e t i o n ,  t h e  m o s t  s i g n i f i c a n t  r e a s o n  f o r  
e a r l y  t e rm i n a t i o n  w i l l  b e  c h e c k e d  i n  t h e  C R B .  R e a s o n s  a r e  l i s t e d  b e l o w  f r om  t h e  m o s t  s i g n i f i c a n t  
P a g e  3 6  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  3 7  o f  7 7  t o  t h e  l e a s t  s i g n i f i c a n t  ( r e f e r  t o  t h e  C R F  C om p l e t i o n  I n s t r u c t i o n s  f o r  a d d i t i o n a l  d e t a i l s  a n d  
e x am p l e s ) :  
A d v e r s e  E v e n t  T o  b e  u s e d  w h e n  t h e  s u b j e c t  i s  p e rm a n e n t l y  t e rm i n a t e d  f r om  t h e  s t u d y  b e c a u s e  o f  a n  A E  
( i n c l u d i n g  a n  S A E ) ,  a s  d e f i n e d  i n  S e c t i o n  9 . 2 . 2 . 1 . 
L o s t  t o  
F o l l o w -u p  T o  b e  u s e d  w h e n  t h e  s u b j e c t  c a n n o t  b e  f o u n d  o r  c o n t a c t e d  i n  s p i t e  o f  e f f o r t s  t o  l o c a t e  
h im / h e r  b e f o r e  t h e  d a t e  o f  h i s / h e r  p l a n n e d  l a s t  v i s i t ,  a s  o u t l i n e d  i n  S e c t i o n  5 . 2 . 9 . T h e  
c e r t i f i e d  l e t t e r  w a s  s e n t  b y  t h e  i n v e s t i g a t o r  a n d  r e t u r n e d  u n s i g n e d ,  a n d  t h e  s u b j e c t  d i d  n o t  
g i v e  a n y  o t h e r  n e w s  a n d  d i d  n o t  c om e  t o  a n y  f o l l o w i n g  v i s i t .  
P r o t o c o l  
D e v i a t i o n  T o  b e  u s e d  w h e n  th e  s u b j e c t  s i g n e d  t h e  c e r t i f i e d  l e t t e r  s e n t  b y  t h e  i n v e s t i g a t o r  b u t  d i d  n o t  
g i v e  a n y  o t h e r  n e w s  a n d  d i d  n o t  c om e  t o  a n y  f o l l o w i n g  v i s i t .  
W i t h d r a w a l  
b y  S u b j e c t   T o  b e  u s e d :  
• W h e n  t h e  s u b j e c t  i n d i c a t e d  u n w i l l i n g n e s s  t o  c o n t i n u e  i n  t h e  s t u d y  
• W h e n  t h e  s u b j e c t  m a d e  t h e  d e c i s i o n  t o  d i s c o n t i n u e  p a r t i c i p a t i o n  i n  t h e  s t u d y  f o r  a n y  
p e r s o n a l  r e a s o n  o t h e r  t h a n  a n  S A E / A E  ( e . g . ,  s u b j e c t  i s  r e l o c a t i n g ,  i n f o rm  c o n s e n t  
w i t h d r a w a l ,  e t c . )  
5 . 2 . 1 1  F o l l o w - u p  o f  D i s c o n t i n u a t i o n s  
T h e  s i t e  s h o u l d  c om p l e t e  a l l  s c h e d u l e d  s a f e t y  f o l l o w - u p s  a n d  c o n t a c t  a n y  s u b j e c t  w h o  h a s  
p r em a t u r e l y  t e rm i n a t e d  t h e  t r i a l  b e c a u s e  o f  a n  A E ,  a  p r o t o c o l  d e v i a t i o n ,  o r  l o s s  o f  e l i g i b i l i t y .  
F o r  s u b j e c t s  w h e r e  t h e  r e a s o n  f o r  e a r l y  t e rm i n a t i o n  w a s  l o s t  t o  f o l l o w - u p  o r  i f  t h e  s u b j e c t  
w i t h d r e w  i n f o rm e d  c o n s e n t  a n d  s p e c i f i e d  t h a t  t h e y  d o  n o t  w a n t  t o  b e  c o n t a c t e d  a g a i n  a n d  i t  i s  
d o c um e n t e d  i n  t h e  s o u r c e  d o c um e n t ,  t h e  s i t e  w i l l  n o t  a t t em p t  t o  o b t a i n  f u r t h e r  s a f e t y  i n f o rm a t i o n .  
I f  t h e  s u b j e c t ' s  s t a t u s  a t  t h e  e n d  o f  t h e  s t u d y  i s  “W i t h d r a w a l  b y  S u b j e c t ” ,  t h e  s i t e  w i l l  a t t em p t  t o  
c o n t a c t  t h em  f o r  t h e  D 1 8 0  s a f e t y  f o l l o w - u p  e x c e p t  i f  t h e y  s p e c i f i e d  t h a t  t h e y  d o  n o t  w a n t  t o  b e  
c o n t a c t e d  a g a i n  a n d  i t  i s  d o c um e n t e d  i n  t h e  s o u r c e  d o c um e n t .  
5 . 3  S a f e t y  Em e r g e n c y  C a l l  
I f ,  a s  p e r  t h e  I n v e s t i g a t o r ' s  j u d gm e n t ,  a  s u b j e c t  e x p e r i e n c e s  a  m e d i c a l  em e r g e n c y ,  t h e  I n v e s t i g a t o r  
m a y  c o n t a c t  t h e  S p o n s o r ' s  R M O  f o r  a d v i c e  o n  t r i a l  r e l a t e d  m e d i c a l  q u e s t i o n  o r  p r o b l em .  I f  t h e  
RM O  i s  n o t  a v a i l a b l e ,  t h e n  t h e  I n v e s t i g a t o r  m a y  c o n t a c t  t h e  C a l l  C e n t e r  —a v a i l a b l e  2 4  h o u r s  a  
d a y ,  7  d a y s  a  w e e k —t h a t  w i l l  f o r w a r d  a l l  s a f e t y  em e r g e n c y  c a l l s  t o  t h e  a p p r o p r i a t e  p r im a r y  o r  
b a c k - u p  S a n o f i  P a s t e u r  c o n t a c t ,  a s  n e e d e d .  T h e  t o l l - f r e e  c o n t a c t  i n f o rm a t i o n  f o r  t h e  C a l l  C e n t e r  i s  
p r o v i d e d  i n  t h e  O p e r a t i n g  G u i d e l i n e s .  
T h i s  p r o c e s s  d o e s  n o t  r e p l a c e  t h e  n e e d  t o  r e p o r t  a n  S A E .  T h e  i n v e s t i g a t o r  i s  s t i l l  r e q u i r e d  t o  
f o l l o w  t h e  p r o t o c o l - d e f i n e d  p r o c e s s  f o r  r e p o r t i n g  S A E s  t o  t h e  G P E  D e p a r tm e n t  ( P l e a s e  r e f e r  t o  
S e c t i o n  1 0 ). 
I n  c a s e  o f  em e r g e n c y  c o d e - b r e a k i n g ,  t h e  I n v e s t i g a t o r  i s  r e q u i r e d  t o  f o l l o w  t h e  c o d e - b r e a k i n g  
p r o c e d u r e s  d e s c r i b e d  i n  S e c t i o n  6 . 4 . S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
 
P a g e  3 7  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141358] of the trial or the safety of subjects, 
require IEC  / IRB approval, and must also be forwarded to regulatory authorities. 
An administrative amendment to a protocol is  one that modifies some administrative or logistical 
aspect of the trial but does not affect its design or objectives  or have an impact on the subjects’ 
safety. Administrative changes do not require IEC  / IRB approval; however, the IEC / IRB must be 
notifi ed whenever one is made.  
The Investigator is responsible for ensuring that changes to an approved trial , during the period 
for which IEC / IRB approval has already been given, are not initiated without IEC / IRB review 
and approval, except to eliminate app arent immediate hazards to subjects.  
5.[ADDRESS_141359] resulting from this or any other trials become available; or for administrative reasons; or on advice of the Sponsor, the Investigators, and / or the IECs / IRBs. If the trial is prematurely terminated or suspended, the 
Sponsor shall promptly inform the Investigators, the regulatory authorities, and the IECs / IRBs of 
the reason for termination or suspension, as specified by [CONTACT_1214]. 
The Investigator shall promptly inform the trial subjects and assure appropriate therapy and / or 
follow-up for them. 
[ADDRESS_141360] (QIV-HD) 
The investigational QIV -HD is a split virion quadrivalent influenza vaccine (60 μg HA/strain) 
containing virus strains chosen by [CONTACT_14300] / VRBPAC for the NH 2017-2018 influenza season. The vaccine contains 2 antigens of type A (H1N1 and H3N2) and 2 antigens of type B (one each from Yamagata and Victoria lineages). Each pre -filled syringe contains a total of [ADDRESS_141361] manufacturing processes except for the DP formulation step, which includes the addition 
of a second influenza B- strain at the same concentration as the other 3 strains (60μg/strain/dose). 
This also results in a slightly higher fill volume. QIV- HD vaccine is thimerosal -free and prepared 
from influenza viruses propagated in embryonated chicken eggs. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 38 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  3 9  o f  7 7  6 . 1 . 1 . 1  C om p o s i t i o n  
E a c h  0 . 7  m L  d o s e  o f  Q I V -H D  v a c c i n e  c o n t a i n s  t h e  f o l l o w i n g  c om p o n e n t s :  
(S t r a i n s  a r e  b a s e d  o n  W H O  /  V R B P A C  r e c o m m e n d a t i o n s  f o r  t h e  2 0 1 7 - 2 0 1 8  N H  i n f l u e n z a  
s e a s o n . ) :  
A c t i v e  s u b s t a n c e s :  
• A /M i c h i g a n / 4 5 / 2 0 1 5  ( H 1 N 1 )  s t r a i n     6 0  µ g  H A  
• A / H o n g  K o n g / 4 8 0 1 / 2 0 1 4  ( H 3 N 2 )  s t r a i n    6 0  µ g  H A  
• B / B r i s b a n e / 6 0 / 2 0 0 8  s t r a i n       6 0  µ g  H A  
• B / P h u k e t / 3 0 7 3 / 2 0 1 3  s t r a i n       6 0  µ g  H A  
E x c i p i e n t s :  
• B u f f e r e d  s a l i n e  s o l u t i o n         q u a n t i t y  s u f f i c i e n t  ( q s )  t o  a p p r o p r i a t e  v o l um e  
• O c t y l p h e n o l  E t h o x y l a t e  ( T r i t o n  X - 1 0 0 ®)   n o t  m o r e  t h a n  ( NM T )  3 5 0  µ g  
P r e s e r v a t i v e  i s  n o t  u s e d  i n  t h e  m a n u f a c t u r e  o f  Q I V - H D .  
B a t c h  n um b e r :  T B D  
6 . 1 . 1 . 2  P r e p a r a t i o n  a n d  A dm i n i s t r a t i o n  
V a c c i n a t i o n  i s  n o t  t o  b e  p e r f o rm e d  i n  s u b j e c t s  a l l e r g i c  t o  o n e  o f  t h e  c o n s t i t u e n t s  o f  t h e  v a c c i n e .   
P r i o r  t o  a dm i n i s t r a t i o n ,  a l l  s t u d y  p r o d u c t s  m u s t  b e  i n s p e c t e d  v i s u a l l y  f o r  c r a c k s ,  b r o k e n  s e a l s ,  
c o r r e c t  l a b e l  c o n t e n t  ( s e e  S e c t i o n  6 . 3 . 1 ) ,  a n d  e x t r a n e o u s  p a r t i c u l a t e  m a t t e r  a n d  /  o r  d i s c o l o r a t i o n ,  
w h e n e v e r  s o l u t i o n  a n d  c o n t a i n e r  p e rm i t .  I f  a n y  o f  t h e s e  c o n d i t i o n s  e x i s t s ,  t h e  v a c c i n e  m u s t  n o t  b e  
a dm i n i s t e r e d .  A  r e p l a c em e n t  d o s e  i s  t o  b e  u s e d ,  a n d  t h e  e v e n t  i s  t o  b e  r e p o r t e d  t o  t h e  S p o n s o r .   
S u b j e c t s  m u s t  b e  k e p t  u n d e r  o b s e r v a t i o n  f o r  3 0  m i n u t e s  a f t e r  v a c c i n a t i o n  t o  e n s u r e  t h e i r  s a f e t y ,  
a n d  a n y  r e a c t i o n s  d u r i n g  t h i s  p e r i o d  w i l l  b e  d o c um e n t e d  i n  t h e  C R B .  A p p r o p r i a t e  m e d i c a l  
e q u i pm e n t  a n d  em e r g e n c y  m e d i c a t i o n s ,  i n c l u d i n g  e p i n e p h r i n e  ( 1 : 1 0 0 0 ) ,  m u s t  b e  a v a i l a b l e  o n  s i t e  
i n  t h e  e v e n t  o f  a n  a n a p h y l a c t i c ,  o r  o t h e r  imm e d i a t e  a l l e r g i c  r e a c t i o n .  
6 . 1 . 1 . 3  D o s e  S e l e c t i o n  a n d  T im i n g  
T h e  v a c c i n a t i o n  s c h e d u l e  o f  a  s i n g l e  d o s e  f o r  t h e  i n f l u e n z a  s e a s o n  i s  p e r  s t a n d a r d  p r a c t i c e  f o r  
r e c e i p t  o f  a n n u a l  i n f l u e n z a  v a c c i n a t i o n .  
6 . 1 . 2  I d e n t i t y  o f  C o n t r o l  P r o d u c t  1  ( L i c e n s e d  T I V -H D  [ T I V -H D 1 ] )  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
F l u z o n e  H i g h - D o s e  I n f l u e n z a  V a c c i n e  ( Z o n a l  P u r i f i e d ,  S u b v i r i o n )  ( T I V - H D 1 )  i s  t h e  l i c e n s e d  ( i n  
t h e  U S )  i n j e c t a b l e  s t e r i l e  s u s p e n s i o n  w i t h  t r i v a l e n t  i n a c t i v a t e d  T y p e  A  a n d  B  i n f l u e n z a  s p l i t  v i r u s  
v a c c i n e ,  p r o v i d e d  i n  a  p r e - f i l l e d  s y r i n g e .  I t  i s  a  s t e r i l e  s u s p e n s i o n  p r e p a r e d  f r om  i n f l u e n z a  v i r u s e s  
p r o p a g a t e d  i n  em b r y o n a t e d  c h i c k e n  e g g s .  
P a g e  3 9  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  4 0  o f  7 7  6 . 1 . 2 . 1  C om p o s i t i o n  
E a c h  0 . 5  m L  d o s e  o f  T I V - H D 1  v a c c i n e  c o n t a i n s  t h e  f o l l o w i n g  c om p o n e n t s :  
(S t r a i n s  a r e  b a s e d  o n  W H O / V R B P A C  r e c o m m e n d a t i o n s  f o r  t h e  2 0 1 7 - 2 0 1 8  N H  i n f l u e n z a  s e a s o n . ) :   
A c t i v e  S u b s t a n c e s :  
• A /M i c h i g a n / 4 5 / 2 0 1 5  ( H 1 N 1 )  s t r a i n     6 0  µ g  H A  
• A / H o n g  K o n g / 4 8 0 1 / 2 0 1 4  ( H 3 N 2 )  s t r a i n    6 0  µ g  H A  
• B / B r i s b a n e / 6 0 / 2 0 0 8  s t r a i n       6 0  µ g  H A  
E x c i p i e n t s :  
• B u f f e r e d  s a l i n e  s o l u t i o n         q s  t o  a p p r o p r i a t e  v o l um e  
• O c t y l p h e n o l  E t h o x y l a t e  ( T r i t o n  X - 1 0 0 ®)  NM T  2 5 0  µ g  
P r e s e r v a t i v e  i s  n o t  u s e d  i n  t h e  m a n u f a c t u r e  o f  l i c e n s e d  T I V -H D 1 .  
B a t c h  n um b e r :  T B D  
6 . 1 . 2 . 2  P r e p a r a t i o n  a n d  A dm i n i s t r a t i o n  
T h e  p r o c e d u r e s  f o r  p r e p a r i n g  a n d  a dm i n i s t e r i n g  t h e  c o n t r o l  p r o d u c t  a r e  t h e  s am e  a s  t h o s e  
d e s c r i b e d  f o r  t h e  t r i a l  p r o d u c t  i n  S e c t i o n  6 . 1 . 1 . 2 .  
6 . 1 . 2 . 3  D o s e  S e l e c t i o n  a n d  T im i n g  
T h e  v a c c i n a t i o n  s c h e d u l e  o f  a  s i n g l e  d o s e  f o r  t h e  i n f l u e n z a  s e a s o n  i s  p e r  s t a n d a r d  p r a c t i c e  f o r  
r e c e i p t  o f  a n n u a l  i n f l u e n z a  v a c c i n a t i o n .  
6 . 1 . 3  I d e n t i t y  o f  C o n t r o l  P r o d u c t  2  ( I n v e s t i g a t i o n a l  T I V -H D  [ T I V -H D 2 ] )  
T h e  i n v e s t i g a t i o n a l  T I V -H D  ( T I V -H D 2 )  i s  a  H i g h -D o s e  I n f l u e n z a  V a c c i n e  ( Z o n a l  P u r i f i e d ,  
S u b v i r i o n )  i n j e c t a b l e  s t e r i l e  s u s p e n s i o n  w i t h  t r i v a l e n t  i n a c t i v a t e d  T y p e  A  a n d  B  i n f l u e n z a  s p l i t  
v i r u s  v a c c i n e ,  p r o v i d e d  i n  a  p r e - f i l l e d  s y r i n g e .  I t  i s  a  s t e r i l e  s u s p e n s i o n  p r e p a r e d  f r om  i n f l u e n z a  
v i r u s e s  p r o p a g a t e d  i n  em b r y o n a t e d  c h i c k e n  e g g s .   
6 . 1 . 3 . 1  C om p o s i t i o n  
E a c h  0 . 5  m L  d o s e  o f  T I V - H D 2  v a c c i n e  c o n t a i n s  t h e  f o l l o w i n g  c om p o n e n t s :  
(S t r a i n s  a r e  b a s e d  o n  W H O / V R B P A C  r e c o m m e n d a t i o n s  f o r  t h e  2 0 1 7 - 2 0 1 8  N H  i n f l u e n z a  s e a s o n . ) :   
A c t i v e  S u b s t a n c e s :  
• A /M i c h i g a n / 4 5 / 2 0 1 5  ( H 1 N 1 )  s t r a i n     6 0  µ g  H A  
• A / H o n g  K o n g / 4 8 0 1 / 2 0 1 4  ( H 3 N 2 )  s t r a i n    6 0  µ g  H A  
• S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
B / P h u k e t / 3 0 7 3 / 2 0 1 3  s t r a i n       6 0  µ g  H A  
P a g e  4 0  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  4 1  o f  7 7  E x c i p i e n t s :  
• B u f f e r e d  s a l i n e  s o l u t i o n         q s  t o  a p p r o p r i a t e  v o l um e  
• O c t y l p h e n o l  E t h o x y l a t e  ( T r i t o n  X - 1 0 0 ®)  NM T  2 5 0  µ g  
P r e s e r v a t i v e  i s  n o t  u s e d  i n  t h e  m a n u f a c t u r e  o f  T I V - H D 2 .  
B a t c h  n um b e r :  T B D  
6 . 1 . 3 . 2  P r e p a r a t i o n  a n d  A dm i n i s t r a t i o n  
T h e  p r o c e d u r e s  f o r  p r e p a r i n g  a n d  a dm i n i s t e r i n g  t h e  c o n t r o l  p r o d u c t  a r e  t h e  s am e  a s  t h o s e  
d e s c r i b e d  f o r  t h e  t r i a l  p r o d u c t  i n  S e c t i o n  6 . 1 . 1 . 2 .  
6 . 1 . 3 . 3  D o s e  S e l e c t i o n  a n d  T im i n g  
T h e  v a c c i n a t i o n  s c h e d u l e  o f  a  s i n g l e  d o s e  f o r  t h e  i n f l u e n z a  s e a s o n  i s  p e r  s t a n d a r d  p r a c t i c e  f o r  
r e c e i p t  o f  a n n u a l  i n f l u e n z a  v a c c i n a t i o n .  
6 . 2  I d e n t i t y  o f  O t h e r  P r o d u c t s  
N o t  a p p l i c a b l e .  
6 . 3  P r o d u c t  L o g i s t i c s  
6 . 3 . 1  L a b e l i n g  a n d  P a c k a g i n g  
A l l  p r o d u c t s  f o r  t h i s  b l i n d e d  t r i a l  w i l l  b e  a dm i n i s t e r e d  b y  IM  i n j e c t i o n .  
A l l  s t u d y  v a c c i n e s  w i l l  b e  s u p p l i e d  w i t h  i n v e s t i g a t i o n a l  l a b e l i n g  a n d  p a c k a g i n g .  E a c h  s i n g l e  d o s e  
o f  i n v e s t i g a t i o n a l  o r  c o n t r o l  p r o d u c t  w i l l  b e  i d e n t i f i e d  b y  a  u n i q u e  m e d i c a t i o n  n um b e r  o n  t h e  l a b e l  
a n d  o n  t h e  c a r t o n .  T h e  c a r t o n  l a b e l  w i l l  a l s o  h a v e  a  d e t a c h a b l e  l a b e l  f o r  t h e  s i t e s  t o  a t t a c h  t o  t h e  
s o u r c e  d o c um e n t s .  S e e  t h e  O p e r a t i n g  G u i d e l i n e s  f o r  a d d i t i o n a l  l a b e l  d e t a i l .  
6 . 3 . 2  P r o d u c t  S h i pm e n t ,  S t o r a g e ,  a n d  A c c o u n t a b i l i t y  
6 . 3 . 2 . 1  P r o d u c t  S h i pm e n t  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
T h e  C l i n i c a l  L o g i s t i c s  C o o r d i n a t o r  o r  d e s i g n e e  w i l l  c o n t a c t  t h e  I n v e s t i g a t o r  o r  a  d e s i g n e e  i n  o r d e r  
t o  d e t e rm i n e  t h e  d a t e s  a n d  t im e s  o f  d e l i v e r y  o f  p r o d u c t s .  
E a c h  v a c c i n e  s h i pm e n t  w i l l  i n c l u d e  a  t em p e r a t u r e -m o n i t o r i n g  d e v i c e  t o  v e r i f y  m a i n t e n a n c e  o f  t h e  
c o l d  c h a i n  d u r i n g  t r a n s i t .  O n  d e l i v e r y  o f  t h e  p r o d u c t  t o  t h e  s i t e ,  t h e  p e r s o n  i n  c h a r g e  o f  p r o d u c t  
r e c e i p t  w i l l  f o l l o w  t h e  i n s t r u c t i o n s  g i v e n  i n  t h e  O p e r a t i n g  G u i d e l i n e s ,  i n c l u d i n g  c h e c k i n g  t h a t  t h e  
c o l d  c h a i n  w a s  m a i n t a i n e d  d u r i n g  s h i pm e n t  ( i . e . ,  v e r i f i c a t i o n  o f  t h e  t em p e r a t u r e  r e c o r d e r s ) .  I f  
t h e r e  i s  a n  i n d i c a t i o n  t h a t  t h e  c o l d  c h a i n  w a s  b r o k e n ,  t h i s  p e r s o n  s h o u l d  imm e d i a t e l y  q u a r a n t i n e  
P a g e  4 1  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141362]. 
[IP_ADDRESS] Product Storage  
The Investigator will be personally responsible for product management or will designate a staff 
member to  assume this responsibility.  
At the site, products must be kept in a secure place with restricted access. Vaccines will be stored in a refrigerator at a temper ature ranging from +2°C to +8°C. The vaccines must not be frozen. 
The temperature must be monitored and documented (see the Operating Guidelines) for the entire time that the vaccine is at the trial site. In case of accidental freezing or disruption of the cold chain, vaccines must not be administered and must be quarantined, and the Investigator or 
authorized designee should contact [CONTACT_35340].  
[IP_ADDRESS] Product Accountability  
The person in charge of product management at the site will maintain records of product delivery 
to the trial site, product inventory at the site, the dose given to each subject, and the disposal of or 
return to the Sponsor of unused doses.  
The necessary information on the product labels is to be entered into the source document and the 
CRB. The Sponsor’s monitoring staff will verify the tri al site’s product accountability records against 
the record of administered doses in the CRBs and the communication from the IRT  (if applicable). 
In case of any expected or potential shortage of product during the trial, the Investigator or an 
authorized d esignee should alert the [COMPANY_011] Pasteur representative as soon as possible, so that a 
shipment of extra doses can be arranged.  
6.3.3 Replacement Doses 
If a replacement dose is required (e.g., because the syringe broke or particulate matter was observed in the syringe), the site personnel must either contact [CONTACT_35341], or follow the instructions given in the Operating Guidelines. 
6.3.[ADDRESS_141363] accountability will be verified throughout the trial period. 
6.3.5 Recall of Products  
If the Sponsor makes a decision to launch a retrieval procedure, the Investigator(s) will be 
informed of what needs to be done. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 42 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  4 3  o f  7 7  6 . 4  B l i n d i n g  a n d  C o d e -b r e a k i n g  P r o c e d u r e s  
T o  e n s u r e  t h a t  o b j e c t i v e  d a t a  a r e  o b t a i n e d ,  t h e  t r i a l  i s  d e s i g n e d  a s  a  m o d i f i e d  d o u b l e - b l i n d  s t u d y  
a s  f o l l o w :  
• T h e  u n b l i n d e d  q u a l i f i e d  t r i a l  s t a f f  m em b e r ,  i n d e p e n d e n t  o f  t h e  s a f e t y  e v a l u a t i o n  a n d  o t h e r  t r i a l  
e v a l u a t i o n s  w i l l  a dm i n i s t e r  t h e  v a c c i n e  
• T h e  I n v e s t i g a t o r s  ( o r  d e l e g a t e s )  i n  c h a r g e  o f  s a f e t y  a s s e s sm e n t ,  t h e  t r i a l  s t a f f  w h o  c o l l e c t  t h e  
s a f e t y  d a t a ,  a n d  t h e  l a b o r a t o r y  p e r s o n n e l  w h o  a n a l y z e  t h e  b l o o d  s am p l e s  w i l l  n o t  k n o w  w h i c h  
p r o d u c t  w a s  a dm i n i s t e r e d  
• T h e  s u b j e c t  w i l l  n o t  k n o w  w h i c h  p r o d u c t  w a s  a dm i n i s t e r e d  
T h e  I n v e s t i g a t o r  r e s p o n s i b l e  f o r  s a f e t y  a s s e s sm e n t  w i l l  n o t  a t t e n d  t h e  v a c c i n a t i o n  s e s s i o n  b u t  w i l l  
b e  a v a i l a b l e  i n  c a s e  o f  em e r g e n c y  ( e . g . ,  a n a p h y l a c t i c  s h o c k ) .  
D o s e  n um b e r s  w i l l  b e  u s e d  t o  i d e n t i f y  e a c h  v a c c i n e  s y r i n g e  f o r  t h e  p u r p o s e  o f  r a n d om i z a t i o n ,  
v a c c i n a t i o n  a n d  t h e  r e c o r d i n g  o f  v a c c i n e  a dm i n i s t e r e d .  D o s e  n um b e r s  w i l l  b e  r a n d om l y  a s s i g n e d  
t o  Q I V -H D  a n d  T I V - H D  s y r i n g e s .  T h e  I R T  v e n d o r  w i l l  b e  r e s p o n s i b l e  f o r  p r o v i d i n g  t h e  t r e a tm e n t  
g r o u p  i d e n t i f i c a t i o n  a n d  d o s e  n um b e r  t o  b e  r e c e i v e d  b y  t h e  e n r o l l e d  s u b j e c t .  T h e  s u b j e c t ,  t h e  
I n v e s t i g a t o r ,  a n d  s t u d y  s t a f f  m em b e r s  w h o  c o l l e c t  t h e  s a f e t y  d a t a  a n d  l a b o r a t o r y  p e r s o n n e l  w h o  
a n a l y z e  t h e  b l o o d  s am p l e s  w i l l  a l l  b e  b l i n d e d  t o  t h e  g r o u p  a s s i g nm e n t .  T h e  i n d i v i d u a l  r e s p o n s i b l e  
f o r  p r e p a r i n g  /  a dm i n i s t e r i n g  v a c c i n e  w i l l  n o t  b e  a u t h o r i z e d  t o  c o l l e c t  a n y  s a f e t y  /  s e r o l o g y  d a t a .  
T h e  c o d e  m a y  b e  b r o k e n  i n  t h e  e v e n t  o f  a n  A E  o n l y  w h e n  t h e  i d e n t i f i c a t i o n  o f  t h e  v a c c i n e  
r e c e i v e d  c o u l d  i n f l u e n c e  t h e  t r e a tm e n t  o f  t h e  s u b j e c t .  C o d e - b r e a k i n g  s h o u l d  b e  l im i t e d  t o  t h e  
s u b j e c t ( s )  e x p e r i e n c i n g  t h e  A E .  
T h e  b l i n d  c a n  b e  b r o k e n  b y  t h e  I n v e s t i g a t o r  o r  a  d e l e g a t e  t h r o u g h  t h e  I R T  s y s t em  a s  e x p l a i n e d  i n  
t h e  c o d e - b r e a k i n g  p r o c e d u r e s  d e s c r i b e d  i n  t h e  O p e r a t i n g  G u i d e l i n e s .  O n c e  t h e  em e r g e n c y  h a s  
b e e n  a d d r e s s e d  b y  t h e  s i t e ,  t h e  I n v e s t i g a t o r  o r  a  d e l e g a t e  m u s t  n o t i f y  t h e  S a n o f i  P a s t e u r  RM O  i f  a  
s u b j e c t ’ s  c o d e  w a s  b r o k e n .  A l l  c o n t a c t  a t t em p t s  w i t h  t h e  S p o n s o r  p r i o r  t o  u n b l i n d i n g  a r e  t o  b e  
d o c um e n t e d  i n  t h e  s o u r c e  d o c um e n t s ,  a n d  t h e  c o d e  b r e a k i n g  C R F  i s  t o  b e  c om p l e t e d .  
A  r e q u e s t  f o r  t h e  c o d e  t o  b e  b r o k e n  m a y  a l s o  b e  m a d e :  
• S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
b y  t h e  G P E  D e p a r tm e n t  t h r o u g h  a n  i n t e r n a l  s y s t em  f o r  r e p o r t i n g  t o  H e a l t h  A u t h o r i t i e s  i n  t h e  
c a s e  o f  a n  S A E  a s  d e s c r i b e d  i n  I C H  E 2 A .  I n  t h i s  c a s e ,  t h e  c o d e  w i l l  b e  b r o k e n  o n l y  f o r  t h e  
s u b j e c t ( s )  i n  q u e s t i o n .  T h e  i n f o rm a t i o n  r e s u l t i n g  f r om  c o d e - b r e a k i n g  ( i . e . ,  t h e  s u b j e c t ’ s  
v a c c i n e  o r  g r o u p  a s s i g nm e n t )  w i l l  n o t  b e  c omm u n i c a t e d  t o  e i t h e r  t h e  I n v e s t i g a t o r  o r  t h e  
imm e d i a t e  t e am  w o r k i n g  o n  t h e  s t u d y ,  e x c e p t  f o r  t h e  G P E  r e p r e s e n t a t i v e .   
Th e  I E C  /  I R B  m u s t  b e  n o t i f i e d  o f  t h e  c o d e - b r e a k i n g .  A l l  d o c um e n t a t i o n  p e r t a i n i n g  t o  t h e  e v e n t  
m u s t  b e  r e t a i n e d  i n  t h e  s i t e ’ s  s t u d y  r e c o r d s  a n d  i n  t h e  S a n o f i  P a s t e u r  f i l e s .  A n y  i n t e n t i o n a l  o r  
u n i n t e n t i o n a l  c o d e - b r e a k i n g  m u s t  b e  r e p o r t e d ,  d o c um e n t e d ,  a n d  e x p l a i n e d ,  a n d  t h e  n am e  o f  t h e  
p e r s o n  w h o  r e q u e s t e d  i t  m u s t  b e  p r o v i d e d  t o  t h e  S p o n s o r .  
I n  a n y  c a s e ,  t h e  c o d e  w i l l  b e  b r o k e n  a f t e r  t h e  f i r s t  d a t a b a s e  l o c k ,  f o r  t h e  p r im a r y  s t a t i s t i c a l  
a n a l y s i s  p l a n n e d  t o  a n a l y z e  t h e  d a t a  c o l l e c t e d  w i t h i n  t h e  2 8  d a y s  f o l l o w i n g  t h e  v a c c i n a t i o n ,  b u t  
t h e  r a n d om i z a t i o n  l i s t  w i l l  n o t  b e  p r o v i d e d  t o  I n v e s t i g a t o r s  a n d  w i l l  b e  k e p t  i n t e r n a l l y  u n t i l  t h e  
f i n a l  d a t a b a s e  l o c k .  
P a g e  4 3  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 44 of 77 6.5 Randomization and Allocation Procedures  
The study will be randomized, modified double-blinded for 3 vaccine groups. Table 6.1 shows the 
allocation of subjects to each vaccine group. No age stratification is applied here. 
Table 6.1: Enrollment of subjects by [CONTACT_125629]-HD TIV-HDs Total Subjects  
 
QIV-HD TIV-HD1 
(licensed 
TIV-HD) TIV-HD2 
(investigational TIV -HD 
with alternate B strain)   
Subjects to be 
Enrolled 1744  [PHONE_2825]  
Expanded 
Immunogenicity 
Subset† 100 100 100 300 
*Safety data and serum for HAI testing will be collected for all subjects.  
†A randomized subset of subjects from each group will be selected for SN testing.  
For the subject list, block randomization is applied for all subjects within strata by [CONTACT_21127]. The 
allocation ratio for the 3 vaccine groups is 4:1:1. Subjects who meet the inclusion / exclusion criteria and sign an ICF will be randomly assigned to one of the groups via IRT. Subjects will also be randomly assigned into the Expanded Immunogenicity S ubset for SN testing via IRT. The site 
administrator will connect to the  IRT, enter the identification and security information , and 
confirm a minimal amount of data in response to IRT prompts. The IRT will then provide the 
subject number, the vaccine assignment, and have the site administrator confirm it. Subject numbers and dose numbers will be recorded on the source documents and CRBs . The full detailed 
procedures for randomization are described in the Operating Guidelines. If the subject is not 
eligib le to participate in the study, then the information will only be recorded on the subject 
recruitment log.  
Subject numbers that are assigned by [CONTACT_29515] a 12-digit string (a 3-digit country identifier, a [ADDRESS_141364] identifier). For example, 
Subject [ADDRESS_141365] enrolled in Center Number 1 in the US (840 being the US country code).  
Subject numbers should not be reassigned for any reason. For packaging list, dose numbers will be 7 digits long. Dose numbers are not used for packaging 
but only in the IRT system.   
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 44 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  4 5  o f  7 7  6 . 6  T r e a tm e n t  C om p l i a n c e  
T h e  f o l l o w i n g  m e a s u r e s  w i l l  e n s u r e  t h a t  t h e  v a c c i n e  d o s e s  a dm i n i s t e r e d  c om p l y  w i t h  t h o s e  p l a n n e d ,  
a n d  t h a t  a n y  n o n - c om p l i a n c e  i s  d o c um e n t e d  s o  t h a t  i t  c a n  b e  a c c o u n t e d  f o r  i n  t h e  d a t a  a n a l y s e s :  
• A l l  v a c c i n a t i o n s  w i l l  b e  a dm i n i s t e r e d  b y  q u a l i f i e d  t r i a l  p e r s o n n e l  
• T h e  p e r s o n  i n  c h a r g e  o f  p r o d u c t  m a n a g em e n t  a t  t h e  s i t e  w i l l  m a i n t a i n  a c c o u n t a b i l i t y  r e c o r d s  
o f  p r o d u c t  d e l i v e r y  t o  t h e  t r i a l  s i t e ,  p r o d u c t  i n v e n t o r y  a t  t h e  s i t e ,  d o s e ( s )  g i v e n  t o  e a c h  s u b j e c t ,  
a n d  t h e  d i s p o s a l  o f  u n u s e d  o r  w a s t e d  d o s e s  
6 . 7  C o n c om i t a n t  M e d i c a t i o n s  a n d  O t h e r  T h e r a p i e s  
A t  t h e  t im e  o f  e n r o l lm e n t ,  o n g o i n g  m e d i c a t i o n s  i n c l u d i n g  o t h e r  t h e r a p i e s  e . g . ,  b l o o d  p r o d u c t s ,  
s h o u l d  b e  r e c o r d e d  i n  t h e  s o u r c e  d o c um e n t  a s  w e l l  a s  n e w  m e d i c a t i o n s  p r e s c r i b e d  f o r  n e w  
m e d i c a l  c o n d i t i o n s  /  A E s  d u r i n g  t r i a l  p a r t i c i p a t i o n .   
D o c um e n t a t i o n  i n  t h e  C R B  o f  c o n c om i t a n t  m e d i c a t i o n  w i l l  b e  l im i t e d  t o  s p e c i f i c  c a t e g o r i e s  o f  
m e d i c a t i o n  o f  i n t e r e s t  b e g i n n i n g  o n  t h e  d a y  o f  v a c c i n a t i o n .  T h i s  m a y  i n c l u d e  m e d i c a t i o n s  o f  
i n t e r e s t  t h a t  w e r e  s t a r t e d  p r i o r  t o  t h e  d a y  o f  v a c c i n a t i o n .  
R e p o r t a b l e  m e d i c a t i o n s  w i l l  b e  c o l l e c t e d  i n  t h e  C R B  f r om  t h e  d a y  o f  v a c c i n a t i o n  t o  t h e  e n d  o f  t h e  
s o l i c i t e d  a n d  u n s o l i c i t e d  f o l l o w - u p  p e r i o d .    
R e p o r t a b l e  m e d i c a t i o n s  i n c l u d e  m e d i c a t i o n s  t h a t  im p a c t  o r  m a y  im p a c t  t h e  c o n s i s t e n c y  o f  t h e  s a f e t y  
i n f o rm a t i o n  c o l l e c t e d  a f t e r  a n y  v a c c i n a t i o n  a n d / o r  t h e  imm u n e  r e s p o n s e  t o  v a c c i n a t i o n .  F o u r  
c a t e g o r i e s  o f  r e p o r t a b l e  m e d i c a t i o n s  a r e  d e f i n e d :  
• C a t e g o r y  1 :  m e d i c a t i o n s  im p a c t i n g  o r  t h a t  m a y  h a v e  a n  im p a c t  o n  t h e  e v a l u a t i o n  o f  t h e  s a f e t y  
( e . g . ,  a n t i p y r e t i c s ,  a n a l g e s i c s ,  n o n - s t e r o i d a l  a n t i - i n f l amm a t o r y  d r u g s )   
• C a t e g o r y  2 :  m e d i c a t i o n s  im p a c t i n g  o r  t h a t  m a y  h a v e  a n  im p a c t  o n  t h e  imm u n e  r e s p o n s e  ( e . g . ,  
o t h e r  v a c c i n e s ,  b l o o d  p r o d u c t s ,  a n t i b i o t i c  c l a s s e s  t h a t  m a y  i n t e r f e r e  w i t h  b i o a s s a y s  u s e d  b y  t h e  
G l o b a l  C l i n i c a l  Imm u n o l o g y  [ G C I ]  d e p a r tm e n t ,  imm u n e - s u p p r e s s o r s ,  imm u n e -m o d u l a t o r s  
w i t h  imm u n o s u p p r e s s i v e  p r o p e r t i e s ,  a n t i - p r o l i f e r a t i v e  d r u g s  s u c h  a s  D N A  s y n t h e s i s  i n h i b i t o r s )  
• C a t e g o r y  3 :  m e d i c a t i o n s  im p a c t i n g  o r  t h a t  m a y  h a v e  a n  im p a c t  o n  b o t h  t h e  s a f e t y  a n d  t h e  
imm u n e  r e s p o n s e  ( e . g . ,  s t e r o i d s / c o r t i c o s t e r o i d s )  
• C a t e g o r y  4 :  t h e  s t a t i n  f am i l y  o f  a n t i - h y p e r l i p i d em i a  m e d i c a t i o n s  ( e . g . ,  a t o r v a s t a t i n ,  
r o s u v a s t a t i n ,  s im v a s t a t i n ,  p r a v a s t a t i n ,  a n d  f l u v a s t a t i n )   
T h e  i n f o rm a t i o n  r e p o r t e d  i n  t h e  C R B  f o r  e a c h  r e p o r t e d  m e d i c a t i o n  w i l l  b e  l im i t e d  t o :  
• T r a d e  n am e  o r  g e n e r i c  n am e  
• O r i g i n  o f  p r e s c r i p t i o n :  p r o p h y l a x i s  Y e s / N o .  M e d i c a t i o n ( s )  p r e s c r i b e d  f o r  A E  p r o p h y l a x i s  w i l l  
b e  r e c o r d e d  i n  t h e  A c t i o n  T a k e n  o f  t h e  A E  c o l l e c t i o n  t a b l e s .  
• M e d i c a t i o n  c a t e g o r y   
• S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
S t a r t  a n d  s t o p  d a t e s  
P a g e  4 5  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141366] that a medication was given in response to an AE will be captured in the “Action Taken” 
section of the AE CRF only. No details will be recorded in the concomitant medication CRF unless  
the medication received belongs to one of the prelisted categories. Medications will not be coded. 
7 Management of Samples  
Blood samples for the assessment of Ab responses will be collected at Visit 1 (D0, pre -
vaccination) and at Visit 2 (D28). See the  Table of Study Procedures  and Section 5.1.[ADDRESS_141367]’s identity; will verify the assigned subject 's number on the pre- printed label that 
contains that subject’s number and the sampling stage; and will attach the label to the tube. Blood is to be taken from the limb opposite to the one that will be used for vaccination. 
7.2 Sample Preparation  
Detailed instructions on how to prepare blood samples for assessment of Ab response are 
contained in the Operating Guidelines provided to the site. An overview of the procedures is provided here. 
Following the blood draw, the tubes are to be left undisturbed, positioned vertically and not 
shaken, for a minimum of one hour and a maximum of 24 hours in order to allow the blood to 
clot. Samples can be stored at room temperature for up to 2 hours; beyond [ADDRESS_141368] be refrigerated at a temperature of +2°C to +8°C after the period of clotting at room temperature and must be centrifuged within a maximum of [ADDRESS_141369]’s number, and 
the sampling stage or visit number. The subject’s number, the date of sampling, the number of aliquots obtained, the date and time of 
preparation, and the subject’s consent for future use of his / her samples are to be specified on a sample identification list and recorded in the source document. Space is provided on this list for comments on the quality of samples. 
7.3 Sample Storage and Shipment  
During storage, serum tubes are to be kept in a freezer whose temperature is set and maintained at -20°C or below. The temperature will be monitored and documented on the appropriate form 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 46 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 47 of 77 during the entire trial. If it rises a bove -10°C for any period of time, the Clinical Logistics 
Coordinator must be notified. See the Operating Guidelines for further details. 
Shipments to the laboratories will be made only after appropriate monitoring, and following 
notification of the Clinic al Logistics Coordinator. Sera will be shipped frozen, using dry ice to 
maintain them in a frozen state, in the packaging container provided by [CONTACT_21440] . Again, 
temperatures will be monitored. Shipments must be compliant with the International Air 
Trans port Association 602 regulations . 
Samples will be shipped to Global Clinical Immunology (GCI) at [COMPANY_011] Pasteur . The address is 
provided in the Operating Guidelines.  
7.4 Future Use of Stored Serum Samples for Research  
Any unused part of the serum samples will be securely stored at the [COMPANY_011] Pasteur  serology 
laboratory (GCI) for at least [ADDRESS_141370] license approval in the relevant market areas has 
been obtained for the vaccine being tested. 
Subjects will be asked to indicate in the ICF  whether they will permit the future use of any unused 
stored serum samples for other tests. If they refuse permission, the samples will not be used for 
any testing other than that directly related to this study. If they agree to this use, they will not be 
paid for giving permission. Anonymity of samples will be ensured. The aim of any possible future research is unknown today, and may not be related to this particular study. It may be to improve the knowledge of vaccines or infectious diseases, or to improve existing t ests or develop new tests 
to assess vaccines. Human genetic tests will never be performed on these samples without specific individual informed consent.  
8 Clinical Supplies  
[COMPANY_011] Pasteur will supply the trial sites with protocols, ICFs, CRBs, SAE  reporting forms , diary 
cards, memory aids, and other trial documents, as well as with the following trial materials: all 
study vaccines, blood collection tubes, cryotubes, cryotube storage boxes, cryotube labels, 
temperature recorders, shippi[INVESTIGATOR_35275], rulers, and digital thermometers.  
The means for performing EDC will be defined by [CONTACT_35346] . If a computer is provided by 
[CONTACT_35346] , it will be retrieved at the end of the trial. 
The Investigator will supply all vaccination supplies, phlebotomy, and centrifugation equipment, including biohazard and / or safety supplies. The biohazard and safety supplies include needles 
and syringes, examination gloves, laboratory coats, sharps disposal containers, and absorbent countertop paper. The site will ensure that all biohazard wastes are autoclaved and disposed of in accordance with local practices. The Investigator will also supply appropriate space in a temperature -monitored refrigerator for the storage of the products and for the blood samples, and 
appropriate s pace in a temperature -monitored freezer for serum aliquots. 
In the event that additional supplies are required, study staff must contact [CONTACT_35346] , 
indicating the quantity required. Contact [CONTACT_35347].  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 47 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  4 8  o f  7 7  9 E n d p o i n t s  a n d  A s s e s sm e n t  M e t h o d s  
9 . 1  P r im a r y  E n d p o i n t s  a n d  A s s e s sm e n t  M e t h o d s  
9 . 1 . 1  Imm u n o g e n i c i t y  
9 . 1 . 1 . 1  Imm u n o g e n i c i t y  E n d p o i n t s  
T h e  p r im a r y  e n d p o i n t s  f o r  t h e  e v a l u a t i o n  o f  imm u n o g e n i c i t y  a r e :  
• H A I  A b  t i t e r s  o b t a i n e d  o n  D 2 8  
• S e r o c o n v e r s i o n  ( t i t e r  <  1 0  [ 1 / d i l ]  a t  D 0  a n d  p o s t - i n j e c t i o n  t i t e r  ≥ 4 0  [ 1 / d i l ]  a t  D 2 8 ,  o r  t i t e r  
≥ 1 0  [ 1 / d i l ]  a t  D 0  a n d  a  ≥  4 - f o l d  i n c r e a s e  i n  t i t e r  [ 1 / d i l ]  a t  D 2 8 )  
9 . 1 . 1 . 2  Imm u n o g e n i c i t y  A s s e s sm e n t  M e t h o d s   
A n t i -I n f l u e n z a  V i r u s  A b  T i t r a t i o n  b y  I n h i b i t i o n  o f  H em a g g l u t i n a t i o n  
A s s a y s  w i l l  b e  p e r f o rm e d  b y  t h e  S p o n s o r ’ s  l a b o r a t o r y  ( G C I ,  S w i f t w a t e r ,  P A ,  U S A )  o r  a t  a n  
e x t e r n a l  t e s t i n g  l a b o r a t o r y  u n d e r  G C I  r e s p o n s i b i l i t y .  T h e  a d d r e s s  i s  p r o v i d e d  i n  t h e  O p e r a t i n g  
G u i d e l i n e s .  
T e s t  s e r um  s am p l e s  a n d  q u a l i t y  c o n t r o l  s e r a  ( s h e e p ,  f e r r e t ,  a n d / o r  h um a n  s e r a )  a r e  i n c u b a t e d  w i t h  
S i gm a  T y p e  I I I  n e u r am i n i d a s e  f r om  v i b r i o  c h o l e r a e  t o  e l im i n a t e  n o n - s p e c i f i c  i n h i b i t o r s .  
A d s o r p t i o n  o f  s p o n t a n e o u s  a n t i - s p e c i e s  a g g l u t i n i n s  i s  t h e n  p e r f o rm e d  b y  i n c u b a t i n g  t h e  t e s t  s e r um  
s am p l e s  a n d  q u a l i t y  c o n t r o l  s e r a  w i t h  a  r e d  b l o o d  c e l l  ( R B C )  s u s p e n s i o n .  F o l l o w i n g  t h i s ,  t h e  
m i x t u r e s  a r e  c e n t r i f u g e d  a n d  t h e  s u p e r n a t a n t s  c o n t a i n i n g  t h e  t r e a t e d  s e r a  a r e  c o l l e c t e d  f o r  t e s t i n g .  
T e n  t w o - f o l d  d i l u t i o n s  ( s t a r t i n g  a t  1 : 1 0 )  o f  t h e  t r e a t e d  t e s t  s e r um  s am p l e s  a n d  q u a l i t y  c o n t r o l  s e r a  
a r e  i n c u b a t e d  w i t h  a  p r e v i o u s l y  t i t r a t e d  i n f l u e n z a  a n t i g e n  a t  a  c o n c e n t r a t i o n  o f  4  h em a g g l u t i n a t i o n  
u n i t  ( H A U ) / 2 5  µ L .  I n f l u e n z a  a n t i g e n  i s  n o t  a d d e d  t o  t h e  s e r um  c o n t r o l  w e l l s  c o n t a i n i n g  o n l y  
s e r um  a n d  R B C s .  T h e  m i x t u r e  i s  t h e n  i n c u b a t e d  a n d  a  R B C  s u s p e n s i o n  i s  a d d e d .  F o l l o w i n g  
i n c u b a t i o n ,  t h e  r e s u l t s  a r e  r e a d .  T h e  e n d p o i n t  o f  t h e  a s s a y  i s  t h e  h i g h e s t  s e r um  d i l u t i o n  i n  w h i c h  
c om p l e t e  i n h i b i t i o n  o f  h em a g g l u t i n a t i o n  o c c u r r e d .  E a c h  s e r um  s am p l e  i s  t i t r a t e d  i n  t w o  
i n d e p e n d e n t  a s s a y  r u n s ,  a n d  t h e  2  v a l u e s ,  w h i c h  c a n n o t  d i f f e r  b y  m o r e  t h a n  1  t w o - f o l d  d i l u t i o n ,  
a r e  r e p o r t e d .  T h e  GM T  b e t w e e n  t h e  2  v a l u e s  i s  c a l c u l a t e d  a t  t h e  t im e  o f  s t a t i s t i c a l  a n a l y s i s .  T h e  
l o w e r  l im i t  o f  q u a n t i t a t i o n  ( L L O Q )  i s  s e t  a t  t h e  l o w e s t  d i l u t i o n  u s e d  i n  t h e  a s s a y ,  1 : 1 0 .  T i t e r s  
b e l o w  t h i s  l e v e l  a r e  r e p o r t e d  a s  <  1 0  ( 1 / d i l ) .  I f  t h e  l o w e s t  /  f i r s t  s e r um  d i l u t i o n  u s e d  i n  t h e  a s s a y  
e x h i b i t s  c om p l e t e  i n h i b i t i o n  o f  h em a g g l u t i n a t i o n ,  t h e  s e r um  A b  t i t e r  w i l l  b e  r e p o r t e d  a s  <  1 0  
( 1 / d i l ) .  I f  t h e  h i g h e s t  /  l a s t  s e r um  d i l u t i o n  u s e d  i n  t h e  a s s a y  e x h i b i t s  c om p l e t e  i n h i b i t i o n  o f  
h em a g g l u t i n a t i o n ,  t h e  s e r um  A b  t i t e r  w i l l  b e  r e p o r t e d  a s  ≥  1 0 2 4 0  ( 1 / d i l ) .  
9 . 1 . 2  S a f e t y  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
T h e r e  a r e  n o  p r im a r y  o b j e c t i v e s  f o r  s a f e t y .  
P a g e  4 8  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  4 9  o f  7 7  9 . 1 . 3  E f f i c a c y  
N o  c l i n i c a l  e f f i c a c y  d a t a  w i l l  b e  o b t a i n e d  i n  t h e  t r i a l .  
9 . 2  S e c o n d a r y  E n d p o i n t s  a n d  A s s e s sm e n t  M e t h o d s  
9 . 2 . 1  Imm u n o g e n i c i t y  
9 . 2 . 1 . 1  Imm u n o g e n i c i t y  E n d p o i n t s  
9 . 2 . 1 . 1 . 1  Imm u n o g e n i c i t y  b y  H A I  M e t h o d  
T h e  s e c o n d a r y  e n d p o i n t s  f o r  t h e  e v a l u a t i o n  o f  imm u n o g e n i c i t y  b y  H A I  m e t h o d  a r e :  
• H A I  A b  t i t e r s  o b t a i n e d  o n  D 0  a n d  D 2 8  
• I n d i v i d u a l  H A I  t i t e r s  r a t i o  D 2 8 / D 0  
• S e r o c o n v e r s i o n  ( t i t e r  <  1 0  [ 1 / d i l ]  a t  D 0  a n d  p o s t - i n j e c t i o n  t i t e r  ≥ 4 0  [ 1 / d i l ]  a t  D 2 8 ,  o r  t i t e r  
≥ 1 0  [ 1 / d i l ]  a t  D 0  a n d  a  ≥  4 - f o l d  i n c r e a s e  i n  t i t e r  [ 1 / d i l ]  a t  D 2 8 )  
• S e r o p r o t e c t i o n  ( t i t e r  ≥  4 0  [ 1 / d i l ] )  a t  D 0  a n d  D 2 8  
9 . 2 . 1 . 1 . 2  Imm u n o g e n i c i t y  b y  S N  M e t h o d  
N e u t r a l i z i n g  A b  t i t e r s  w i l l  b e  m e a s u r e d  f o r  e a c h  i n f l u e n z a  s t r a i n  w i t h  t h e  S N  m e t h o d  i n  a  
r a n d om l y  s e l e c t e d  s u b s e t  o f  s u b j e c t s  f r om  e a c h  s t u d y  g r o u p .  T h e y  w i l l  b e  o b t a i n e d  o n  D 0  a n d  
D 2 8 .   
T h e  s e c o n d a r y  e n d p o i n t s  f o r  t h e  e v a l u a t i o n  o f  imm u n o g e n i c i t y  b y  S N  m e t h o d  a r e :  
• I n d i v i d u a l  n e u t r a l i z a t i o n  t e s t  ( N T )  A b  t i t e r  o n  D 0  a n d  D 2 8   
• I n d i v i d u a l  N T  A b  t i t e r  r a t i o  ( f o l d  i n c r e a s e  i n  s e r um  N T  p o s t - v a c c i n a t i o n  r e l a t i v e  t o  D 0 )  a t  
D 2 8   
• S u b j e c t s  w i t h  N T  A b  t i t e r s  ≥  2 0  ( 1 / d i l ) ,  ≥  4 0  ( 1 / d i l ) ,  ≥  8 0  ( 1 / d i l )  a t  D 2 8   
• F o l d -i n c r e a s e  i n  N T  A b  t i t e r  [ p o s t / p r e ]  ≥ 2  a n d  ≥  4  a t  D 2 8   
• D e t e c t a b l e  N T  ( N T  A b  t i t e r  ≥  1 0  [ 1 / d i l ] )  a t  D 0  a n d  D 2 8  
9 . 2 . 1 . 2  Imm u n o g e n i c i t y  A s s e s sm e n t  M e t h o d s  
9 . 2 . 1 . 2 . 1  Imm u n o g e n i c i t y  b y  H A I  M e t h o d  
T h e  imm u n o g e n i c i t y  a s s e s sm e n t  m e t h o d s  f o r  t h e  s e c o n d a r y  e n d p o i n t s  a r e  t h e  s am e  a s  t h o s e  
p r e s e n t e d  i n  S e c t i o n  9 . 1 . 1 . 2 . S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
 
P a g e  4 9  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  5 0  o f  7 7  9 . 2 . 1 . 2 . 2  Imm u n o g e n i c i t y  b y  S N  M e t h o d  
I n f l u e n z a  V i r u s  N e u t r a l i z a t i o n  T e s t  
A s s a y s  w i l l  b e  p e r f o rm e d  b y  t h e  S p o n s o r ’ s  l a b o r a t o r y  ( G C I ,  S w i f t w a t e r ,  P A ,  U S A )  o r  a t  a n  
e x t e r n a l  t e s t i n g  l a b o r a t o r y  u n d e r  G C I  r e s p o n s i b i l i t y .   
T h i s  N T  m e a s u r e s  A b s  d i r e c t e d  a g a i n s t  t h e  v i r a l  n e u t r a l i z a t i o n  e p i t o p e s  o f  t h e  i n f l u e n z a  v i r u s ,  
w h i c h  m a y  b e  d i f f e r e n t  f r om  t h e  h em a g g l u t i n a t i o n  e p i t o p e s ,  t h e r e f o r e ,  t h e  N T  t i t e r s  m a y  b e  
d i f f e r e n t  f r om  t h e  H A I  t i t e r s .  
T o  m e a s u r e  N T ,  s e r i a l l y  d i l u t e d ,  h e a t -i n a c t i v a t e d  h um a n  s e r um  s am p l e s  w i l l  b e  p r e - i n c u b a t e d  
w i t h  a  f i x e d  am o u n t  o f  c h a l l e n g e  v i r u s  p r i o r  t o  t h e  a d d i t i o n  o f  M a d i n - D a r b y  c a n i n e  k i d n e y  
(M D C K )  c e l l s .  A f t e r  o v e r n i g h t  i n c u b a t i o n ,  t h e  v i r a l  n u c l e o p r o t e i n  p r o d u c t i o n  i n  i n f e c t e d  M D C K  
c e l l s  i s  m e a s u r e d  b y  e n z ym e  l i n k e d  imm u n o s o r b e n t  a s s a y  ( E L I S A ) ,  u s i n g  m o n o c l o n a l  A b  s p e c i f i c  
t o  e i t h e r  i n f l u e n z a  A  n u c l e o p r o t e i n  o r  i n f l u e n z a  B  n u c l e o p r o t e i n .  S i n c e  s e r um  n e u t r a l i z i n g  A b s  t o  
t h e  i n f l u e n z a  v i r u s  i n h i b i t s  t h e  v i r a l  i n f e c t i o n  o f  M D C K  c e l l s ,  t h e  E L I S A  o p t i c a l  d e n s i t y  r e s u l t s  
a r e  i n v e r s e l y  p r o p o r t i o n a l  t o  t h e  t i t e r s  o f  n e u t r a l i z i n g  A b  p r e s e n t  i n  t h e  s e r um .  T h e  L L O Q  i s  s e t  a t  
t h e  r e c i p r o c a l  o f  t h e  l o w e s t  d i l u t i o n  u s e d  i n  t h e  a s s a y ,  i . e . ,  1 0  ( 1 / d i l ) .  T i t e r s  b e l o w  t h i s  l e v e l  a r e  
r e p o r t e d  a s  <  1 0  ( 1 / d i l ) .   
 
9 . 2 . 2  S a f e t y  
9 . 2 . 2 . 1  S a f e t y  D e f i n i t i o n s  
T h e  f o l l o w i n g  d e f i n i t i o n s  a r e  t a k e n  f r om  t h e  I C H  E 2 A  G u i d e l i n e  f o r  C l i n i c a l  S a f e t y  D a t a  
M a n a g em e n t :  D e f i n i t i o n s  a n d  S t a n d a r d s  f o r  E x p e d i t e d  R e p o r t i n g .  
A d v e r s e  E v e n t  ( A E ) :  
A n  A E  i s  a n y  u n t o w a r d  m e d i c a l  o c c u r r e n c e  i n  a  p a t i e n t  o r  c l i n i c a l  i n v e s t i g a t i o n  s u b j e c t  
a dm i n i s t e r e d  a  p h a rm a c e u t i c a l  p r o d u c t  a n d  w h i c h  d o e s  n o t  n e c e s s a r i l y  h a v e  t o  h a v e  a  c a u s a l  
r e l a t i o n s h i p  w i t h  t h i s  t r e a tm e n t .  A n  A E  c a n  t h e r e f o r e  b e  a n y  u n f a v o r a b l e  a n d  u n i n t e n d e d  s i g n  
( i n c l u d i n g  a n  a b n o rm a l  l a b o r a t o r y  f i n d i n g ,  f o r  e x am p l e ) ,  s ym p t om  o r  d i s e a s e  t em p o r a l l y  
a s s o c i a t e d  w i t h  t h e  u s e  o f  a  m e d i c i n a l  p r o d u c t ,  w h e t h e r  o r  n o t  c o n s i d e r e d  r e l a t e d  t o  t h e  m e d i c i n a l  
p r o d u c t .   
T h e r e f o r e  a n  A E  m a y  b e :  
• A  n e w  i l l n e s s  
• T h e  w o r s e n i n g  o f  a  p r e - e x i s t i n g  c o n d i t i o n  
• A n  e f f e c t  o f  t h e  v a c c i n a t i o n ,  i n c l u d i n g  t h e  c om p a r a t o r  
• S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
A  c om b i n a t i o n  o f  t h e  a b o v e  
A l l  A E s  i n c l u d e  s e r i o u s  a n d  n o n - s e r i o u s  A E s .  
S u r g i c a l  p r o c e d u r e s  a r e  n o t  A E s ;  t h e y  a r e  t h e  a c t i o n  t a k e n  t o  t r e a t  a  m e d i c a l  c o n d i t i o n .  I t  i s  t h e  
c o n d i t i o n  l e a d i n g  t o  t h e  a c t i o n  t a k e n  t h a t  i s  t h e  A E  ( i f  i t  o c c u r s  d u r i n g  t h e  t r i a l  p e r i o d ) .  
P a g e  5 0  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  5 1  o f  7 7  P r e - e x i s t i n g  m e d i c a l  c o n d i t i o n s  a r e  n o t  t o  b e  r e p o r t e d  a s  A E s .  H o w e v e r ,  i f  a  p r e - e x i s t i n g  
c o n d i t i o n  w o r s e n s  i n  f r e q u e n c y  o r  i n t e n s i t y ,  o r  i f  i n  t h e  a s s e s sm e n t  o f  t h e  t r e a t i n g  p h y s i c i a n ,  t h e r e  
i s  a  c h a n g e  i n  i t s  c l i n i c a l  s i g n i f i c a n c e ,  t h i s  c h a n g e  s h o u l d  b e  r e p o r t e d  a s  a n  A E  ( e x a c e r b a t i o n ) .  
T h i s  a p p l i e s  e q u a l l y  t o  r e c u r r i n g  e p i s o d e s  o f  p r e - e x i s t i n g  c o n d i t i o n s  ( e . g . ,  a s t hm a )  i f  t h e  
f r e q u e n c y  o r  i n t e n s i t y  i n c r e a s e s  p o s t - v a c c i n a t i o n .  
S e r i o u s  A d v e r s e  E v e n t  ( S A E ) :  
S e r i o u s  a n d  s e v e r e  a r e  n o t  s y n o n ym o u s .  T h e  t e rm  s e v e r e  i s  o f t e n  u s e d  t o  d e s c r i b e  t h e  i n t e n s i t y  o f  
a  s p e c i f i c  e v e n t  a s  c o r r e s p o n d i n g  t o  G r a d e  3 .  T h i s  i s  n o t  t h e  s am e  a s  s e r i o u s  w h i c h  i s  b a s e d  o n  
p a t i e n t  /  e v e n t  o u t c o m e  o r  a c t i o n  c r i t e r i a  u s u a l l y  a s s o c i a t e d  w i t h  e v e n t s  t h a t  p o s e  a  t h r e a t  t o  a  
p a t i e n t ’ s  l i f e  o r  f u n c t i o n i n g .  S e r i o u s n e s s ,  n o t  s e v e r i t y ,  s e r v e s  a s  a  g u i d e  f o r  d e f i n i n g  r e g u l a t o r y  
r e p o r t i n g  o b l i g a t i o n s .  
A n  S A E  i s  a n y  u n t o w a r d  m e d i c a l  o c c u r r e n c e  t h a t  a t  a n y  d o s e   
• R e s u l t s  i n  d e a t h  
• I s  l i f e - t h r e a t e n i n g a 
• R e q u i r e s  i n p a t i e n t  h o s p i t a l i z a t i o n  o r  p r o l o n g a t i o n  o f  e x i s t i n g  h o s p i t a l i z a t i o n b 
• R e s u l t s  i n  p e r s i s t e n t  o r  s i g n i f i c a n t  d i s a b i l i t y  /  i n c a p a c i t y c 
• I s  a  c o n g e n i t a l  a n om a l y  /  b i r t h  d e f e c t  
• I s  a n  im p o r t a n t  m e d i c a l  e v e n t d  
Ad v e r s e  R e a c t i o n :  
A l l  n o x i o u s  a n d  u n i n t e n d e d  r e s p o n s e s  t o  a  m e d i c i n a l  p r o d u c t  r e l a t e d  t o  a n y  d o s e  s h o u l d  b e  
c o n s i d e r e d  a d v e r s e  r e a c t i o n s  ( A R ) .  
( T h e  p h r a s e  “ r e s p o n s e s  t o  a  m e d i c i n a l  p r o d u c t ”  m e a n s  t h a t  a  c a u s a l  r e l a t i o n s h i p  b e t w e e n  a  
m e d i c i n a l  p r o d u c t  a n d  a n  A E  i s  a t  l e a s t  a  r e a s o n a b l e  p o s s i b i l i t y )  
                                                 
a  T h e  t e rm  “ l i f e -t h r e a t e n i n g ”  r e f e r s  t o  a n  e v e n t  i n  w h i c h  t h e  s u b j e c t  w a s  a t  r i s k  o f  d e a t h  a t  t h e  t im e  o f  t h e  e v e n t ;  i t  
d o e s  n o t  r e f e r  t o  a n  e v e n t  w h i c h  h y p o t h e t i c a l l y  m i g h t  h a v e  c a u s e d  d e a t h  i f  i t  w e r e  m o r e  s e v e r e .  
b  A l l  m e d i c a l  e v e n t s  l e a d i n g  t o  h o s p i t a l i z a t i o n s  w i l l  b e  r e c o r d e d  a n d  r e p o r t e d  a s  S A E s ,  w i t h  t h e  e x c e p t i o n  o f :  
h o s p i t a l i z a t i o n  p l a n n e d  b e f o r e  i n c l u s i o n  i n t o  t h e  s t u d y  o r  o u t -p a t i e n t  t r e a tm e n t  w i t h  n o  h o s p i t a l i z a t i o n .   
c   “ P e r s i s t e n t  o r  s i g n i f i c a n t  d i s a b i l i t y  o r  i n c a p a c i t y ”  m e a n s  t h a t  t h e r e  i s  a  s u b s t a n t i a l  d i s r u p t i o n  o f  a  p e r s o n ’ s  a b i l i t y  
t o  c a r r y  o u t  n o rm a l  l i f e  f u n c t i o n s .  
d  M e d i c a l  a n d  s c i e n t i f i c  j u d gm e n t  s h o u l d  b e  e x e r c i s e d  i n  d e c i d i n g  w h e t h e r  e x p e d i t e d  r e p o r t i n g  i s  a p p r o p r i a t e  i n  
o t h e r  s i t u a t i o n s ,  s u c h  a s  im p o r t a n t  m e d i c a l  e v e n t s  t h a t  m a y  n o t  b e  imm e d i a t e l y  l i f e -t h r e a t e n i n g  o r  r e s u l t  i n  d e a t h  
o r  h o s p i t a l i z a t i o n  b u t  m a y  j e o p a r d i z e  t h e  h e a l t h  o f  t h e  s u b j e c t  o r  m a y  r e q u i r e  i n t e r v e n t i o n  t o  p r e v e n t  o n e  o f  t h e  
o t h e r  o u t c om e s  l i s t e d  i n  t h e  d e f i n i t i o n  a b o v e .  T h e s e  s h o u l d  a l s o  u s u a l l y  b e  c o n s i d e r e d  s e r i o u s .  E x am p l e s  o f  s u c h  
e v e n t s  i n c l u d e  a l l e r g i c  b r o n c h o s p a sm  r e q u i r i n g  i n t e n s i v e  t r e a tm e n t  i n  a n  em e r g e n c y  r o om  o r  a t  h om e ,  b l o o d  
d y s c r a s i a s  o r  c o n v u l s i o n s  t h a t  d o  n o t  r e s u l t  i n  i n p a t i e n t  h o s p i t a l i z a t i o n ,  o r  t h e  d e v e l o pm e n t  o f  d r u g  d e p e n d e n c y  o r  
d r u g  a b u s e ,  n e w  o n s e t  d i a b e t e s ,  o r  a u t o imm u n e  d i s e a s e .S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
 
P a g e  5 1  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  5 2  o f  7 7  U n e x p e c t e d  A d v e r s e  R e a c t i o n :  
A n  u n e x p e c t e d  a d v e r s e  r e a c t i o n  i s  a n  A R ,  t h e  n a t u r e  o r  s e v e r i t y  o f  w h i c h  i s  n o t  c o n s i s t e n t  w i t h  
t h e  a p p l i c a b l e  p r o d u c t  i n f o rm a t i o n  ( e . g . ,  I n v e s t i g a t o r ’ s  B r o c h u r e  f o r  a n  u n a p p r o v e d  
i n v e s t i g a t i o n a l  m e d i c i n a l  p r o d u c t ) .   
T h e  f o l l o w i n g  a d d i t i o n a l  d e f i n i t i o n s  a r e  u s e d  b y  S a n o f i  P a s t e u r :  
S o l i c i t e d  R e a c t i o n :  
A  s o l i c i t e d  r e a c t i o n  i s  a n  e v e n t  t h a t  i s  p r e l i s t e d  i n  t h e  C R B .  T h e  a s s e s sm e n t  o f  t h e s e  A E s  p o s t -
v a c c i n a t i o n  i s  m a n d a t o r y .  A  s o l i c i t e d  r e a c t i o n  i s  d e f i n e d  b y  a  c om b i n a t i o n  o f :  
• S ym p t om  a n d  
• O n s e t  p o s t - v a c c i n a t i o n  
e . g . ,  i n j e c t i o n  s i t e  p a i n  b e t w e e n  D 0  a n d  D 7  p o s t - v a c c i n a t i o n ,  o r  h e a d a c h e  b e t w e e n  D 0  a n d  D 7 .   
A  s o l i c i t e d  r e a c t i o n  i s  t h e r e f o r e  a n  A R  o b s e r v e d  a n d  r e p o r t e d  u n d e r  t h e  c o n d i t i o n s  ( s ym p t om  a n d  
o n s e t )  p r e l i s t e d  ( i . e . ,  s o l i c i t e d )  i n  t h e  C R B  a n d  c o n s i d e r e d  a s  r e l a t e d  t o  t h e  p r o d u c t  a dm i n i s t e r e d .  
U n s o l i c i t e d  A E  /  A R :  
A n  u n s o l i c i t e d  A E  i s  a n  o b s e r v e d  A E  t h a t  d o e s  n o t  f u l f i l l  t h e  c o n d i t i o n s  p r e l i s t e d  i n  t h e  C R B  i n  
t e rm s  o f  d i a g n o s i s  a n d  /  o r  o n s e t  p o s t - v a c c i n a t i o n ,  i . e . ,  e x c l u d i n g  s o l i c i t e d  r e a c t i o n s ,  e . g . ,  i f  
h e a d a c h e  b e t w e e n  D 0  a n d  D 7  i s  a  s o l i c i t e d  r e a c t i o n  ( i . e . ,  p r e l i s t e d  i n  t h e  C R B ) ,  t h e n  a  h e a d a c h e  
s t a r t i n g  o n  D 7  i s  a  s o l i c i t e d  r e a c t i o n ,  w h e r e a s  h e a d a c h e  s t a r t i n g  o n  D 8  p o s t - v a c c i n a t i o n  i s  a n  
u n s o l i c i t e d  A E .  U n s o l i c i t e d  A E s  i n c l u d e s  b o t h  s e r i o u s  ( S A E s )  a n d  n o n - s e r i o u s  u n s o l i c i t e d  A E s .  
I n j e c t i o n  S i t e  R e a c t i o n :  
A n  i n j e c t i o n  s i t e  r e a c t i o n a i s  a n  A R  a t  a n d  a r o u n d  t h e  i n j e c t i o n  s i t e .  I n j e c t i o n  s i t e  r e a c t i o n s  a r e  
c omm o n l y  i n f l amm a t o r y  r e a c t i o n s .  T h e y  a r e  c o n s i d e r e d  t o  b e  r e l a t e d  t o  t h e  p r o d u c t  a dm i n i s t e r e d .   
S y s t em i c  A E :  
S y s t em i c  A E s  a r e  a l l  A E s  t h a t  a r e  n o t  i n j e c t i o n  s i t e  r e a c t i o n s .  T h e y  t h e r e f o r e  i n c l u d e  s y s t em i c  
m a n i f e s t a t i o n s  s u c h  a s  h e a d a c h e ,  f e v e r ,  a s  w e l l  a s  l o c a l i z e d  o r  t o p i c a l  m a n i f e s t a t i o n s  t h a t  a r e  n o t  
a s s o c i a t e d  w i t h  t h e  v a c c i n a t i o n  s i t e ,  e . g . ,  e r y t h em a  t h a t  i s  l o c a l i z e d  b u t  t h a t  i s  n o t  a t  t h e  i n j e c t i o n  
s i t e .  
A d v e r s e  E v e n t s  o f  S p e c i a l  I n t e r e s t  ( A E S I s) :  
A n  A E S I  i s  o n e  o f  s c i e n t i f i c  a n d  m e d i c a l  c o n c e r n  s p e c i f i c  t o  t h e  S p o n s o r ’ s  p r o d u c t  o r  p r o g r am ,  
f o r  w h i c h  o n g o i n g  m o n i t o r i n g  a n d  r a p i d  c omm u n i c a t i o n  b y  t h e  i n v e s t i g a t o r  t o  t h e  s p o n s o r  c a n  b e  
a p p r o p r i a t e .  S u c h  a n  e v e n t  m i g h t  w a r r a n t  f u r t h e r  i n v e s t i g a t i o n  i n  o r d e r  t o  c h a r a c t e r i z e  a n d  
                                                 
a  A l l  i n j e c t i o n  s i t e  A E s  a r e  c o n s i d e r e d  t o  b e  r e l a t e d  t o  v a c c i n a t i o n  a n d  a r e  t h e r e f o r e  a l l  i n j e c t i o n  s i t e  r e a c t i o n s S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
.  
P a g e  5 2  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  5 3  o f  7 7  u n d e r s t a n d  i t .  D e p e n d i n g  o n  t h e  n a t u r e  o f  t h e  e v e n t ,  r a p i d  c omm u n i c a t i o n  b y  t h e  s t u d y  S p o n s o r  t o  
o t h e r  p a r t i e s  ( e . g . ,  r e g u l a t o r s )  m i g h t  a l s o  b e  w a r r a n t e d .  
9 . 2 . 2 . 2  S a f e t y  E n d p o i n t s  
T h e  s e c o n d a r y  e n d p o i n t s  f o r  t h e  e v a l u a t i o n  o f  s a f e t y  a r e :  
• O c c u r r e n c e ,  n a t u r e  (M e d i c a l  D i c t i o n a r y  f o r  R e g u l a t o r y  A c t i v i t i e s  [M e d D R A ]  p r e f e r r e d  t e r m  
[ P T ] ) ,  d u r a t i o n ,  i n t e n s i t y ,  a n d  r e l a t i o n s h i p  t o  v a c c i n a t i o n  o f  a n y  u n s o l i c i t e d  s y s t em i c  A E s  
r e p o r t e d  i n  t h e  3 0  m i n u t e s  a f t e r  v a c c i n a t i o n .  
• O c c u r r e n c e ,  t im e  t o  o n s e t ,  n um b e r  o f  d a y s  o f  o c c u r r e n c e ,  i n t e n s i t y ,  a c t i o n  t a k e n ,  a n d  w h e t h e r  
t h e  r e a c t i o n  l e d  t o  e a r l y  t e rm i n a t i o n  f r om  t h e  t r i a l ,  o f  s o l i c i t e d  ( p r e l i s t e d  i n  t h e  s u b j e c t ’ s  d i a r y  
c a r d  a n d  C R B )  i n j e c t i o n  s i t e  r e a c t i o n s  a n d  s y s t em i c  r e a c t i o n s  o c c u r r i n g  u p  t o  7  d a y s  a f t e r  
v a c c i n a t i o n .  
• O c c u r r e n c e ,  n a t u r e  (M e d D R A  P T ) ,  t im e  t o  o n s e t ,  d u r a t i o n ,  i n t e n s i t y ,  r e l a t i o n s h i p  t o  
v a c c i n a t i o n  ( f o r  s y s t em i c  A E s  o n l y ) ,  a n d  w h e t h e r  t h e  e v e n t  l e d  t o  e a r l y  t e rm i n a t i o n  f r om  t h e  
t r i a l ,  o f  u n s o l i c i t e d  A E s  u p  t o  2 8  d a y s  a f t e r  v a c c i n a t i o n .  
• O c c u r r e n c e ,  n a t u r e  (M e d D R A  P T ) ,  t im e  t o  o n s e t ,  s e r i o u s n e s s  c r i t e r i a ,  r e l a t i o n s h i p  t o  
v a c c i n a t i o n ,  o u t c om e ,  a n d  w h e t h e r  t h e  S A E  l e d  t o  e a r l y  t e rm i n a t i o n  f r om  t h e  t r i a l ,  o f  S A E s  
t h r o u g h o u t  t h e  t r i a l .  
• O c c u r r e n c e ,  n a t u r e  (M e d D R A  P T ) ,  a n d  r e l a t i o n s h i p  t o  v a c c i n a t i o n  o f  A E S I s  t h r o u g h o u t  t h e  
t r i a l .  
9 . 2 . 2 . 3  S a f e t y  A s s e s sm e n t  M e t h o d s  
A t  V 0 1 ,  t h e  I n v e s t i g a t o r  o r  a  d e l e g a t e  w i l l  p e r f o rm  a  c l i n i c a l  o r  m e d i c a l l y - d r i v e n  p h y s i c a l  
e x am i n a t i o n .   
A t  V 0 2 ,  t h e  I n v e s t i g a t o r  o r  a  d e l e g a t e  m a y  p e r f o rm  a  t a r g e t e d  c l i n i c a l  o r  m e d i c a l l y - d r i v e n  
p h y s i c a l  e x am i n a t i o n ,  a s  n e c e s s a r y ,  a n d  w i l l  a s k  t h e  s u b j e c t  a b o u t  a n y  s o l i c i t e d  r e a c t i o n s  a n d  
u n s o l i c i t e d  A E s  r e c o r d e d  i n  t h e  d i a r y  c a r d ,  a s  w e l l  a s  a b o u t  a n y  o t h e r  A E s  t h a t  m a y  h a v e  o c c u r r e d  
s i n c e  t h e  p r e v i o u s  v i s i t .   
A l l  r e l e v a n t  d a t a  w i l l  b e  t r a n s c r i b e d  i n t o  t h e  C R B  a c c o r d i n g  t o  t h e  i n s t r u c t i o n s  p r o v i d e d  b y  t h e  
S p o n s o r .  
9 . 2 . 2 . 3 . 1  Imm e d i a t e  P o s t - v a c c i n a t i o n  S u r v e i l l a n c e  P e r i o d  
S u b j e c t s  w i l l  b e  k e p t  u n d e r  o b s e r v a t i o n  f o r  3 0  m i n u t e s  a f t e r  v a c c i n a t i o n  t o  e n s u r e  t h e i r  s a f e t y .  
T h e  p o s t - v a c c i n a t i o n  s u r v e i l l a n c e  s h o u l d  b e  d o c um e n t e d  i n  t h e  s o u r c e  d o c um e n t .  A n y  A E  t h a t  
o c c u r s  d u r i n g  t h i s  p e r i o d  w i l l  b e  n o t e d  o n  t h e  s o u r c e  d o c um e n t  a n d  r e c o r d e d  i n  t h e  C R B ,  a s  
f o l l o w s :  
• S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
Un s o l i c i t e d  s y s t em i c  A E s  w i l l  b e  r e c o r d e d  a s  imm e d i a t e  A E s  i n  t h e  C R B  ( p r e s e n c e  m a r k e d  b y  
“ y e s ”  a n d  d e t a i l s  c o l l e c t e d ) .   
P a g e  5 3  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  5 4  o f  7 7  • S o l i c i t e d  a n d  u n s o l i c i t e d  i n j e c t i o n  s i t e  r e a c t i o n s  a n d  s o l i c i t e d  s y s t em i c  r e a c t i o n s  w i l l  b e  
r e c o r d e d  a n d  a n a l y z e d  a s  s t a r t i n g  o n  t h e  d a y  o f  v a c c i n a t i o n .   
• A n y  S A E  o c c u r r e d  d u r i n g  t h e  f i r s t  3 0  m i n u t e s  p o s t - v a c c i n a t i o n  w i l l  b e  r e p o r t e d  i n  t h e  s am e  
w a y  a s  a n y  o t h e r  S A E  a n d  t o  t h e  S p o n s o r ,  a c c o r d i n g  t o  t h e  p r o c e d u r e s  d e s c r i b e d  i n  S e c t i o n  1 0 .  
9 . 2 . 2 . 3 . 2  R e a c t o g e n i c i t y  ( S o l i c i t e d  R e a c t i o n s  F r om  D 0  t o  D 7 A f t e r  V a c c i n a t i o n )  
A f t e r  v a c c i n a t i o n ,  s u b j e c t s  w i l l  b e  p r o v i d e d  w i t h  a  d i a r y  c a r d ,  a  d i g i t a l  t h e rm om e t e r ,  a n d  a  
f l e x i b l e  r u l e r ,  a n d  w i l l  b e  i n s t r u c t e d  h o w  t o  u s e  t h em .  T h e  f o l l o w i n g  i t em s  w i l l  b e  r e c o r d e d  b y  t h e  
s u b j e c t s  i n  t h e  d i a r y  c a r d  o n  t h e  d a y  o f  v a c c i n a t i o n  a n d  f o r  t h e  n e x t  7  d a y s  ( i . e . ,  D 0  t o  D 7 )  u n t i l  
r e s o l u t i o n :  
• D a i l y  t em p e r a t u r e ,  w i t h  t h e  r o u t e  b y  w h i c h  i t  w a s  t a k e n  
• D a i l y  m e a s u r em e n t  o r  i n t e n s i t y  g r a d e  o f  a l l  o t h e r  s o l i c i t e d  i n j e c t i o n  s i t e  a n d  s y s t em i c  
r e a c t i o n s  
• A c t i o n  t a k e n  f o r  e a c h  e v e n t  ( e . g . ,  m e d i c a t i o n )  
T h e  a c t i o n ( s )  t a k e n  b y  t h e  s u b j e c t  t o  t r e a t  a n d / o r  m a n a g e  a n y  s o l i c i t e d  r e a c t i o n s  w i l l  b e  
c l a s s i f i e d  i n  t h e  C R B  u s i n g  t h e  f o l l o w i n g  l i s t  ( a l l  a p p l i c a b l e  i t em s  s h o u l d  b e  c h e c k e d ) :  
• N o n e  
• M e d i c a t i o n  
• H e a l t h  c a r e  p r o v i d e r  c o n t a c t  
• H o s p i t a l i z e d  
S u b j e c t s  w i l l  b e  c o n t a c t e d  b y  t e l e p h o n e  8  d a y s  ( + 2  d a y s )  a f t e r  v a c c i n a t i o n  t o  r em i n d  t h em  t o  
r e c o r d  a l l  s a f e t y  i n f o rm a t i o n  i n  t h e  d i a r y  c a r d  a n d  t o  f i n d  o u t  i f  t h e y  h a v e  e x p e r i e n c e d  a n y  S A E s  
n o t  y e t  r e p o r t e d .  
I f  t h e  t im i n g  o f  t h e  t e l e p h o n e  c a l l  s h o u l d  f a l l  o n  a  w e e k e n d  o r  a  h o l i d a y ,  t h e  c a l l  s h o u l d  b e  m a d e  
o n  t h e  n e x t  b u s i n e s s  d a y .  I f  c o n t a c t  i s  n o t  m a d e  o n  t h e  d e s i g n a t e d  d a y ,  s t u d y  s t a f f  w i l l  c o n t i n u e  
c a l l i n g  u n t i l  c o n t a c t  i s  m a d e .  E v e r y  t e l e p h o n e  a t t em p t  a n d  i t s  o u t c om e  w i l l  b e  d o c um e n t e d  i n  t h e  
s o u r c e  d o c um e n t .  
T a b l e  9 . 1  a n d  T a b l e  9 . 2  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
p r e s e n t ,  r e s p e c t i v e l y ,  t h e  i n j e c t i o n  s i t e  r e a c t i o n s  a n d  s y s t em i c  r e a c t i o n s  
t h a t  a r e  p r e l i s t e d  i n  t h e  d i a r y  c a r d s  a n d  C R B ,  t o g e t h e r  w i t h  t h e  i n t e n s i t y  s c a l e s .  
 
 
P a g e  5 4  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 55 of 77 Table 9.1: Solicited injection site  reactions: terminology, definitions, and intensity scales  
CRB term 
(MedDRA 
lowest level 
term) Injection site pain  Injection site erythema  Injection site swelling  Injection site induration  Injection site 
bruising 
MedDRA PT  Injection site pain  Injection s ite erythema  Injection site swelling  Injection site induration  Injection site 
bruising  
Diary card term  Pain Redness  Swelling  Hardening  Bruising  
Definition Pain either present spontaneously or when 
the injection site is 
touched or injected limb 
is mobiliz ed
 Presence of a redness 
including the approximate point of needle entry  Swelling at or near the injection site  
Swelling or edema is caused by a fluid infiltration in tissue or cavity and, 
depending on the space available for the 
fluid to disperse, swellin g may be either 
soft (typi[INVESTIGATOR_897]) or firm (less typi[INVESTIGATOR_2855]) to 
touch and thus can be best described by 
[CONTACT_35351].  
Hardening is caused by a slow diffusion of the product 
in the tissue leading to 
a thick 
or hard area to touch at or 
near the injection site and thus 
can be best described by 
[CONTACT_35352].  Bruising  is the result 
of the diffusion of 
blood in the skin from 
ruptured blood vessels 
that forms a purple or 
black and bl ue spot on 
the skin. It can be best 
described by [CONTACT_35356].  
Intensity scale*  
 Grade 1: A type of AE 
that is usually transient 
and may require only 
minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living. 
 Grade 1: ≥ 25 to ≤ 50 mm  
Grade 2: ≥ 51 to ≤ 100 mm  
Grade 3: > 100 mm  Grade 1: ≥ 25 to ≤ 50 mm  
Grade 2: ≥ 51 to ≤ 100 mm  
Grade 3: > 100 mm  Grade 1: ≥ 25 to ≤ 50 mm  
Grade 2: ≥ 51 to ≤ 100 mm  
Grade 3: > 100 mm  Grade 1: ≥ 25 to 
≤ 50 mm  
Grade 2: ≥ 51 to ≤ 100 mm  
Grade 3: >  100 mm 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 55 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 56 of 77 Grade 2: A type of AE 
that is usually alleviated 
with additional therapeutic intervention. The event interferes with 
usual activities of daily 
living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 
Grade 3: A type of  AE 
that interrupts usual 
activities of daily living, 
or significantly affects 
clinical status, or may require intensive 
therapeutic intervention.
 
* For the subjective reaction of pain, subjects will record the intensity level (Grade 1, 2, or 3) in the diary card. For the measurable reactions of redness, swelling, hardening, and 
bruising, they will record just the size of the reaction, and the classification as Grade 1, 2, or 3 will be assigned at  the time of the statistical analysis  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 56 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 57 of 77 Table 9.2: Solicited systemic reactions: terminology, definitions, and intensity scales  
CRB term  
(MedDRA 
lowest level 
term) Fever Headache Malaise Myalgia Shivering  
MedDRA 
PT Pyrexia  Headache  Malaise  Myalgia  Chills  
Diary card 
term Temperature  Headache  Feeling unwell  Muscle aches and pains  Chills  
Definition  Fever is defined by a 
temperature of  
≥ 38.0°C/≥ 100.4°F A headache is pain or 
discomfort in the head, or 
scalp. Does not include 
migraine. General ill feeling.  
Malaise is a generalized feeling 
of discomfort, illness, or lack 
of well -being that can be 
associated with a disease state. It can be accompanied by a 
sensation of exhaustion or 
inadequate energy to 
accompli sh usual activities.  Muscle aches and pains are 
common and can involve more than one muscle at the same time. 
Muscle pain can also involve the 
soft tissues that surround muscles. 
These structures, which are often 
referred to as connective tissues, 
include ligaments, tendons, and 
fascia (thick bands of tendons).  
Does not apply to muscle pain at 
the injection site which should be 
reported as injection site pain.  Cold feeling.  
Intensity 
scale*: Grade 1: ≥ 38.0°C to 
≤ 38.4°C  
Grade 2: ≥ 38.5°C to 
≤ 38.9°C 
Grade 3: ≥ 39.0°C  Grade  1: A type of AE that 
is usually transient and may 
require only minimal treatment or therapeutic 
intervention. The event 
does not generally interfere with usual activities of 
daily living.  Grade  1: A type of AE that 
is usually transie nt and may 
require only minimal treatment or therapeutic 
intervention. The event does 
not generally interfere with usual activities of daily 
living.  Grade  1: A type of AE that is 
usually transient and may require only minimal treatment or therapeutic inter vention. The 
event does not generally interfere with usual activities of daily living.
 Grade  1: A type of AE that is usually 
transient and may require only minimal treatment or therapeutic intervention. The event does not generally interfere 
with usual act ivities of daily living.
 
  
Or Grade  2: A type of AE that 
is usually alleviated with 
additional therapeutic Grade  2: A type of AE that 
is usually alleviated with 
additional therapeutic Grade  2: A type of AE that is 
usually alleviated with 
additional therapeutic Grade  2: A type of AE that is usually 
alleviated with additional therapeutic 
intervention. The event interferes with 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 57 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 58 of 77 intervention. The event 
interferes with usual 
activities of daily living, causing discomfort but 
poses no significant or 
permanent risk of harm to 
the research participant.  intervention. The event 
interferes with usual activities of daily living, causing discomfort but 
poses no significant or 
permanent risk of harm to 
the res earch participant.  intervention. The event 
interferes with usual activities of daily living, causing discomfort but poses no 
significant or permanent risk of 
harm to the research 
participant.  usual activities of daily living, causing 
discomfort but poses no significant or permanent risk of harm to the research participant.
 
 Grade 1: ≥100.4°F to 
≤ 101.1°F 
Grade 2: ≥  101.2°F to 
≤ 102.0°F Grade 3: ≥  102.1°F  Grade  3: A type of AE that 
interrupts usual activities of 
daily living, or significantly 
affects clinical status, or 
may require intensive 
therapeutic intervention.  Grade  3: A type of AE that 
interrupts usual activities of daily living, or significantly 
affects clinical status, or 
may require intensive 
therapeutic intervention.  Grade  3: A type of AE that 
interrupts usual activities of daily living, or significantly 
affects clinical status, or may 
require intensive therapeutic 
intervention.  Grade  3: A type of AE that interrupts 
usual activities of daily living, or 
significantly affects clinical status, or 
may require intensive therapeutic 
intervention.  
* For all react ions but fever, subjects will record the intensity level (Grade 1, 2, 3) in the diary card. For fever, they will record the body temperature, and the classification as Grade 1, 2, or 3 will be 
assigned a t the time of the statistical analysis based on the u nit used to measure the temperature and the intensity scale.  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 58 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  5 9  o f  7 7  Im p o r t a n t  n o t e s  f o r  t h e  a c c u r a t e  a s s e s sm e n t  o f  t em p e r a t u r e :  
S u b j e c t s  a r e  t o  m e a s u r e  b o d y  t em p e r a t u r e  o n c e  p e r  d a y  ( i n  d e g r e e s  F a h r e n h e i t ) ,  p r e f e r a b l y  a l w a y s  
a t  t h e  s am e  t im e .  T h e  o p t im a l  t im e  f o r  m e a s u r em e n t  i s  t h e  e v e n i n g ,  w h e n  b o d y  t em p e r a t u r e  i s  t h e  
h i g h e s t .  T em p e r a t u r e  i s  a l s o  t o  b e  m e a s u r e d  a t  t h e  t im e  o f  a n y  a p p a r e n t  f e v e r .  T h e  o b s e r v e d  d a i l y  
t em p e r a t u r e  a n d  t h e  r o u t e  o f  m e a s u r em e n t  a r e  t o  b e  r e c o r d e d  i n  t h e  d i a r y  c a r d  a n d  t h e  h i g h e s t  
t e m p e r a t u r e  w i l l  b e  r e c o r d e d  b y  t h e  s i t e  i n  t h e  C R B .  T h e  p r e f e r r e d  r o u t e  f o r  t h i s  t r i a l  i s  o r a l .  P r e -
v a c c i n a t i o n  t em p e r a t u r e  i s  a l s o  s y s t em a t i c a l l y  c o l l e c t e d  b y  t h e  i n v e s t i g a t o r  o n  t h e  s o u r c e  
d o c um e n t .  T ym p a n i c  a n d  t em p o r a l  a r t e r y  t h e rm om e t e r s  m u s t  n o t  b e  u s e d .  
9 . 2 . 2 . 3 . 3  U n s o l i c i t e d  A E s   
I n  a d d i t i o n  t o  r e c o r d i n g  s o l i c i t e d  r e a c t i o n s ,  s u b j e c t s  w i l l  b e  i n s t r u c t e d  t o  r e c o r d  a n y  o t h e r  m e d i c a l  
e v e n t s  t h a t  m a y  o c c u r  d u r i n g  t h e  2 8 - d a y  p e r i o d  a f t e r  v a c c i n a t i o n .  S p a c e  w i l l  b e  p r o v i d e d  i n  t h e  
d i a r y  c a r d  f o r  t h i s  p u r p o s e .  
I n f o rm a t i o n  o n  S A E s  w i l l  b e  c o l l e c t e d  a n d  a s s e s s e d  t h r o u g h o u t  t h e  s t u d y ,  f r om  i n c l u s i o n  u n t i l  6  
m o n t h s  a f t e r  v a c c i n a t i o n .  A n y  S A E  o c c u r r i n g  a t  a n y  t im e  d u r i n g  t h e  s t u d y  w i l l  b e  r e p o r t e d  b y  t h e  
I n v e s t i g a t o r  i n  t h e  C R B  a c c o r d i n g  t o  t h e  c om p l e t i o n  i n s t r u c t i o n s  p r o v i d e d  b y  t h e  S p o n s o r ;  t h i s  
i n c l u d e s  c h e c k i n g  t h e  “S e r i o u s ” b o x  o n  t h e  A E  C R F  a n d  c om p l e t i n g  t h e  a p p r o p r i a t e  D e a t h / S a f e t y  
C om p l em e n t a r y  I n f o rm a t i o n  C R F s .  A l l  i n f o rm a t i o n  c o n c e r n i n g  t h e  S A E  i s  t o  b e  r e p o r t e d  e i t h e r  a s  
p a r t  o f  t h e  i n i t i a l  r e p o r t i n g  o r  d u r i n g  f o l l o w - u p  r e p o r t i n g  i f  r e l e v a n t  i n f o rm a t i o n  b e c am e  a v a i l a b l e  
l a t e r  ( e . g . ,  o u t c om e ,  m e d i c a l  h i s t o r y ,  r e s u l t s  o f  i n v e s t i g a t i o n s ,  c o p y  o f  h o s p i t a l i z a t i o n  r e p o r t s .  
S e e  S e c t i o n  1 0  f o r  f u r t h e r  d e t a i l s  o n  S A E  r e p o r t i n g .  
 F o r  e a c h  u n s o l i c i t e d  A E  ( w h e t h e r  s e r i o u s  o r  n o n - s e r i o u s ) ,  t h e  f o l l o w i n g  i n f o rm a t i o n  i s  t o  b e  
r e c o r d e d :  
• S t a r t  a n d  s t o p  d a t e s a  
• I n t e n s i t y  o f  t h e  e v e n t :  
F o r  m e a s u r a b l e  u n s o l i c i t e d  A E s  t h a t  a r e  p a r t  o f  t h e  l i s t  o f  s o l i c i t e d  r e a c t i o n s ,  t h e  s i z e  o f  t h e  A E  
a s  w e l l  a s  t h e  t em p e r a t u r e  f o r  f e v e r  w i l l  b e  c o l l e c t e d  a n d  a n a l y z e d  b a s e d  o n  t h e  c o r r e s p o n d i n g  
s c a l e  u s e d  f o r  s o l i c i t e d  r e a c t i o n s  ( s e e  T a b l e  9 . 1  a n d  T a b l e  9 . 2 )  
A l l  o t h e r  u n s o l i c i t e d  A E s  w i l l  b e  c l a s s i f i e d  a c c o r d i n g  t o  t h e  f o l l o w i n g  i n t e n s i t y  s c a l e :  
• G r a d e  1 :  A  t y p e  o f  A E  t h a t  i s  u s u a l l y  t r a n s i e n t  a n d  m a y  r e q u i r e  o n l y  m i n im a l  t r e a tm e n t  o r  
t h e r a p e u t i c  i n t e r v e n t i o n .  T h e  e v e n t  d o e s  n o t  g e n e r a l l y  i n t e r f e r e  w i t h  u s u a l  a c t i v i t i e s  o f  
d a i l y  l i v i n g .  
• G r a d e  2 :  A  t y p e  o f  A E  t h a t  i s  u s u a l l y  a l l e v i a t e d  w i t h  a d d i t i o n a l  t h e r a p e u t i c  i n t e r v e n t i o n .  
T h e  e v e n t  i n t e r f e r e s  w i t h  u s u a l  a c t i v i t i e s  o f  d a i l y  l i v i n g ,  c a u s i n g  d i s c om f o r t  b u t  p o s e s  n o  
s i g n i f i c a n t  o r  p e rm a n e n t  r i s k  o f  h a rm  t o  t h e  r e s e a r c h  p a r t i c i p a n t .   
                                                 
aS a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
 T h e  s t o p  d a t e  o f  a l l  r e l a t e d  A E s  w i l l  b e  a c t i v e l y  s o l i c i t e d .  F o r  o t h e r  e v e n t s ,  t h e  i n v e s t i g a t o r  w i l l  p r o v i d e  t h e  s t o p  
d a t e  w h e n  i t  b e c om e s  a v a i l a b l e .  A E s  f o r  w h i c h  n o  s t o p  d a t e  w a s  o b t a i n e d  d u r i n g  t h e  c o u r s e  o f  t h e  t r i a l  w i l l  b e  
c o n s i d e r e d  a s  o n g o i n g  a t  t h e  e n d  o f  t h e  t r i a l .  
P a g e  5 9  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  6 0  o f  7 7  • G r a d e  3 :  A  t y p e  o f  A E  t h a t  i n t e r r u p t s  u s u a l  a c t i v i t i e s  o f  d a i l y  l i v i n g ,  o r  s i g n i f i c a n t l y  a f f e c t s  
c l i n i c a l  s t a t u s ,  o r  m a y  r e q u i r e  i n t e n s i v e  t h e r a p e u t i c  i n t e r v e n t i o n .  
• W h e t h e r  t h e  A E  w a s  r e l a t e d  t o  t h e  i n v e s t i g a t i o n a l  p r o d u c t  ( f o r  u n s o l i c i t e d  s y s t em i c  A E s )  
T h e  I n v e s t i g a t o r  w i l l  a s s e s s  t h e  c a u s a l  r e l a t i o n s h i p  b e t w e e n  t h e  A E  a n d  t h e  i n v e s t i g a t i o n a l  
p r o d u c t  a s  e i t h e r  “ N o t  r e l a t e d ”  o r  “ R e l a t e d ” ,  a s  d e s c r i b e d  i n  S e c t i o n  9 . 2 . 2 . 3 . 5 .  
• A c t i o n  t a k e n  f o r  e a c h  A E  ( e . g . ,  m e d i c a t i o n )  
T h e  a c t i o n ( s )  t a k e n  b y  t h e  s u b j e c t  t o  t r e a t  a n d / o r  m a n a g e  a n y  u n s o l i c i t e d  A E s  w i l l  b e  
c l a s s i f i e d  i n  t h e  C R B  u s i n g  t h e  f o l l o w i n g  l i s t  ( a l l  a p p l i c a b l e  i t em s  s h o u l d  b e  c h e c k e d ) :  
• N o n e  
• M e d i c a t i o n  
• H e a l t h  c a r e  p r o v i d e r  c o n t a c t  
• H o s p i t a l i z e d  
• W h e t h e r  t h e  A E  w a s  s e r i o u s  
F o r  e a c h  S A E ,  t h e  I n v e s t i g a t o r  w i l l  c om p l e t e  a l l  s e r i o u s n e s s  c r i t e r i a  t h a t  a p p l y  ( o u t c om e ,  
e l a p s e d  t im e ,  a n d  r e l a t i o n s h i p  t o  s t u d y  p r o c e d u r e s )  
• W h e t h e r  t h e  A E  c a u s e d  s t u d y  d i s c o n t i n u a t i o n  
9 . 2 . 2 . 3 . 4  A d v e r s e  E v e n t s  o f  S p e c i a l  I n t e r e s t  
A E S I s  w i l l  b e  c a p t u r e d  a s  S A E s  ( c o l l e c t e d  t h r o u g h o u t  t h e  t r i a l ) .  T h e s e  i n c l u d e  ( 1 0 ) :  
• n e w  o n s e t  o f  G B S  
• e n c e p h a l i t i s  /  m y e l i t i s  ( i n c l u d i n g  t r a n s v e r s e  m y e l i t i s )  
• B e l l ’ s  p a l s y  
• o p t i c  n e u r i t i s  
• b r a c h i a l  n e u r i t i s  
9 . 2 . 2 . 3 . 5  A s s e s sm e n t  o f  C a u s a l i t y   
T h e  I n v e s t i g a t o r  w i l l  a s s e s s  t h e  c a u s a l  r e l a t i o n s h i p  b e t w e e n  e a c h  u n s o l i c i t e d  s y s t em i c  A E  a n d  
t h e  p r o d u c t  a dm i n i s t e r e d  a s  e i t h e r  n o t  r e l a t e d  o r  r e l a t e d ,  b a s e d  o n  t h e  f o l l o w i n g  d e f i n i t i o n s a:  
0 :  N o t  r e l a t e d  –  T h e  A E  i s  c l e a r l y  /  m o s t  p r o b a b l y  c a u s e d  b y  o t h e r  e t i o l o g i e s  s u c h  a s  
s u b j e c t ’ s  u n d e r l y i n g  c o n d i t i o n ,  t h e r a p e u t i c  i n t e r v e n t i o n ,  o r  c o n c om i t a n t  t h e r a p y ;  o r  t h e  
d e l a y  b e t w e e n  v a c c i n a t i o n  a n d  t h e  o n s e t  o f  t h e  A E  i s  i n c om p a t i b l e  w i t h  a  c a u s a l  
r e l a t i o n s h i p ;  o r  t h e  A E  s t a r t e d  b e f o r e  t h e  v a c c i n a t i o n   
                                                 
aS a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
  I C H  G u i d e l i n e s ,  C l i n i c a l  S a f e t y  D a t a  M a n a g em e n t  E 2 A  
P a g e  6 0  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 61 of 77 1:  Related – There is a “reasonable possibility” that th e AE was caused by [CONTACT_35361], meaning that there is evidence or arguments to suggest a causal relationship 
Note: By [CONTACT_559], all injection site AEs (solicited and unsolicited) and all solicited systemic 
AEs are considered to be related to  the administered product and therefore are referred to as 
reactions  and do not require the Investigator’s opi[INVESTIGATOR_125611]. 
AEs likely to be related to the product, whether serious or not, that persist at the end of the trial 
will be followed up by [CONTACT_125630]’s condition. The Investigator will inform the Sponsor of the date of final disappearance of the event  or the date of the “chronicity” establishment. 
9.2.[ADDRESS_141371] document all SAEs regardless of causal relationship, and notify th e Sponsor and 
the Clinical Research Associate ( CRA) within the notification timelines stated in the following 
sections. The Investigator will give access and provide the Sponsor and the CRA with all necessary information to allow the Sponsor to conduct a detailed analysis of the safety of the investigational product(s). It is the responsibility of the Investigator to request all necessary documentation (e.g., medical records, discharge summary, autopsy) in order to provide comprehensive safety information. All relevant information must then be transcribed onto the AE 
CRF and the appropriate Death/Safety Complementary Information CRFs. 
10.[ADDRESS_141372]’s participation in the trial or experiment must be repo rted within 
24 hours to the Sponsor’s GPE Department and to the CRA. Every SAE must be reported, even if 
the Investigator considers that it is not related to the vaccine. The Investigator ( licensed physician 
[M.D. or D.O.] ) must validate the information entered on the AE CRF by [CONTACT_125631] . 
The Investigator must indicate on the AE CRF that the event was serious and must complete the 
relevant SAE section of this form as well as the appropriate Death/Safety Complementary Information CRFs. An e- mail alert will automatically be sent by [CONTACT_125632] E 
mailbox, the CRA and the CTL with relevant SAE information details . 
If the EDC system is unavailable, the site must notify the Sponsor using the paper version of the CRB, as described in the operating guidelines: 
The Investigator must complete the paper copi[INVESTIGATOR_35289]/Safety Complementary Information CRFs and send them  to the Sponsor by [CONTACT_35369]: 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 61 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  6 2  o f  7 7  • B y  f a x ,  t o  t h e  f o l l o w i n g  n um b e r :  
• I n  P D F  f o rm a t  t o  t h e  f o l l o w i n g  e -m a i l  a d d r e s s ,  u s i n g  a  m e t h o d  o f  t r a n sm i s s i o n  t h a t  
i n c l u d e s  p a s s w o r d  p r o t e c t i o n :   
• B y  e x p r e s s  m a i l ,  t o  t h e  f o l l o w i n g  a d d r e s s :   
    G l o b a l  P h a rm a c o V i g i l a n c e ,  S a n o f i  P a s t e u r  
    D i s c o v e r y  D r i v e  
    S w i f t w a t e r ,  P A  1 8 3 7 0  
W h e n  t h e  E D C  s y s t em  b e c om e s  a v a i l a b l e ,  t h e  I n v e s t i g a t o r  m u s t  t r a n s c r i b e  t h e  i n f o rm a t i o n  f r om  
t h e  p a p e r  f o rm s  i n t o  t h e  E D C  s y s t em .  
I f  t h e r e  i s  n e e d  f o r  u r g e n t  c o n s u l t a t i o n ,  t h e  I n v e s t i g a t o r  i s  t o  c o n t a c t  t h e  RM O .  I f  t h e  RM O  c a n n o t  
b e  r e a c h e d ,  t h e  I n v e s t i g a t o r  m a y  c o n t a c t  t h e  C a l l  C e n t e r  a s  d e s c r i b e d  i n  S e c t i o n  5 . 3 .   
1 0 . 2  F o l l o w -u p  R e p o r t i n g  b y  t h e  I n v e s t i g a t o r  
T h e  A E  C R F  c om p l e t e d  i n i t i a l l y  m u s t  b e  u p d a t e d  w i t h i n  2 4  h o u r s  a f t e r  t h e  I n v e s t i g a t o r  h a s  
b e c om e  a w a r e  o f  a n y  n e w  r e l e v a n t  i n f o rm a t i o n  c o n c e r n i n g  t h e  S A E  ( e . g . ,  o u t c om e ,  p r e c i s e  
d e s c r i p t i o n  o f  m e d i c a l  h i s t o r y ,  r e s u l t s  o f  t h e  i n v e s t i g a t i o n ) .  A l l  r e l e v a n t  i n f o rm a t i o n  m u s t  b e  
i n c l u d e d  d i r e c t l y  i n  t h e  A E  C R F  a n d  t h e  a p p r o p r i a t e  D e a t h / S a f e t y  C om p l em e n t a r y  I n f o rm a t i o n  
C R F s .  A n  e - m a i l  a l e r t  w i l l  b e  s e n t  a u t om a t i c a l l y  t o  t h e  G P E  D e p a r tm e n t  a n d  t o  t h e  C R A .  C o p i e s  
o f  d o c um e n t s  ( e . g . ,  m e d i c a l  r e c o r d s ,  d i s c h a r g e  s umm a r y ,  a u t o p s y )  m a y  b e  r e q u e s t e d  b y  t h e  G P E  
D e p a r tm e n t .   
T h e  a n o n ym i t y  o f  t h e  s u b j e c t  m u s t  a l w a y s  b e  r e s p e c t e d  w h e n  f o r w a r d i n g  t h i s  i n f o rm a t i o n .  
1 0 . 3  R e p o r t i n g  o f  S A E s  O c c u r r i n g  A f t e r  a  S u b j e c t  H a s  C om p l e t e d  t h e  S t u d y  
A n y  S A E  t h a t  o c c u r s  a f t e r  a  s u b j e c t  h a s  c om p l e t e d  t h e  s t u d y  b u t  t h a t  i s  l i k e l y  t o  b e  r e l a t e d  t o  t h e  
i n v e s t i g a t i o n a l  p r o d u c t s  o r  t o  t h e  e x p e r im e n t  m u s t  a l s o  b e  r e p o r t e d  a s  s o o n  a s  p o s s i b l e .  I n  s u c h  a  
c a s e ,  t h e  r e p o r t i n g  p r o c e d u r e  t o  b e  f o l l o w e d  i s  i d e n t i c a l  t o  t h a t  d e s c r i b e d  i n  S e c t i o n  1 0 . 1 .  
1 0 . 4  A s s e s sm e n t  o f  C a u s a l i t y  
T h e  c a u s a l  r e l a t i o n s h i p  b e t w e e n  t h e  S A E  a n d  t h e  p r o d u c t  a dm i n i s t e r e d  w i l l  b e  e v a l u a t e d  b y  t h e  
I n v e s t i g a t o r  a s  d e s c r i b e d  i n  S e c t i o n  9 . 2 . 2 . 3 . 5 . S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
 
F o l l o w i n g  t h i s ,  t h e  S p o n s o r ’ s  P h a rm a c o v i g i l a n c e  ( P V )  G l o b a l  S a f e t y  E x p e r t  ( G S E )  w i l l  a l s o  
a s s e s s  t h e  c a u s a l  r e l a t i o n s h i p  t o  t h e  p r o d u c t ,  b a s e d  o n  t h e  a v a i l a b l e  i n f o rm a t i o n  a n d  c u r r e n t  
m e d i c a l  k n o w l e d g e .  
T h e  c a u s a l  r e l a t i o n s h i p  t o  s t u d y  p r o c e d u r e s  w i l l  b e  a l s o  a s s e s s e d  i n  t h e  C R B .  
T h e  d e c i s i o n  t o  m o d i f y  o r  d i s c o n t i n u e  t h e  t r i a l  m a y  b e  m a d e  a f t e r  m u t u a l  a g r e em e n t  b e t w e e n  t h e  
S p o n s o r  a n d  t h e  I n v e s t i g a t o r ( s ) .  
P a g e  6 2  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 63 of 77 10.5 Reporting SAEs to Health Authorities and IECs  / IRBs 
The Sponsor will inform the relevant health authorities of any reportable SAEs according to the 
local regulatory requirements. Reporting to the health authorities will be according to the Sponsor’s standard operating procedures. 
The Sponsor’s RMO ( , ) will notify t he Investigators in writing of the 
occurrence of any reportable SAEs. The Investigators / Sponsor will be responsible for informing 
the IECs or IRBs that reviewed the trial protocol. 
11 Data Collection and Management  
11.1 Data Collection and CRB Completion 
Individual diary cards, specifically designed for this trial by [CONTACT_125633], will be given to study participants for the recording of daily safety information as described 
in Section [IP_ADDRESS].  These diary cards will include prelisted terms and intensity scales (see 
Table 9.1 and  Table 9.2)  as well as areas for free text to capture additional safety information or 
other relevant details. Subjects will also be provided with rulers for measuring the size of injection 
site reactions, and with standard digital thermometers for measuring daily temperatures. To ensure 
consistency of reporting, the study sites will instruct subjects on how to correctly use these tools. 
The D180 follow -up will be done by [CONTACT_125634] a 
questionnaire to capture SAEs and AE SIs, if applicable. A memory aid will be provided to the 
subjects at the preceding trial visit to help them record information on events occurring between 
this visit and the D180 follow-up. 
Relevant information will be transcribed into the AE CRF . Any SAEs captured during this 6-
month follow-up period will be reported and followed-up as per the normal process for reporting 
SAEs.  
At specified intervals, the Investigator or an authorized designee will interview the subjects t o 
collect the information recorded in the diary card, and will attempt to clarify anything that is incomplete or unclear. All clinical trial information gathered by [CONTACT_125635] a web -based CRB. (Any 
information that was not docume nted in the diary card will first be captured in the source 
document and then reported electronically). The CRB has been designed specifically for this trial 
under the responsibility of the Sponsor, using a validated Electronic Records / Electronic Signature -compliant platform (21 CFR Part 11). 
To ensure the correct and consistent completion of the CRBs, the Sponsor or authorized 
representative will provide all necessary tools, instructions, and training to all site staff involved in data entry prior to stu dy start. Additional instructional documents such as training manuals and 
completion instructions will be provided to assist with data entry during the course of the trial. 
Upon completion of training, each user requiring access to the EDC system will be issued a 
unique username [CONTACT_2383]. In the event of a change in trial personnel, each newly assigned 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 63 of 78

[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141373]; the username [CONTACT_35395] a 
previous user may not be reissued. If any trial personnel leave the study, the Investigator is 
responsible for informing the Sponsor immediately so that their access is deactivated. An audit trail will be initiated in the EDC system at the time of the first data entry in order to track all modifications and to ensure dat abase integrity.  
The Investigator is responsible for the timeliness, completeness, and accuracy of the information in the CRBs; must provide explanations for all missing information; and must sign the CRB using an e- signature.  
11.2 Data Management  
Management of SAE Data  
During the study, SAE data (reported on the AE, Death, and Safety Complementary Information CRFs) will be integrated into the Sponsor’s centralized GPE database upon receipt of these forms 
and after a duplicate check. Each case will be assigned a case identification number. Each case will be assessed by [CONTACT_35375]. The assessment of related cases will be done in collaboration with the PV GSE and the RMO. Follow-up information concerning a completed case will be entered into the GPE database, and a new version of the case will be created.  
The information from the GPE database cases will be reconciled with that in the clinical database.  
Management of Cli nical and Laboratory Data  
Clinical data, defined as all data reported in the CRB , and laboratory data will be handled by [CONTACT_429]’s Clinical Data Management (CDM) platform or authorized representative.  
During the trial, clinical data reported in the CRBs will be integrated into the clinical database 
under the responsibility of the [COMPANY_011] Pasteur  CDM platform. Data monitoring at the sites and 
quality control in the form of computerized logic and / or consistency checks will be 
systematically applied in order to detect errors or omissions. In addition, data reviews may be 
performed several times by [CONTACT_1034]’s staff in the course of the trial. Any questions pertaining to the reported clinical data will be submitted to the investigator for resolution using  the EDC 
system. Each step of this process will be monitored through the implementation of individual passwords to maintain appropriate database access and to ensure database integrity.  
The validation of the immunogenicity data will be performed at the lab oratory level following the 
laboratory’s procedures. Information from the laboratory will be checked for consistency before integration into the clinical Datawarehouse . 
After integration of all corrections in the complete set of data, and after the SAE information available from CDM and the GPE Department has been reconciled, the database will be released for 
statistical analysis.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 64 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  6 5  o f  7 7  1 1 . 3  D a t a  R e v i e w  
A  b l i n d  r e v i e w  o f  t h e  d a t a  i s  a n t i c i p a t e d  t h r o u g h  t h e  d a t a  r e v i e w  p r o c e s s  l e d  b y  D a t a  Ma n a g em e n t  
b e f o r e  d a t a b a s e  l o c k .   
1 2  S t a t i s t i c a l  M e t h o d s  a n d  D e t e rm i n a t i o n  o f  S am p l e  S i z e  
1 2 . 1  S t a t i s t i c a l  M e t h o d s  
C l i n i c a l  d a t a b a s e  d a t a  w i l l  b e  a n a l y z e d  u n d e r  t h e  r e s p o n s i b i l i t y  o f  t h e  B i o s t a t i s t i c s  P l a t f o rm  o f  t h e  
S p o n s o r ,  U S ,  w i t h  t h e  S A S  s o f t w a r e ,  a t  l e a s t  v e r s i o n  9 . 4  ( S A S  I n s t i t u t e ,  C a r y ,  N o r t h  C a r o l i n a ,  
U S A ) .  
A  s t a t i s t i c a l  a n a l y s i s  p l a n  ( S A P )  w i l l  b e  w r i t t e n  a n d  p e e r  r e v i e w e d  b e f o r e  a n y  a n a l y s e s .  I n  
a c c o r d a n c e  w i t h  t h e  p r o t o c o l ,  t h e  S A P  w i l l  d e s c r i b e  a l l  a n a l y s e s  t o  b e  p e r f o rm e d  b y  t h e  S p o n s o r  
a n d  a l l  t h e  c o n v e n t i o n s  t o  b e  t a k e n .  
F o r  t h e  p u r p o s e s  o f  t h e  s t a t i s t i c a l  m e t h o d s  s e c t i o n ,  t h e  4  v i r u s  s t r a i n s  i n  t h e  Q I V -H D  t r i a l  g r o u p s  
a n d  t h e  T I V - H D  t r i a l  g r o u p s  w i l l  b e  l a b e l e d  a s  f o l l o w s :  
• A /M i c h i g a n / 4 5 / 2 0 1 5  ( H 1 N 1 )  s t r a i n    A 1  
• A / H o n g  K o n g / 4 8 0 1 / 2 0 1 4  ( H 3 N 2 )  s t r a i n   A 2  
• B / B r i s b a n e / 6 0 / 2 0 0 8  s t r a i n      B 1  
• B / P h u k e t / 3 0 7 3 / 2 0 1 3  s t r a i n      B 2  
1 2 . 1 . 1  H y p o t h e s e s  a n d  S t a t i s t i c a l  M e t h o d s  f o r  P r im a r y  O b j e c t i v e  
1 2 . 1 . 1 . 1  Imm u n o g e n i c i t y  
1 2 . 1 . 1 . 1 . 1  H y p o t h e s e s  
T h e  imm u n o g e n i c i t y  o f  Q I V - H D  w i l l  b e  c om p a r e d  t o  t h a t  o f  T I V -H D 1  a n d  /  o r  T I V - H D 2 .  F o r  
e a c h  A  s t r a i n ,  t h e  c om p a r i s o n  w i l l  b e  m a d e  w i t h  t h e  p o o l e d  T I V - H D  g r o u p s .  F o r  e a c h  B  s t r a i n ,  
t h e  c om p a r i s o n  w i l l  b e  m a d e  w i t h  t h e  T I V - H D  g r o u p  c o n t a i n i n g  t h e  c o r r e s p o n d i n g  B  s t r a i n .  
F o r  e a c h  s t r a i n ,  a  n o n - i n f e r i o r i t y  a p p r o a c h  w i l l  b e  u s e d  t o  c om p a r e  t h e  p o s t - v a c c i n a t i o n  GM T s  
a n d  t h e  s e r o c o n v e r s i o n  r a t e s  b e t w e e n  t h e  g r o u p s  u s i n g  a  1 -s i d e d  T y p e  I  e r r o r  r a t e  o f  0 . 0 2 5  w i t h  t h e  
g i v e n  i n d i v i d u a l  h y p o t h e s i s :  
 
• S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
 
P a g e  6 5  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  6 6  o f  7 7   
 
•  
 
 
w i t h :   
• s :  s t r a i n  i n  { A 1 ,  A 2 ,  B 1  a n d  B 2 }  
• I f  s  i n  { A 1  a n d  A 2 } ,  T I V - H D  r e p r e s e n t s  t h e  p o o l e d  T I V - H D 1  a n d  T I V - H D 2  g r o u p s   
• I f  s  =  B 1 ,  T I V - H D  r e p r e s e n t s  t h e  T I V - H D 1  g r o u p   
• I f  s  =  B 2 ,  T I V - H D  r e p r e s e n t s  t h e  T I V - H D 2  g r o u p   
• :  T h e  s e r o c o n v e r s i o n  r a t e  
1 2 . 1 . 1 . 1 . 2  S t a t i s t i c a l  M e t h o d s  
A s s um i n g  t h a t  l o g 1 0  t r a n s f o rm a t i o n  o f  t h e  d a t a  f o l l o w s  a  n o rm a l  d i s t r i b u t i o n ,  t h e  l o g 1 0  ( d a t a )  w i l l  
b e  u s e d  f o r  t h e  s t a t i s t i c a l  a n a l y s i s ,  t h e n  a n t i l o g  t r a n s f o rm a t i o n s  w i l l  b e  a p p l i e d  t o  t h e  r e s u l t s  o f  
c a l c u l a t i o n s ,  i n  o r d e r  t o  p r o v i d e  t h e  r e s u l t s  i n  t e rm s  o f  g e om e t r i c  m e a n s  ( GM s ) .  
T h e  s t a t i s t i c a l  m e t h o d o l o g y  w i l l  b e  b a s e d  o n  t h e  u s e  o f  t h e  2 - s i d e d  9 5%  C I  o f  t h e  r a t i o  o f  p o s t - 
v a c c i n a t i o n  GM T s  a n d  d i f f e r e n c e  i n  s e r o c o n v e r s i o n  r a t e s  b e t w e e n  Q I V -H D  a n d  T I V - H D  g r o u p s .  
T h e  9 5%  C I s  w i l l  b e  c a l c u l a t e d  b y  n o rm a l  a p p r o x im a t i o n  o f  l o g - t r a n s f o rm e d  t i t e r s  f o r  GM T s  a n d  
b y  t h e  N e w c om b e -W i l s o n  s c o r e  m e t h o d  w i t h o u t  c o n t i n u i t y  c o r r e c t i o n  f o r  s e r o c o n v e r s i o n  r a t e s .  
T h e  m a r g i n s  u s e d  f o r  n o n - i n f e r i o r i t y  h y p o t h e s i s  t e s t i n g  a r e  1 . 5  f o r  GM T s  a n d  1 0%  f o r  
s e r o c o n v e r s i o n  r a t e s  b a s e d  o n  F o o d  a n d  D r u g  A dm i n i s t r a t i o n  ( F D A )  g u i d e l i n e s  f o r  l i c e n s u r e  o f  
s e a s o n a l  i n f l u e n z a  v a c c i n e  ( 1 1 ) . S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
 
T h e  n o n - i n f e r i o r i t y  o b j e c t i v e  w i l l  b e  a c h i e v e d  o n l y  i f  i t  i s  d em o n s t r a t e d  f o r  4  s t r a i n s  a n d  f o r  b o t h  
GM T s  a n d  s e r o c o n v e r s i o n  r a t e s .  A n a l y s e s  w i l l  b e  p e r f o rm e d  f o r  b o t h  t h e  F u l l  A n a l y s i s  S e t  ( F A S )  
a n d  t h e  P e r -p r o t o c o l  A n a l y s i s  S e t  ( P P A S ) ,  b u t  t h e  c o n c l u s i o n  w i l l  b e  m a d e  f r om  P P A S  r e s u l t s .  
A  s e n s i t i v i t y  a n a l y s i s  w i l l  b e  p e r f o rm e d  w i t h  a d j u s tm e n t  o n  t h e  p r e -v a c c i n a t i o n  H A I  t i t e r s .  
P a g e  6 6  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  6 7  o f  7 7  1 2 . 1 . 2  H y p o t h e s e s  a n d  S t a t i s t i c a l  M e t h o d s  f o r  S e c o n d a r y  O b j e c t i v e s  
1 2 . 1 . 2 . 1  Imm u n o g e n i c i t y   
1 2 . 1 . 2 . 1 . 1  H y p o t h e s e s  
S u p e r i o r i t y  o f  Q I V -H D  t o  T I V -H D 1  o r  T I V - H D 2   
T h e  s u p e r i o r i t y  a n a l y s e s  w i l l  b e  d em o n s t r a t e d  i n  a l l  s u b j e c t s .  F o r  e a c h  B  s t r a i n ,  t h e  
imm u n o g e n i c i t y  o f  Q I V - H D  w i l l  b e  c om p a r e d  t o  t h a t  o f  T I V - H D  g r o u p  w h i c h  d o e s  n o t  c o n t a i n  
t h e  c o r r e s p o n d i n g  B  s t r a i n .  
A  s u p e r i o r i t y  a p p r o a c h  w i l l  b e  u s e d  t o  c om p a r e  p o s t - v a c c i n a t i o n  GM T s  a n d  s e r o c o n v e r s i o n  r a t e s  
b e t w e e n  g r o u p s  u s i n g  a  1 - s i d e d  t e s t  w i t h  T y p e  I  e r r o r  r a t e  o f  0 . 0 2 5  f o l l o w i n g  t h e  i n d i v i d u a l  
h y p o t h e s e s :  
 
•  
 
 
•  
 
 
w i t h :   
• s :  s t r a i n  i n  { B 1  a n d  B 2 }  
• I f  s  =  B 1 ,  T I V - H D  r e p r e s e n t s  t h e  T I V - H D 2  g r o u p   
• I f  s  =  B 2 ,  T I V - H D  r e p r e s e n t s  t h e  T I V - H D 1  g r o u p   
• :  T h e  s e r o c o n v e r s i o n  r a t e  
Imm u n o g e n i c i t y  b y  H A I  M e t h o d  
N o  h y p o t h e s e s  w i l l  b e  t e s t e d .  
Imm u n o g e n i c i t y  b y  S N  M e t h o d  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
N o  h y p o t h e s e s  w i l l  b e  t e s t e d .  
P a g e  6 7  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 68 of 77 [IP_ADDRESS].2 Statistical Methods  
Assuming that log 10 transformation of the data follows a normal distribution, the log 10 (data) will 
be used for the statistical analysis, then antilog transformations will be applied to the results of 
calculations, in order to provide the results in terms of GMs.  
Superiority of QIV -HD to TIV -HD1 or TIV- HD2  
The statistical methodology will be based on the use of the 2-sided 95% CI of the ratio of post-
vaccination GMTs and difference in seroconversion rates between the QIV -HD group and TIV-
HD group. The 95% CIs will be calculated using normal approximation of log- transformed titers 
for GMTs and using the Newcombe-Wilson score method without continuity correction for seroconversion rates. For each strai n, the 2-sided 95% CI should lie above 1.5 for GMTs and 
above 10% for seroconversion rates. 
The superiority objective will be achieved if the superiority is demonstrated for both B strains and 
for both GMTs and seroconversion rates. Analyses will be performed for both FAS and PPAS but the conclusion will be made from FAS results. 
Immunogenicity by [CONTACT_125636] 95% CIs (Clopper-
Pearson method)  (12) will be performed for pre- vaccination (V01) and post -vaccination 
immunogenicity (V02). The geometric mean titer ratios (GMTRs) will be calculated for post-vaccination immunogenicity (V02) over the baseline immunogenicity (V01) with the corresponding 95% CIs (assuming normal approximation of log-transformed values). Reverse cumulative distribution curves (RCDCs) against each strain will be performed for baseline (V01) and post- vaccination immunogenicity (V02). Additional parameters may be displayed as 
appropriate. 
Immunogenicity by [CONTACT_125637], seroconversion, and percent of subjects with GMTs 
≥ 1/40 [dil] will be summarized along with their 95% CIs for post- vaccination immunogenicity 
(V02). The normal approximation of log- transformed titers will be applied to calculate the 
95% CIs for GMTs. The 95% CIs will be calculated using Clopper-Pearson method for percentages. The GMTRs  will be calculated for post -vaccination immunogenicity (V02) over the 
baseline immunogenicity (V01) with the corresponding 95% CIs (assuming normal approximation 
of log- transformed values).  RCDCs against each strain will be performed for baseline (V01) and 
post-vaccination immunogenicity (V02). Additional parameters may be displayed as appropriate.  
[IP_ADDRESS] Safety 
[IP_ADDRESS].1 Hypotheses  
No hypotheses will be tested. 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 68 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  6 9  o f  7 7  1 2 . 1 . 2 . 2 . 2  S t a t i s t i c a l  M e t h o d s  
S a f e t y  r e s u l t s  w i l l  b e  a n a l y z e d  d e s c r i p t i v e l y  f o r  s u b j e c t s  i n  S a f A S  w h o  r e c e i v e d  o n e  o f  t h e  
v a c c i n e s .  S o l i c i t e d  r e a c t i o n s  ( s o l i c i t e d  i n j e c t i o n  s i t e  a n d  s y s t em i c  r e a c t i o n s ) ,  u n s o l i c i t e d  A E s ,  
S A E s ,  a n d  A E S I s  w i l l  b e  s umm a r i z e d .  T h e  m a i n  p a r am e t e r s  w i l l  b e  d e s c r i b e d  w i t h  9 5%  C I s  
( C l o p p e r - P e a r s o n  m e t h o d )  ( 1 2 ) .  
• U n s o l i c i t e d  s y s t em i c  A E s  o c c u r r i n g  w i t h i n  3 0  m i n u t e s  o f  i n j e c t i o n  ( imm e d i a t e  u n s o l i c i t e d  
A E s )  
• S o l i c i t e d  i n j e c t i o n  s i t e  r e a c t i o n s  ( p a i n ,  e r y t h em a ,  s w e l l i n g ,  i n d u r a t i o n ,  a n d  b r u i s i n g )  o c c u r r i n g  
w i t h i n  7  d a y s  a f t e r  t h e  d a y  o f  i n j e c t i o n  ( D 0  t o  D 7 )  a c c o r d i n g  t o  p r e s e n c e ,  t im e  t o  o n s e t ,  
in t e n s i t y  ( G r a d e  1 ,  G r a d e  2 ,  o r  G r a d e  3 ) ,  n um b e r  o f  d a y s  o f  o c c u r r e n c e ,  a c t i o n  t a k e n ,  a n d  
w h e t h e r  t h e  r e a c t i o n  l e d  t o  e a r l y  t e rm i n a t i o n  f r om  t h e  t r i a l .  W h e n  m o r e  t h a n  1  i n t e n s i t y  l e v e l  
i s  r e p o r t e d  w i t h i n  a  t im e  p e r i o d ,  t h e  h i g h e s t  i n t e n s i t y  w i l l  b e  u s e d  
• S o l i c i t e d  s y s t em i c  r e a c t i o n s  ( f e v e r ,  h e a d a c h e ,  m a l a i s e ,  m y a l g i a ,  a n d  s h i v e r i n g )  o c c u r r i n g  
w i t h i n  7  d a y s  a f t e r  t h e  d a y  o f  i n j e c t i o n  ( D 0  t o  D 7 )  a c c o r d i n g  t o  p r e s e n c e ,  t im e  t o  o n s e t ,  
i n t e n s i t y  ( G r a d e  1 ,  G r a d e 2 ,  o r  G r a d e  3 ) ,  n um b e r  o f  d a y s  o f  o c c u r r e n c e ,  a c t i o n  t a k e n ,  a n d  
w h e t h e r  t h e  r e a c t i o n  l e d  t o  e a r l y  t e rm i n a t i o n  f r om  t h e  t r i a l .  W h e n  m o r e  t h a n  1  i n t e n s i t y  l e v e l  
i s  r e p o r t e d  w i t h i n  a  t im e  p e r i o d ,  t h e  h i g h e s t  i n t e n s i t y  w i l l  b e  u s e d  
• U n s o l i c i t e d  A E s  o c c u r r i n g  w i t h i n  2 8  d a y s  a f t e r  i n j e c t i o n  b y  s y s t em  o r g a n  c l a s s  ( S O C )  a n d  P T ,  
r e l a t i o n s h i p ,  i n t e n s i t y ,  t im e  t o  o n s e t ,  a n d  d u r a t i o n  
• A l l  S A E s  t h a t  o c c u r  t h r o u g h o u t  t h e  t r i a l  b y  S O C  a n d  P T ,  s e r i o u s n e s s  c r i t e r i a ,  t im e  t o  o n s e t ,  
o u t c om e ,  r e l a t i o n s h i p ,  a n d  w h e t h e r  t h e  S A E  l e d  t o  e a r l y  t e rm i n a t i o n  t h r o u g h o u t  t h e  t r i a l  
• A l l  A E S I s  r e p o r t e d  t h r o u g h o u t  t h e  t r i a l  b y  S O C  a n d  P T  a n d  r e l a t i o n s h i p  
1 2 . 2  A n a l y s i s  S e t s  
F o u r  m a i n  a n a l y s i s  s e t s  w i l l  b e  u s e d :  t h e  P P A S ,  t h e  F A S ,  t h e  E x p a n d e d  Imm u n o g e n i c i t y  S u b s e t ,  
a n d  t h e  S a f e t y  A n a l y s i s  S e t  ( S a f A S ) .  
1 2 . 2 . 1  F u l l  A n a l y s i s  S e t s  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
T h e  F A S  i s  d e f i n e d  a s  t h e  s u b s e t  o f  r a n d om i z e d  s u b j e c t s  w h o  r e c e i v e d  a t  l e a s t  1  d o s e  o f  a  t r i a l  
v a c c i n e  a n d  h a d  a  p o s t - v a c c i n a t i o n  b l o o d  s am p l e  H A I  r e s u l t  f o r  a t  l e a s t  1  s t r a i n .  S u b j e c t s  w i l l  b e  
a n a l y z e d  a c c o r d i n g  t o  t h e  v a c c i n e  g r o u p  t o  w h i c h  t h e y  w e r e  r a n d om i z e d .   
F o r  t h e  a s s e s sm e n t  o f  t h e  imm u n e  r e s p o n s e  b y  v i r u s  S N  m e t h o d ,  t h e  a n a l y s i s  w i l l  b e  p e r f o rm e d  
o n  t h e  s u b j e c t s  f r om  t h e  F A S  r a n d om i z e d  i n t o  t h e  E x p a n d e d  Imm u n o g e n i c i t y  S u b s e t  w i t h  a t  l e a s t  
o n e  p o s t - v a c c i n a t i o n  S N  a s s a y  r e s u l t  f o r  a t  l e a s t  1  s t r a i n .   
P a g e  6 9  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  7 0  o f  7 7  1 2 . 2 . 2  S a f e t y  A n a l y s i s  S e t  
T h e  S a f A S  i s  d e f i n e d  a s  t h o s e  s u b j e c t s  w h o  h a v e  r e c e i v e d  s t u d y  v a c c i n ea.  A l l  s u b j e c t s  w i l l  h a v e  
t h e i r  s a f e t y  a n a l y z e d  a c c o r d i n g  t o  t h e  v a c c i n e  t h e y  a c t u a l l y  r e c e i v e d .  
S a f e t y  d a t a  r e c o r d e d  f o r  a  v a c c i n e  r e c e i v e d  o u t  o f  t h e  p r o t o c o l  d e s i g n  w i l l  b e  e x c l u d e d  f r om  t h e  
a n a l y s i s  ( a n d  l i s t e d  s e p a r a t e l y ) .  
1 2 . 2 . 3  P e r - P r o t o c o l  A n a l y s i s  S e t  
T h e  P P A S  i s  a  s u b s e t  o f  t h e  F A S .  T h e  s u b j e c t s  p r e s e n t i n g  w i t h  a t  l e a s t  o n e  o f  t h e  f o l l o w i n g  
r e l e v a n t  p r o t o c o l  d e v i a t i o n s  w i l l  b e  e x c l u d e d  f r om  t h e  P P A S :  
• S u b j e c t  d i d  n o t  m e e t  a l l  p r o t o c o l - s p e c i f i e d  i n c l u s i o n  c r i t e r i a  o r  m e t  a t  l e a s t  o n e  o f  t h e  
p r o t o c o l - s p e c i f i e d  e x c l u s i o n  c r i t e r i a  
• S u b j e c t  d i d  n o t  r e c e i v e  v a c c i n e  
• S u b j e c t  r e c e i v e d  a  v a c c i n e  o t h e r  t h a n  t h e  o n e  t h a t  h e  /  s h e  w a s  r a n d om i z e d  t o  r e c e i v e  
• P r e p a r a t i o n  a n d  /  o r  a dm i n i s t r a t i o n  o f  v a c c i n e  w a s  n o t  d o n e  a s  p e r - p r o t o c o l  
• S u b j e c t  d i d  n o t  p r o v i d e  t h e  p o s t - d o s e  s e r o l o g y  s am p l e  ( V 0 2 )  i n  t h e  p r o p e r  t im e  w i n d o w  ( i . e . ,  
2 8  t o  3 5  d a y s  a f t e r  v a c c i n a t i o n )  o r  a  p o s t -d o s e  s e r o l o g y  s am p l e  ( V 0 2 )  w a s  n o t  d r a w n  
• S u b j e c t  r e c e i v e d  a  p r o t o c o l - p r o h i b i t e d  t h e r a p y  /  m e d i c a t i o n  /  v a c c i n e  
I n  a d d i t i o n  t o  t h e  c r i t e r i a  l i s t e d  a b o v e ,  s u b j e c t s  w i l l  a l s o  b e  e x c l u d e d  f r om  t h e  P P A S  i f  t h e i r  p o s t - 
v a c c i n a t i o n  s e r o l o g y  s am p l e  d i d  n o t  p r o d u c e  a  v a l i d  H A I  t e s t  r e s u l t  ( i . e . ,  H A I  r e s u l t s  f o r  a l l  
a n t i g e n s  a r e  m i s s i n g ) .   
T h e  a b o v e  p r o t o c o l  d e v i a t i o n s  l e a d i n g  t o  e x c l u s i o n  f r om  t h e  P P A S  m a y  b e  d e t a i l e d  a n d  c om p l e t e d  
i f  n e c e s s a r y  i n  t h e  S A P ,  f o l l o w i n g  t h e  r e v i e w  o f  p r o t o c o l  d e v i a t i o n s  d u r i n g  t h e  s t u d y  c o n d u c t .  I n  
a n y  c a s e ,  t h e  P P A S  d e f i n i t i o n  w i l l  b e  f i n a l i z e d  b e f o r e  t h e  f i r s t  d a t a b a s e  l o c k .  
1 2 . 2 . 4  P o p u l a t i o n s  U s e d  i n  A n a l y s e s  
A l l  s u b j e c t s  w i t h  d a t a  i n  t h e  C R B  w i l l  b e  t a k e n  i n t o  a c c o u n t  i n  t h e  d e s c r i p t i o n  o f  t h e  p o p u l a t i o n  
( e . g . ,  t h e  d i s p o s i t i o n ,  t h e  d em o g r a p h i c  o r  b a s e l i n e  c h a r a c t e r i s t i c s ) .   
T h e  s a f e t y  a n a l y s e s  w i l l  b e  p e r f o rm e d  o n  t h e  S a f A S .  
A l l  imm u n o g e n i c i t y  a n a l y s e s  f r om  H A I  m e t h o d  f o r  p r im a r y  a n d  s e c o n d a r y  o b j e c t i v e s  w i l l  b e  
p e r f o rm e d  o n  b o t h  F A S  a n d  P P A S .   
T h e  s e c o n d a r y  S N  imm u n o g e n i c i t y  a n a l y s e s  w i l l  b e  p e r f o rm e d  o n  t h e  E x p a n d e d  Imm u n o g e n i c i t y  
S u b s e t .  
                                                 
aS a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
  f o r  w h i c h  s a f e t y  d a t a  a r e  s c h e d u l e d  t o  b e  c o l l e c t e d  
P a g e  7 0  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  7 1  o f  7 7  1 2 . 3  H a n d l i n g  o f  M i s s i n g  D a t a  a n d  O u t l i e r s  
1 2 . 3 . 1  S a f e t y  
N o  r e p l a c em e n t  w i l l  b e  d o n e .  N e v e r t h e l e s s ,  m i s s i n g  r e l a t i o n s h i p  w i l l  b e  c o n s i d e r e d  a s  r e l a t e d  a t  
t h e  t im e  o f  t h e  s t a t i s t i c a l  a n a l y s i s .  N o  s e a r c h  f o r  o u t l i e r s  w i l l  b e  p e r f o rm e d .  I n  a l l  s u b j e c t  l i s t i n g s ,  
p a r t i a l  a n d  m i s s i n g  d a t a  w i l l  b e  c l e a r l y  i n d i c a t e d  a s  m i s s i n g .  
1 2 . 3 . 2  Imm u n o g e n i c i t y  
I n  o r d e r  t o  a p p r o p r i a t e l y  m a n a g e  r e p l i c a t e  v a l u e s  f o r  a n a l y s i s  p u r p o s e s ,  t h e  i n d i v i d u a l  GM  o f  a l l  
v a l u e s  w i l l  b e  c om p u t e d  f o r  e a c h  b l o o d  s am p l e  a f t e r  m a n a g i n g  e x t r em e  v a l u e s  a s  d e s c r i b e d .  T h e  
c om p u t e d  v a l u e  i s  t h e n  c o n s i d e r e d  t h e  t i t e r  f o r  t h a t  p a r t i c u l a r  b l o o d  s am p l e .  
• I f  a  t i t e r  i s  <  L L O Q ,  t h e n  t h e  c om p u t e d  v a l u e ,  L L O Q / 2 ,  w i l l  b e  u s e d .  
• I f  a  t i t e r  i s  ≥  L L O Q  a n d  <  U L O Q  ( o r  ≤  U L O Q ) ,  t h e n  t h e  t i t e r  i t s e l f  w i l l  b e  u s e d .  
• I f  a  t i t e r  i s  ≥  U L O Q  ( o r  ˃  U L O Q ) ,  t h e n  c om p u t e d  v a l u e ,  U L O Q ,  w i l l  b e  u s e d .  
A n y  o t h e r  r e p l a c em e n t  t o  b e  a p p l i e d  t o  s p e c i f i c  e n d p o i n t s  w i l l  b e  d e s c r i b e d  i n  t h e  S A P .  
N o  t e s t  o r  s e a r c h  f o r  o u t l i e r s  w i l l  b e  p e r f o rm e d .  
N o  r e p l a c em e n t  w i l l  b e  d o n e  f o r  m i s s i n g  v a l u e s .  B a s e d  o n  t h e  p r e v i o u s  T I V - H D  a n d  Q I V -S D  
t r i a l s  i n  t h i s  p o p u l a t i o n ,  t h e  am o u n t  o f  m i s s i n g  imm u n o g e n i c i t y  d a t a  i s  e x p e c t e d  t o  b e  ≤  5%  i n  t h i s  
t r i a l .  U s u a l l y  i n  v a c c i n e  t r i a l s ,  i t  s e em s  g e n e r a l l y  r e a s o n a b l e  t o  a s s um e  m i s s i n g  imm u n o g e n i c i t y  
d a t a  a r e  m i s s i n g  c om p l e t e l y  a t  r a n d om  (M C A R )  ( 1 3 ) .  I n d e e d ,  i t  i s  h i g h l y  u n e x p e c t e d  t h a t  t h e  
d r o p o u t  ( o r  a n y  o t h e r  r e a s o n  f o r  m i s s i n g  d a t a )  c o u l d  b e  l i n k e d  t o  t h e  imm u n e  r e s p o n s e  o f  t h e  
s u b j e c t .  T h e r e f o r e ,  c o n f i rm i n g  t h e  r e s u l t s  o f  t h e  P P A S  f o r  t h e  p r im a r y  a n a l y s i s  w i t h  t h e  F A S  
w o u l d  b e  s a t i s f a c t o r y  i n  t e rm s  o f  s e n s i t i v i t y  a n a l y s i s .  
1 2 . 4  I n t e r im  /  P r e l im i n a r y  A n a l y s i s  
T h e  s t a t i s t i c a l  a n a l y s e s  w i l l  b e  p e r f o rm e d  i n  2  s t e p s :  
• F i r s t  s t e p  w i l l  b e  t h e  a n a l y s i s  o f  m a i n  H A I  imm u n o g e n i c i t y  a n d  s a f e t y  r e s u l t s  o b t a i n e d  o n  d a t a  
c o l l e c t e d  w i t h i n  a p p r o x im a t e l y  2 8  d a y s  f o l l o w i n g  v a c c i n a t i o n  ( f r om  D 0  t o  V i s i t  2 ) .  T h e  s t u d y  
b l i n d  w i l l  b e  b r o k e n  a t  t h a t  t im e .  
• S e c o n d  s t e p  w i l l  b e  a s s e s s i n g  t h e  r em a i n i n g  o b j e c t i v e s  o f  t h e  s t u d y .  
N o  s t a t i s t i c a l  a d j u s tm e n t  f o r  t h e  i n t e r im  a n a l y s i s  i s  n e c e s s a r y  b e c a u s e  t h e r e  a r e  n o  r e p e a t  a n a l y s e s  
o f  t h e  s am e  h y p o t h e s e s .  
1 2 . 5  D e t e rm i n a t i o n  o f  S am p l e  S i z e  a n d  P o w e r  C a l c u l a t i o n  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
A  t o t a l  o f  2 6 1 6  a d u l t s  a g e d  6 5  y e a r s  a n d  o l d e r  w i l l  b e  e n r o l l e d .  A  s am p l e  s i z e  o f  2 6 1 6  i s  
d e t e rm i n e d  b a s e d  o n  a n  o v e r a l l  p o w e r  o f  9 0%  f o r  d em o n s t r a t i n g  n o n - i n f e r i o r i t y  f o r  b o t h  t h e  H A I  
GM T s  a n d  s e r o c o n v e r s i o n  r a t e s  c om p a r i n g  Q I V - H D  v s  T I V -H D 1  a n d  /  o r  T I V - H D 2  f o r  a l l  4  
P a g e  7 1  o f  7 8 
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  7 2  o f  7 7  v i r u s  s t r a i n s .  T h e  n o n - i n f e r i o r i t y  m a r g i n s  a r e  d e f i n e d  a s  1 . 5  f o r  GM T s  a n d  1 0%  f o r  
s e r o c o n v e r s i o n  r a t e s .   
A s s um p t i o n s  f o r  t h e  a b o v e  c a l c u l a t i o n s  a r e :  
• T h e  e x p e c t e d  s e r o c o n v e r s i o n  r a t e s  f o r  t h e  4  s t r a i n s :  4 5%  f o r  A 1  s t r a i n ,  7 0%  f o r  A 2  s t r a i n ,  a n d  
4 0%  f o r  b o t h  B  s t r a i n s .   
• A s s um e d  s t a n d a r d  d e v i a t i o n s  f o r  H A I  GM T s  a r e  0 . 6 3  f o r  b o t h  A  s t r a i n s  a n d  0 . 5 5  f o r  b o t h  B  
s t r a i n s .   
• A n  8%  a t t r i t i o n  r a t e  w h i c h  p r o v i d e s  a p p r o x im a t e l y  2 4 0 7  e v a l u a b l e  a d u l t s  f o r  imm u n o g e n i c i t y  
a n a l y s i s .  
B a s e d  o n  c u r r e n t  s am p l e  s i z e ,  t h e r e  i s  5 5 . 4%  p o w e r  t o  d e t e c t  t h e  s u p e r i o r i t y  o f  e a c h  B  s t r a i n  
c om p a r i n g  Q I V - H D  g r o u p s  v e r s u s  e i t h e r  t h e  T I V -H D 1  o r  T I V - H D 2  g r o u p  i n  t h e  s e c o n d a r y  
o b j e c t i v e .  I t  i s  b a s e d  o n  a n  a s s um p t i o n  o f  e x p e c t e d  GM T  r a t i o  o f  1 . 8  w i t h  a  s t a n d a r d  d e v i a t i o n  o f  
0 . 5 5 ,  s e r o c o n v e r s i o n  r a t e  o f  8%  i n  t h e  g r o u p  w i t h o u t  t h e  B  s t r a i n  a n d  2 2%  i n c r e a s e  i n  t h e  g r o u p  
w i t h  t h e  B  s t r a i n ,  a n d  a  5%  a t t r i t i o n  r a t e  i n  F A S .   
A  s u b s e t  o f  3 0 0  s u b j e c t s  w i t h  1 0 0  s u b j e c t s  f r om  e a c h  g r o u p  w i l l  b e  r a n d om l y  s e l e c t e d  f o r  S N  
t e s t i n g .  
1 3  E t h i c a l  a n d  L e g a l  I s s u e s  a n d  I n v e s t i g a t o r  /  S p o n s o r  R e s p o n s i b i l i t i e s  
1 3 . 1  E t h i c a l  C o n d u c t  o f  t h e  T r i a l  /  G o o d  C l i n i c a l  P r a c t i c e  
T h e  c o n d u c t  o f  t h i s  t r i a l  w i l l  b e  c o n s i s t e n t  w i t h  t h e  s t a n d a r d s  e s t a b l i s h e d  b y  t h e  D e c l a r a t i o n  o f  
H e l s i n k i  a n d  c om p l i a n t  w i t h  t h e  I C H  g u i d e l i n e s  f o r  G C P  a s  w e l l  a s  w i t h  a l l  l o c a l  a n d  /  o r  n a t i o n a l  
r e g u l a t i o n s  a n d  d i r e c t i v e s .  
1 3 . 2  S o u r c e  D a t a  a n d  S o u r c e  D o c um e n t s  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
“ S o u r c e  d a t a ”  a r e  t h e  d a t a  c o n t a i n e d  i n  s o u r c e  d o c um e n t s .  S o u r c e  d o c um e n t s  a r e  o r i g i n a l  
d o c um e n t s  o r  c e r t i f i e d  c o p i e s ,  a n d  i n c l u d e ,  b u t  a r e  n o t  l im i t e d  t o ,  d i a r y  c a r d s ,  m e d i c a l  a n d  
h o s p i t a l  r e c o r d s ,  s c r e e n i n g  l o g s ,  i n f o rm e d  c o n s e n t  /  a s s e n t  f o rm s ,  t e l e p h o n e  c o n t a c t  l o g s ,  a n d  
w o r k s h e e t s .  T h e  p u r p o s e  o f  t r i a l  s o u r c e  d o c um e n t s  i s  t o  d o c um e n t  t h e  e x i s t e n c e  o f  s u b j e c t s  a n d  t o  
s u b s t a n t i a t e  t h e  i n t e g r i t y  o f  t h e  t r i a l  d a t a  c o l l e c t e d .  I n v e s t i g a t o r s  m u s t  m a i n t a i n  s o u r c e  d o c um e n t s  
s o  t h a t  t h e y  a r e  a c c u r a t e ,  c om p l e t e ,  l e g i b l e ,  a n d  u p  t o  d a t e .  
F o r  m i s s i n g  o r  d i s c r e p a n t  d a t a  o n  a  d i a r y  c a r d ,  t h e  s t u d y  c o o r d i n a t o r  w i l l  o b t a i n  v e r b a l  c l a r i f i c a t i o n  
f r om  t h e  s u b j e c t ,  e n t e r  t h e  r e s p o n s e  i n t o  t h e  “ i n v e s t i g a t o r ’ s  c omm e n t ”  p a g e  o f  t h e  d i a r y  c a r d ,  a n d  
t r a n s f e r  t h e  i n f o rm a t i o n  t o  t h e  C R B .  
T h e  s u b j e c t  p r e -s c r e e n i n g  l o g  s h o u l d  l i s t  a l l  i n d i v i d u a l s  c o n t a c t e d  b y  t h e  I n v e s t i g a t o r s  t o  
p a r t i c i p a t e  i n  t h e  t r i a l ,  r e g a r d l e s s  o f  t h e  o u t c om e .  
P a g e  7 2  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141374] to be re -printed, dated (with an indication of the date of change), and 
signed. Such records must also be kept together with the original printed copy. 
13.[ADDRESS_141375] Records  
Prior to initiation of the trial, the Investigator will sign a fully ex ecuted confidentiality agreement 
with [COMPANY_011] Pasteur . 
[COMPANY_011] Pasteur personnel (or designates), the IECs / IRBs, and regulatory agencies, including the 
FDA, require direct access to all study records, and will treat these documents in a confidential manner. 
In the event a subject’s medical records are not at the investigational site, it is the responsibility of 
the investigator to obtain those records if needed. 
13.4 Monitoring, Auditing, and Archiving  
13.4.1 Monitoring   
Before the start of the trial (i.e., before the inclusion of the first subject at the first center), the 
Investigators and the Sponsor’s staff or a representative will meet at the site -initiation visit to 
discuss the trial protocol and the detailed trial procedures. Emphasis will be placed on inclusion 
and exclusion criteria, visit timing, safety procedures, informed consent procedures, SAE reporting procedures, CRB  completion, and the handling of samples and products. The Sponsor’s 
staff or a representative will ensure and document that all material to be used during the trial has 
been received at the site; and that the study investigator team and local Sponsor /delegate  staff 
have been properly informed about the trial, GCP and regulatory requirements, and the Sponsor’s procedures. Specific training sess ions for the study investigator team and the CRAs on these 
topi[INVESTIGATOR_35291], and should be documented. 
The following instruction manuals will be provided: the CRF Completion Instructions  for entering 
data into the CRB, and the Operating Guidelines for detailed trial procedures such as the product 
management and sample-handling procedures. After the start of the trial, the Sponsor’s staff or a representative will be in regular contact [CONTACT_125638]-up visits. The Investigator or delegate must be available for these visits, and must allow the Sponsor/delegate staff direct access 
to subject medical files and CRBs. During these visits, the Sponsor/delegate staff will:  
                                                 
a  Unless the electronic medical records are managed by [CONTACT_35385] 
21 CFR Part 11, in which case they are acceptable on their own.  
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 73 of 78
S a n o f i  P a s t e u r  QH D 0 0 0 1 3  
5 2 2  –  F l u  U S  Q I V - H D  P r o t o c o l  V e r s i o n  4 . 0  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  
P a g e  7 4  o f  7 7  • E v a l u a t e  t h e  q u a l i t y  o f  t h e  t r i a l  p r o g r e s s  ( a d h e r e n c e  t o  p r o t o c o l  a n d  a n y  s t u d y - s p e c i f i c  
g u i d e l i n e s ,  q u a l i t y  o f  d a t a  c o l l e c t i o n  a n d  d o c um e n t  c om p l e t i o n ,  s i g n a t u r e  o f  c o n s e n t  f o rm s ,  
o c c u r r e n c e  o f  S A E s ,  s am p l e  a n d  p r o d u c t  m a n a g em e n t ,  c o l d - c h a i n  m o n i t o r i n g ,  a r c h i v i n g )  
• S o u r c e - v e r i f y  c om p l e t e d  C R B s  a n d  a n y  c o r r e s p o n d i n g  a n s w e r e d  q u e r i e s  
• D e t e rm i n e  t h e  n um b e r  o f  c om p l e t e  o r  o n g o i n g  i s s u e s  i d e n t i f i e d  a t  m o n i t o r i n g  v i s i t s  ( e . g . ,  
p r o t o c o l  d e v i a t i o n s ,  S A E s ) .  A n y  i d e n t i f i e d  p r o b l em s  w i l l  b e  d i s c u s s e d  w i t h  t h e  I n v e s t i g a t o r ,  
a n d  c o r r e c t i v e  o r  p r e v e n t i v e  a c t i o n s  w i l l  b e  d e t e rm i n e d ,  a s  a p p r o p r i a t e .  
• A f t e r  a l l  p r o t o c o l  p r o c e d u r e s  h a v e  b e e n  c om p l e t e d  a n d  t h e  d a t a  h a v e  b e e n  e n t e r e d  i n t o  t h e  
C R B ,  t h e  I n v e s t i g a t o r  m u s t  s t i l l  b e  a v a i l a b l e  t o  a n s w e r  a n y  q u e r i e s  f o r w a r d e d  b y  t h e  S p o n s o r .  
A l l  d a t a - r e l a t e d  q u e r i e s  m u s t  b e  c om p l e t e d  p r i o r  t o  d a t a b a s e  l o c k .   
A t  t h e  e n d  o f  t h e  t r i a l ,  a  c l o s e - o u t  v i s i t  w i l l  b e  p e r f o rm e d  t o  e n s u r e  t h a t :  
• T h e  c e n t e r  h a s  a l l  t h e  d o c um e n t s  n e c e s s a r y  f o r  a r c h i v i n g  
• A l l  s am p l e s  h a v e  b e e n  s h i p p e d  t o  t h e  a p p r o p r i a t e  l a b o r a t o r i e s  
• A l l  u n u s e d  m a t e r i a l s  a n d  p r o d u c t s  h a v e  b e e n  e i t h e r  d e s t r o y e d  o r  r e t u r n e d  t o  t h e  S p o n s o r  
1 3 . 4 . 2  A u d i t s  a n d  I n s p e c t i o n s  
A  q u a l i t y  a s s u r a n c e  a u d i t  m a y  b e  p e r f o rm e d  a t  a n y  t im e  b y  t h e  S p o n s o r ’ s  C l i n i c a l  Q u a l i t y  
A s s e s sm e n t  d e p a r tm e n t  ( C Q A )  o r  b y  i n d e p e n d e n t  a u d i t o r s  t o  v e r i f y  t h a t  t h e  t r i a l  h a s  b e e n  
c o n d u c t e d  a c c o r d i n g  t o  t h e  p r o t o c o l ,  G C P  a n d  I C H  r e q u i r em e n t s ,  a n d  o t h e r  a p p l i c a b l e  
r e g u l a t i o n s .  A n  i n s p e c t i o n  m a y  b e  c o n d u c t e d  b y  r e g u l a t o r y  a u t h o r i t i e s .  T h e  I n v e s t i g a t o r  m u s t  
a l l o w  d i r e c t  a c c e s s  t o  t r i a l  d o c um e n t s  d u r i n g  t h e s e  i n s p e c t i o n s  a n d  a u d i t s .  
1 3 . 4 . 3  A r c h i v i n g  S a n o f i  P a s t e u r  
 
C o n f i d e n t i a l / P r o p r i e t a r y  I n f o rm a t i o n  QH D 0 0 0 1 3 
                5 2 2  –  F l u  U S  Q I V  H D P r o t o c o l  V e r s i o n  4 . 0 
T h e  I n v e s t i g a t o r  m u s t  k e e p  a l l  t r i a l  d o c um e n t s  a f t e r  t h e  c om p l e t i o n  o r  d i s c o n t i n u a t i o n  o f  t h e  t r i a l ,  
w h a t e v e r  t h e  n a t u r e  o f  t h e  i n v e s t i g a t i o n a l  c e n t e r  ( p r i v a t e  p r a c t i c e ,  h o s p i t a l ,  o r  i n s t i t u t i o n ) ,  f o r  a s  
l o n g  a s  r e q u i r e d  b y  a p p l i c a b l e  l a w s  a n d  r e g u l a t i o n s .  I n  t h e  a b s e n c e  o f  a n y  a p p l i c a b l e  l a w s  o r  
r e g u l a t i o n s ,  t r i a l  d o c um e n t s  w i l l  b e  k e p t  a t  a  m i n im um  f o r  t h e  d u r a t i o n  i n d i c a t e d  o n  t h e  C l i n i c a l  
T r i a l  A g r e em e n t  ( C T A ) .  I n  n o  e v e n t ,  s h o u l d  s t u d y  p e r s o n n e l  d e s t r o y  o r  p e rm i t  t h e  d e s t r u c t i o n  o f  
a n y  t r i a l  d o c um e n t s  u p o n  l e s s  t h a n  9 0  d a y s  a d v a n c e  w r i t t e n  n o t i f i c a t i o n  t o  t h e  S p o n s o r .  I n  
a d d i t i o n ,  t r i a l  d o c um e n t s  s h o u l d  c o n t i n u e  t o  b e  s t o r e d ,  a t  S p o n s o r ' s  s o l e  e x p e n s e ,  i n  t h e  e v e n t  t h a t  
t h e  S p o n s o r  r e q u e s t s  i n  w r i t i n g  t h a t  s u c h  s t o r a g e  c o n t i n u e s  f o r  a  p e r i o d  o f  t im e  t h a t  e x c e e d s  t h a t  
r e q u i r e d  b y  a n y  a p p l i c a b l e  l a w  o r  r e g u l a t i o n  o r  t h e  C T A .  T h e  I n v e s t i g a t o r  w i l l  i n f o rm  S a n o f i  
P a s t e u r  o f  a n y  a d d r e s s  c h a n g e  o r  i f  t h e y  w i l l  n o  l o n g e r  b e  a b l e  t o  h o u s e  t h e  t r i a l  d o c um e n t s .  
A r c h i v e d  d a t a  m a y  b e  h e l d  o n  e l e c t r o n i c  r e c o r d s ,  p r o v i d e d  t h a t  a  b a c k - u p  e x i s t s  a n d  t h a t  a  h a r d  
c o p y  c a n  b e  o b t a i n e d  i f  r e q u i r e d .  T h e  p r o t o c o l ,  d o c um e n t a t i o n ,  a p p r o v a l s ,  a n d  a l l  o t h e r  
d o c um e n t s  r e l a t e d  t o  t h e  t r i a l  w i l l  b e  k e p t  b y  t h e  S p o n s o r  i n  t h e  T r i a l  M a s t e r  F i l e  ( TM F ) .  D a t a  o n  
A E s  a r e  i n c l u d e d  i n  t h e  TM F .  A l l  d a t a  a n d  d o c um e n t s  w i l l  b e  m a d e  a v a i l a b l e  i f  r e q u e s t e d  b y  
r e l e v a n t  a u t h o r i t i e s .  
P a g e  7 4  o f  7 8 
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141376] and Insurance Coverage  
A CTA will be signed by [CONTACT_125639]’s performance, if relevant. The 
Sponsor has an insurance policy to cover any liabilities that may arise from use of the product and 
/ or the study protocol. 
13.[ADDRESS_141377] 90  days prior to submission for publication / presentation. 
Any information identified by [CONTACT_125640], 
it being understood that the results of this trial are not to be considered conf idential.  
[COMPANY_011] Pasteur’s review can be expedited to meet publication guidelines. 
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 75 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page [ADDRESS_141378] Rev. 2007;(2):CD001269. Review. 
2 Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality 
associated with influenza and respi[INVESTIGATOR_35293]. JAMA. 2003;289(2):179-86. 
3 Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza 
vaccine in elderly persons. Ann Intern Med. 1995;123(7):518-27. 
4 Centers for Disease Control and Prevention (CDC). Licensure of a high-dose inactivated 
influenza vaccine for persons aged 65 years and older (Fluzone High-Dose) and guidance for use-[LOCATION_002]. Morb Mortal Wkly Rep. 2010;59(16):485-6. 
[ADDRESS_141379] -dose influenza vaccine in older adults. N Engl J Med. 
2014;371(7):635-45. 
6 Caini S, Huang QS, Ciblak MA, et al. Epi[INVESTIGATOR_125612] B: results of the Global Influenza B Study. Influenza and Other Respir Viruses. 2015;9(Suppl. 1):3-12. 
7 Gorse GJ, Falsey AR, Ozol -Godfrey A, Landolfi V, Tsang PH. Safety and immunogenicity 
of a quadrivalent intradermal influenza vaccine in adults. Vaccine. 2015;33(9):1151-9. 
8 Fluzone Quadrivalent package inser t. Swiftwater, Pennsylvania, [LOCATION_003], [COMPANY_011] Pasteur Inc. 
27 October 2014. 
9 Fluzone High- Dose package insert. Swiftwater, Pennsylvania, [LOCATION_003], [COMPANY_011] Pasteur Inc. 16 
February 2016. 
10 Brighton Collaboration Website. https://brightoncollaboration.org/public/what- we-
do/standards/case -definitions.html. Accessed 30 March 2015. 
11 U.S. Food and Drug Administration. Guidance for Industry: Clinical data needed to support 
the licensure of seasonal inactivated influenza vaccines. Last updated: 15 September 2014. Available from: http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm074794.htm.. Accessed 09 February 2017. 
12 Newcombe R.G. Two -sided confidence intervals for the single proportion: comparison of 
seven methods. Statistics in Medicine. 1998;17:857-72. 
13 Li X, Wang WWB, Liu GF, Chan ISF. Handling missing data in vaccine clinical trials for 
immunogenicity and safety evaluation. J Biopharm Stat. 2011;21(2):294-310. 
 
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 76 of 78
[COMPANY_011] Pasteur QHD00013 
522 – Flu US QIV-HD Protocol Version 4.0 
 
Confidential/Proprietary Information  
Page 77 of 77 15 Signature [CONTACT_125641]/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.[ADDRESS_141380] Name
[CONTACT_29565]
-
-
-
Approver Name [CONTACT_1782]
(Universal Time)Reason for Signature
[CONTACT_125642] 20 Jul 2017
13:25:09I am approving this document
-
-
 
[COMPANY_011] Pasteur 
 
Confidential/Proprietary Information 
                
QHD00013
522 – Flu US QIV HD
Protocol Version 4.0
Page 78 of 78
